Blog

Stimulants and Atomoxetine Have Defined ADHD Treatment for Decades. Simtriyo Is the First Drug Approved That Simultaneously Targets All Three Monoamine Neurotransmitter Systems. Here Is Why That Matters.

July 31, 2026

The essentials: On July 24, 2026, the FDA approved Simtriyo (centanafadine, Otsuka Pharmaceutical) extended-release capsules for the treatment of ADHD in adults and pediatric patients aged 6 years and older weighing at least 20 kg (approximately 44 pounds). Simtriyo is the first and only approved norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) for any indication. This is a first-in-class mechanism that distinguishes centanafadine from every currently approved ADHD medication. What centanafadine is: an oral once-daily extended-release capsule that inhibits the reuptake of norepinephrine, dopamine, and serotonin simultaneously, increasing the availability of all three monoamines in the brain pathways involved in attention, executive function, and emotional regulation. Stimulants (amphetamines, methylphenidate) primarily increase dopamine and norepinephrine through reuptake inhibition and release. Atomoxetine (Strattera) is a selective norepinephrine reuptake inhibitor. Centanafadine is the first approved agent to add serotonin to the dopamine and norepinephrine target profile. The serotonin component is what differentiates Simtriyo from prior dual-mechanism ADHD drugs and is responsible for the emotional dysregulation and comorbid anxiety benefits observed in clinical data. The clinical basis: four Phase 3 trials across three age groups. Two adult trials (NCT03605680 and NCT03605836; n=859 total adults with ADHD aged 18 to 55): primary endpoint: change from baseline in AISRS (Adult ADHD Investigator Symptom Rating Scale) total score at week 6; both centanafadine 200 mg/day and 400 mg/day showed statistically significant and clinically meaningful improvements versus placebo; onset at week 1 (first post-baseline assessment); sustained through week 6. One adolescent trial (ages 13 to 17): primary endpoint: change from baseline in ADHD-RS-5 total score at week 6; high-dose group met primary endpoint with statistically significant improvement; benefit emerging by week 1. One pediatric trial (ages 6 to 12): primary endpoint: change from baseline in ADHD-RS-5 total score at week 6; high-dose group met primary endpoint with statistically significant improvement; benefit emerging by week 1. Low-dose groups did not reach statistical significance in pediatric or adolescent trials. Notable Phase 3b finding: in 315 adults with ADHD and comorbid anxiety (NCT06973577): AISRS improvement LS mean change minus 18.5 versus minus 12.6 for placebo; treatment difference minus 5.87; p less than 0.0001; HAM-A improvement (anxiety scale) also statistically significant (p=0.02); separation at week 1 maintained through week 8. Regulatory designations: Priority Review. DEA scheduling: Simtriyo is classified as a CNS stimulant and must receive a DEA Schedule classification before commercial launch; this standard process takes up to 3 months. How the DEA classifies it (Schedule II like amphetamines, or a lower schedule) will affect prescribing practices and commercial potential. Boxed warnings: suicidal ideation and behavior in children aged 6 to 12; and abuse, misuse, and addiction (with risk mitigation counseling on storage, disposal, and ongoing patient reassessment). Common adverse reactions: decreased appetite, nausea, rash, fatigue, upper abdominal pain, somnolence. Population: approximately 7 million children and 15.5 million adults in the United States have ADHD.

Attention-deficit/hyperactivity disorder is the most commonly diagnosed neurodevelopmental condition in childhood and affects a substantial and often undertreated adult population. The FDA approved its first treatments for ADHD over 60 years ago. Since then, the pharmacological toolkit has evolved, but it has stayed within two broad categories: stimulants that drive up dopamine and norepinephrine in the prefrontal cortex, and non-stimulants that work more selectively on norepinephrine alone.

That framework has worked well for millions of patients. But it has also left clear gaps. The emotional dysregulation that characterizes many ADHD presentations, the hair-trigger frustration, the mood swings that follow a bad day, the inability to manage disappointment proportionally, these are not adequately addressed by dopamine and norepinephrine manipulation alone. The comorbid anxiety that co-occurs with ADHD in an estimated 50% of patients is poorly served by stimulants, which can exacerbate anxiety in many individuals. The 30% of patients who do not respond to or cannot tolerate existing medications continue cycling through options that were designed around the same two-target pharmacology.

Simtriyo (centanafadine, Otsuka) is the first drug for ADHD that adds serotonin to the target profile. Its three-neurotransmitter mechanism is not just a numbers upgrade. It is a qualitatively different pharmacological approach to a condition that has long been understood to involve more than two neurochemical systems.

The four Phase 3 trials, conducted across all ages from children to adults, showed consistent, statistically significant improvement in ADHD symptoms. A Phase 3b trial in adults with ADHD and comorbid anxiety showed that centanafadine improved both conditions simultaneously. And the drug demonstrated low abuse and dependence potential in clinical studies, which is a meaningful clinical consideration in a condition where stimulant diversion, misuse, and concerns about controlled substance prescribing remain persistent barriers to treatment access.

What ADHD Is: The Neurobiology and the Clinical Picture

Attention-deficit/hyperactivity disorder is a chronic neurodevelopmental disorder characterized by a persistent pattern of inattention, hyperactivity, and impulsivity that is inconsistent with the developmental level of the individual and interferes with functioning across settings. The DSM-5-TR recognizes three presentations: predominantly inattentive, predominantly hyperactive-impulsive, and combined presentation.

The prevalence of ADHD is substantial. In the United States, approximately 7 million children (approximately 9.4% of children aged 2 to 17 years) have a diagnosed ADHD, and approximately 15.5 million adults are currently estimated to have the condition. These numbers have grown with improved diagnostic criteria and increased awareness of adult ADHD, which was underrecognized for decades as a condition that was assumed to be outgrown in adolescence.

ADHD is highly heritable (heritability estimates of 70 to 80%) and is associated with dysregulation of the prefrontal cortex and its dopaminergic and noradrenergic inputs, which modulate attention, working memory, response inhibition, and executive function. Functional neuroimaging consistently shows reduced activation in fronto-striatal circuits in individuals with ADHD during tasks requiring sustained attention and executive control.

What standard neurobiology discussions of ADHD have historically underweighted is the role of serotonin. Serotonergic projections from the dorsal raphe nucleus reach the prefrontal cortex, striatum, and limbic system, where they modulate emotional reactivity, frustration tolerance, and mood stability, precisely the domains in which many individuals with ADHD experience their most functionally limiting symptoms. The emotional dysregulation of ADHD, which some researchers have proposed is a core feature rather than a comorbidity, is substantially serotonin-mediated. This is the gap that centanafadine’s third mechanism targets.

The ADHD Treatment Landscape and Where Simtriyo Fits

ADHD pharmacotherapy before Simtriyo was organized around two treatment classes:

Stimulants (Schedule II controlled substances)

Stimulants are the most prescribed and most effective first-line treatment for ADHD across all ages. They include:

Amphetamine-based stimulants: Amphetamine salts (Adderall, Adderall XR), lisdexamfetamine (Vyvanse), dextroamphetamine (Dexedrine). Mechanism: release of dopamine and norepinephrine from presynaptic terminals and inhibition of their reuptake.

Methylphenidate-based stimulants: Methylphenidate (Ritalin, Concerta, Daytrana, numerous others), dexmethylphenidate (Focalin). Mechanism: primarily reuptake inhibition of dopamine and norepinephrine without significant release.

Both classes produce robust improvements in attention, hyperactivity, and impulsivity in 70 to 80% of patients. Both are Schedule II controlled substances, requiring specific prescribing procedures, limiting the quantity dispensed, and restricting refills. Both carry abuse potential and are diverted for non-therapeutic use. Some patients cannot tolerate them due to cardiovascular effects, anxiety exacerbation, appetite suppression, or sleep disruption.

Non-stimulants

Atomoxetine (Strattera): A selective norepinephrine reuptake inhibitor, approved for ADHD in 2002 for children and adults. Takes 4 to 6 weeks to reach therapeutic effect. Effective for inattention; less effective than stimulants for hyperactivity in many patients. Not a controlled substance. Carries a boxed warning for suicidal ideation in pediatric patients.

Viloxazine ER (Qelbree): A selective norepinephrine reuptake inhibitor, approved 2021 for children and adolescents, 2022 for adults. Similar profile to atomoxetine but with some evidence of faster onset.

Alpha-2 adrenergic agonists (guanfacine ER/Intuniv; clonidine ER/Kapvay): Non-stimulant, non-controlled. Particularly useful for hyperactivity, impulsivity, and emotional dysregulation. Less effective for inattention as monotherapy. Often used as adjuncts to stimulants.

Where Simtriyo sits

Simtriyo occupies a novel position in this landscape. It is classified as a CNS stimulant (reflecting its dopaminergic and noradrenergic mechanism, which produces the physiological profile of a stimulant) but it is not a traditional amphetamine or methylphenidate. It adds serotonin reuptake inhibition to the dopamine and norepinephrine target profile. And it demonstrated low abuse and dependence potential in clinical studies, which is the basis for Otsuka’s expectation that the DEA may grant it a Schedule III or lower classification rather than the Schedule II designation that applies to amphetamines and methylphenidate.

The DEA scheduling decision will have significant commercial and clinical implications. A Schedule III or lower classification would allow phone-in and electronic prescriptions with refills (unlike Schedule II, which requires a new written or electronic prescription each month), which is a meaningful practical barrier reduction for patients on long-term ADHD therapy.

How Centanafadine Works: The Triple Reuptake Mechanism

Centanafadine inhibits the reuptake transporters for all three monoamine neurotransmitters: the norepinephrine transporter (NET), the dopamine transporter (DAT), and the serotonin transporter (SERT). By blocking these transporters, centanafadine prevents the reabsorption of norepinephrine, dopamine, and serotonin from the synaptic cleft back into the presynaptic neuron, increasing the availability of all three neurotransmitters in the synapse.

Dopamine transporter (DAT) inhibition: Increases synaptic dopamine in the prefrontal cortex and striatum, improving attention, motivation, and executive function. This is the mechanism shared with methylphenidate, though without the amphetamine-like release component.

Norepinephrine transporter (NET) inhibition: Increases synaptic norepinephrine in the prefrontal cortex, improving working memory, sustained attention, and response inhibition. This is the mechanism shared with atomoxetine and viloxazine, as well as with amphetamines.

Serotonin transporter (SERT) inhibition: Increases synaptic serotonin in the prefrontal cortex, limbic system, and striatum. Serotonin modulates emotional reactivity, frustration tolerance, anxiety, and mood stability. This is the mechanism shared with SSRIs and SNRIs, but in a drug designed primarily for ADHD rather than depression or anxiety.

The combination of all three mechanisms in a single molecule produces a pharmacological effect that simultaneously addresses the attention and executive function deficits of ADHD (via dopamine and norepinephrine) and the emotional dysregulation and comorbid anxiety that frequently accompany them (via serotonin). As Dr. Greg Mattingly noted in a discussion of centanafadine’s mechanism: the serotonin component was shown to help anxiety and mood in people with ADHD, since the drug kind of has an SSRI built in.

The extended-release capsule formulation delivers the drug over the course of the day, enabling once-daily dosing that maintains therapeutic concentrations through school or work hours without the rebound effects that can accompany immediate-release formulations.

The Four Phase 3 Trials: What the Data Shows

The FDA based its approval on the totality of evidence from four Phase 3 trials, spanning adults, adolescents, and children, with consistent findings of statistically significant and clinically meaningful ADHD symptom improvement in the higher-dose groups.

Adult trials: NCT03605680 and NCT03605836

Two randomized, double-blind, placebo-controlled Phase 3 trials in 859 adults aged 18 to 55 years with ADHD evaluated centanafadine sustained-release at 200 mg/day or 400 mg/day (administered in divided twice-daily doses) versus placebo over 6 weeks. The primary endpoint was the change from baseline in the AISRS (Adult ADHD Investigator Symptom Rating Scale) total score at week 6.

Both centanafadine doses (200 mg/day and 400 mg/day) demonstrated statistically significant and clinically meaningful improvement in AISRS total score versus placebo at week 6. Statistical separation from placebo emerged as early as week 1, the first post-baseline assessment time point, and was maintained through the 6-week study period.

Post-hoc analyses of the 744-patient adult dataset showed improvements in patient-reported executive function, including time management, planning and prioritization, task initiation and completion, and working memory. Improvements in emotional regulation measures, including reduced mood shifts, emotional overactivity, and anger outbursts, were also observed in the same post-hoc analyses.

Adolescent trial (ages 13 to 17)

A 6-week, randomized, double-blind, placebo-controlled, fixed-dose trial with weight-based dosing evaluated centanafadine extended-release in adolescents aged 13 to 17 years. The primary endpoint was change from baseline in ADHD-RS-5 (ADHD Rating Scale, fifth edition) total score at week 6. The high-dose group met the primary endpoint with statistically significant improvement versus placebo. Benefit was observed as early as week 1. The low-dose group did not reach statistical significance.

Pediatric trial (ages 6 to 12)

A 6-week, randomized, double-blind, placebo-controlled, fixed-dose trial with weight-based dosing evaluated centanafadine extended-release in children aged 6 to 12 years. The primary endpoint was change from baseline in ADHD-RS-5 total score at week 6. The high-dose group met the primary endpoint with statistically significant improvement versus placebo. Benefit was observed as early as week 1. The low-dose group did not reach statistical significance.

The weight minimum of 20 kg (approximately 44 pounds) for the approved indication reflects both the weight-based dosing approach in the pediatric trials and the pharmacokinetic considerations for centanafadine at the approved doses in the youngest and smallest children.

Phase 3b trial in ADHD with comorbid anxiety (NCT06973577)

Beyond the core NDA-supporting trials, Otsuka conducted a Phase 3b study in 315 adults aged 18 to 65 years with ADHD and comorbid anxiety (generalized anxiety disorder and/or social anxiety disorder) to evaluate centanafadine XR 280 mg once daily over 8 weeks.

Endpoint	Centanafadine 280 mg (n=approximately 158)	Placebo (n=approximately 157)	Result
AISRS change from baseline at week 8 (primary)	LS mean minus 18.5	LS mean minus 12.6	Treatment difference minus 5.87; p less than 0.0001
HAM-A change from baseline at week 8 (key secondary)	LS mean minus 12.5	LS mean minus 10.6	p=0.02
Statistical separation	Week 1 (first post-baseline)	—	Maintained through week 8

Source: Otsuka Phase 3b press release. June 25, 2026. NCT06973577.

The simultaneous improvement in both ADHD and anxiety symptoms from a single drug in a population that traditionally requires two medications addresses one of the most clinically significant gaps in ADHD management. The 50% of ADHD patients who have comorbid anxiety are often undertreated for one or both conditions because stimulants can exacerbate anxiety, and adding an SSRI or SNRI to a stimulant regimen increases medication burden and interaction risk. A single drug that addresses both represents a meaningful clinical advance for this population.

Safety: What the Prescribing Information Covers

Boxed warnings

Simtriyo carries two boxed warnings, the FDA’s strongest safety designation:

Suicidal ideation and behavior in children aged 6 to 12: Centanafadine carries a boxed warning for suicidal ideation and behavior specifically in the 6-to-12 age group. This warning is supported by data from the pediatric trials and reflects the same class-level concern that applies to other ADHD treatments including atomoxetine and viloxazine. Caregivers should monitor children for new or worsening depression, unusual changes in behavior, or suicidal thoughts, particularly early in treatment or after dose changes. Clinical monitoring with frequent follow-up visits is recommended during initial titration in this age group.

Abuse, misuse, and addiction: As a CNS stimulant with dopaminergic mechanism, centanafadine carries an abuse potential warning. The prescribing information requires counseling patients and caregivers on the risk of abuse and misuse, safe storage (keeping the medication secure and away from others), proper disposal of unused medication, and ongoing reassessment of the patient’s need for the drug at each visit. Centanafadine demonstrated low abuse and dependence potential in clinical studies, which is factored into the pending DEA scheduling decision.

Common adverse reactions

The most common adverse reactions reported in ADHD clinical trials, occurring at higher rates than placebo, include: decreased appetite, nausea, rash, fatigue, upper abdominal pain, and somnolence. This adverse reaction profile is broadly consistent with CNS stimulant class effects, though the absence of headache from the list and the presence of rash distinguish the centanafadine profile somewhat from amphetamine formulations.

Key warnings and precautions

Cardiovascular monitoring: As with all CNS stimulants, centanafadine may affect heart rate and blood pressure. Cardiovascular status should be evaluated before initiating and monitored during treatment. Centanafadine should be used with caution in patients with pre-existing cardiac conditions, and the prescribing information should be reviewed for specific guidance.

Psychiatric adverse effects: Beyond the suicidality boxed warning in young children, psychiatric adverse effects including irritability, mood changes, and psychotic or manic episodes have been reported with stimulant class medications. Monitor for emergence of psychiatric symptoms during treatment.

Growth monitoring in children: As with other stimulant medications, height and weight monitoring is appropriate in pediatric patients on long-term centanafadine therapy.

The DEA Scheduling Question: A Critical Pre-Commercial Consideration

Before Simtriyo can be commercially dispensed in the United States, the Drug Enforcement Administration must assign it a controlled substance schedule. This is a standard regulatory process for all drugs with CNS activity and abuse potential, and it can take up to three months from FDA approval.

The question of which schedule is genuinely important:

A Schedule II designation (the classification of amphetamines and methylphenidate) would impose: no telephone or electronic prescriptions with refills; patients must obtain a new written or electronic prescription each month; some states impose additional restrictions. This schedule reflects the highest abuse potential among clinical controlled substances.

A Schedule III, IV, or V designation would allow: prescriptions with refills; electronic transmission; fewer administrative burdens per refill. Schedule III is where buprenorphine for opioid use disorder and many other abusable but non-amphetamine drugs sit.

Centanafadine’s clinical trial data showing low abuse potential, and its structural and pharmacological differentiation from classical amphetamines, support Otsuka’s expectation that the DEA may assign a lower schedule than amphetamines. Jefferies analysts noted that a lower schedule could give Simtriyo a competitive edge in a crowded ADHD market, and that how the DEA classifies it could determine its commercial potential.

What This Means for Clinicians and Patients

For psychiatrists, pediatricians, and primary care providers

Simtriyo introduces a genuinely new pharmacological option in the ADHD landscape. The triple reuptake mechanism is not a repackaging of existing approaches. It provides a new tool for the following patient profiles:

Patients with ADHD and comorbid anxiety, who cannot tolerate stimulants or who have had anxiety exacerbated by them. The Phase 3b comorbid anxiety data showing simultaneous improvement in both ADHD and anxiety symptoms from one drug is a clinically important finding.

Patients with prominent emotional dysregulation, the impulsive anger, frustration intolerance, and mood lability that sit at the intersection of ADHD and emotional disorders and are poorly addressed by traditional stimulants.

Patients who have not responded to or cannot tolerate existing stimulants or non-stimulants. The additional mechanistic target (serotonin) may produce therapeutic benefit in patients where dopamine/norepinephrine-focused agents have been insufficient.

Patients or families concerned about controlled substance prescribing, if the DEA assigns a lower schedule than amphetamines.

The DEA scheduling outcome, expected within approximately three months of the July 24 approval, will be an important milestone that determines the practical prescribing workflow. Most clinicians will want to wait for this clarification before integrating Simtriyo into their prescribing routines.

For patients and families

ADHD is a highly individualized condition. Not every patient will respond the same way to any given medication, and finding the right ADHD treatment often involves trial and adjustment of medications, doses, and formulations over time. Simtriyo adds a new first-in-class option to that process, with a mechanism specifically designed to address the emotional and anxiety-related dimensions of ADHD that current medications often leave inadequately treated.

As Dr. Lenard Adler, director of the adult ADHD program at NYU Langone Health and an investigator on the centanafadine trials, noted: having more therapeutic choices is important because ADHD is a highly individualized condition and treatment decisions should reflect the unique needs of each patient.

For families navigating a pediatric ADHD diagnosis, the weight requirement of at least 20 kg (approximately 44 pounds) should be confirmed before treatment initiation. The suicidal ideation boxed warning in children aged 6 to 12 is a prescribing information requirement that warrants close communication with the prescribing clinician about monitoring, visit frequency in early treatment, and what behavioral changes to watch for and report.

The Attention Deficit Disorder Association (ADDA) (add.org) and CHADD (Children and Adults with ADHD) (chadd.org; 1-800-233-4050) maintain current treatment information, prescriber directories, and patient community resources for adults and families navigating ADHD management.

Sources

FDA approval announcement: FDA approves centanafadine extended-release capsules for ADHD. FDA.gov. July 24, 2026. Full announcement.

Otsuka FDA approval press release: Otsuka receives FDA approval for first-in-class SIMTRIYO (centanafadine) for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients aged 6 years and older. Otsuka. July 24, 2026.

Drugs.com approval news: FDA Approves Simtriyo (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD). drugs.com. July 24, 2026.

Psychiatric Times (first-in-class NDSRI mechanism, four Phase 3 trials, executive function post-hoc): FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults. psychiatrictimes.com. July 2026. Full article.

Psychiatric Times (clinical development path, AISRS primary endpoint, adult and pediatric trial design): Centanafadine’s Route to FDA Review: A Clinical Path of the ADHD Medication. psychiatrictimes.com.

Managed Healthcare Executive (AISRS week 1 onset, boxed warning detail, DEA scheduling context): FDA approves Simtriyo, the first triple reuptake inhibitor for ADHD. managedhealthcareexecutive.com. July 2026. Full article.

Fierce Pharma (DEA schedule, commercial analysis, Jefferies note, Dr. Adler quote): FDA approves Otsuka’s first-in-class ADHD drug Simtriyo. fiercepharma.com. July 2026.

Drug Topics (adult n=744 post-hoc data, pediatric/adolescent high-dose-only result, boxed warnings, week 1 onset): FDA Approves First-in-Class Centanafadine for Treatment of ADHD. drugtopics.com. July 2026.

ADDitude Magazine (serotonin-SSRI analogy quote, FDA approval context, 280 mg anxiety trial): Centanafadine (Simtriyo) Receives FDA Approval as ADHD Medication. additudemag.com.

ADDitude clinical path article (Phase 2 dose, pediatric trial design, low-dose negative results, Dr. Wilens investigator reference): Centanafadine: Forthcoming Triple Reuptake Inhibitor ADHD Drug. additudemag.com.

Otsuka Phase 3b comorbid anxiety press release (exact LS mean data, p-values): Otsuka Announces Positive Phase 3b Results for Centanafadine in Adults with ADHD and Comorbid Anxiety. otsuka-us.com. June 25, 2026.

Pharmacy Times (AISRS LS mean data, HAM-A secondary endpoint, pediatric trial detail): Centanafadine Demonstrates Statistically Significant, Clinically Relevant Improvements in ADHD Symptoms. pharmacytimes.com.

Otsuka ASCP 2026 post-hoc press release (executive function, emotional dysregulation domains from n=744): Otsuka Presents New Phase 3 Post Hoc Analyses of Centanafadine at ASCP 2026. otsuka-us.com. May 2026.

Medscape (first NDSRI approved, prevalence statistics): FDA Approves First NDSRI for ADHD in Adults and Children. medscape.com. July 2026.

OncoDaily / OncoLibrary (mechanism overview, 20 kg weight requirement): FDA Approves Zidesamtinib (Jideytro) for ROS1-Positive NSCLC. oncodaily.com.

Adult Phase 3 trial registrations: NCT03605680 and NCT03605836. ClinicalTrials.gov.

Phase 3b comorbid anxiety trial registration: NCT06973577. ClinicalTrials.gov.

ADHD overview: Attention Deficit Hyperactivity Disorder. StatPearls. NCBI.

Simtriyo prescribing information: SIMTRIYO (centanafadine) Extended-Release Capsules Prescribing Information. Otsuka. 2026.

Simtriyo approval history: Simtriyo FDA Approval History. drugs.com.

Patient resources: CHADD (Children and Adults with ADHD): 1-800-233-4050 | Attention Deficit Disorder Association (ADDA) | Otsuka Simtriyo patient support | CDC ADHD information

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Simtriyo (centanafadine) carries a boxed warning for suicidal ideation and behavior in children aged 6 to 12 years, and a boxed warning for abuse, misuse, and addiction. Commercial availability awaits DEA scheduling, which is expected within approximately three months of FDA approval. Treatment decisions for ADHD, including the selection and initiation of any pharmacologic therapy, should be made in close collaboration with a board-certified psychiatrist, pediatrician, or primary care provider experienced in ADHD management, taking into account the individual patient’s clinical profile, comorbidities, and treatment history.

ROS1-Positive Lung Cancer Tends to Affect Younger, Non-Smoking Patients. First-Line TKI Therapy Works (Until It Doesn’t). Jideytro Is Now the First Approved Option When It Stops Working.

July 30, 2026

The essentials: On July 22, 2026, the FDA approved Jideytro (zidesamtinib, GSK/Nuvalent) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have received at least one prior ROS1 tyrosine kinase inhibitor (TKI). The approval came approximately two months ahead of the original PDUFA target action date of September 18, 2026. Jideytro received Breakthrough Therapy Designation and Orphan Drug Designation from the FDA. It is GSK’s first approved lung cancer medicine, developed by Nuvalent Inc., which GSK acquired in 2025. Regulatory context: this is an accelerated approval based on overall response rate and duration of response. What zidesamtinib is: a next-generation, brain-penetrant, ROS1-selective kinase inhibitor engineered to address the two primary failure modes of earlier ROS1 TKIs: acquired resistance mutations (particularly the G2032R solvent front mutation) and inadequate central nervous system (CNS) penetration. Importantly, zidesamtinib avoids inhibition of the structurally related TRK family kinases, which is expected to reduce TRK-related CNS adverse events (cognitive effects, dizziness, ataxia) that limit tolerability of some dual TRK/ROS1 inhibitors. The clinical basis: Phase 1/2 ARROS-1 (NCT05118789), global, multicenter, single-arm, open-label, multi-cohort. Efficacy population: 117 adults with previously treated ROS1-positive NSCLC who had received at least one prior ROS1 TKI. ORR: 44% (95% CI not reported in early sources; durable). Durability: 78% of responders remained in response at 12 months; 62% at 18 months. Subgroup ORR after one prior ROS1 TKI: 51%. Subgroup ORR in G2032R resistance mutation: 54%. Intracranial ORR in patients with measurable brain metastases: 48%; complete intracranial responses: 20%. Tolerability: adverse event-related dose reductions in 10%; discontinuations due to AEs in 2%. The comparison context: the most commonly used first-line ROS1 TKIs are crizotinib (approved, but older generation), entrectinib (Rozlytrek, brain-penetrant dual ROS1/TRK inhibitor), and lorlatinib (approved for ROS1-positive NSCLC). Repotrectinib (Augtyro) and taletrectinib are later-generation options. ARROS-1 included patients who had received lorlatinib, repotrectinib, and taletrectinib as prior therapy, meaning zidesamtinib demonstrated activity even after the most potent existing ROS1 inhibitors had been used. Population context: approximately 50,000 people worldwide are diagnosed with ROS1-positive NSCLC each year; in the United States, 1 to 2% of NSCLC cases carry ROS1 rearrangements. The population is characterized by younger median age, female predominance, and a high proportion of never-smokers.

Lung cancer is the leading cause of cancer death in the United States. But within lung cancer, the approximately 1 to 2% of patients whose tumors carry a ROS1 gene rearrangement face a distinct clinical experience from most of the other 98 to 99%. They tend to be younger. Many have never smoked. Their tumors are often adenocarcinomas with a predilection for brain metastases. And when they receive a matched ROS1 tyrosine kinase inhibitor, they frequently respond dramatically.

The problem, as with essentially every other targeted oncology therapy, is that the response eventually ends. Resistance mutations develop. The cancer finds molecular workarounds. Brain metastases progress. And until July 22, 2026, there was no FDA-approved therapy specifically designed for this post-first-line moment.

Jideytro (zidesamtinib, GSK/Nuvalent) is the first. Approved two months ahead of its PDUFA date, zidesamtinib was engineered from the ground up to address the specific failure modes of earlier ROS1 inhibitors: the resistance mutations that drive progression, the inadequate brain penetration that allows CNS disease to advance, and the off-target TRK inhibition that compromises tolerability of some existing brain-penetrant options.

The ARROS-1 trial enrolled 117 patients with previously treated ROS1-positive NSCLC, including patients who had already received the newest and most potent ROS1 inhibitors available: lorlatinib, repotrectinib, and taletrectinib. In this heavily pretreated population, zidesamtinib produced a 44% overall response rate, with 78% of responders still in response at one year. In patients with the most common resistance mutation (G2032R), the response rate was 54%. And in patients with brain metastases, nearly half achieved an intracranial response, with one in five achieving complete intracranial clearance.

What ROS1-Positive NSCLC Is and Who Gets It

Non-small cell lung cancer accounts for approximately 85% of all lung cancers. Within NSCLC, molecular profiling has identified multiple distinct oncogenic driver subtypes, each with its own therapeutic vulnerabilities and clinical characteristics. EGFR mutations, ALK rearrangements, KRAS mutations, MET amplifications, BRAF mutations, HER2 alterations, and RET fusions each define patient populations for whom specific targeted therapies have transformed the treatment landscape over the past two decades.

ROS1 gene rearrangements are present in approximately 1 to 2% of NSCLC cases. In the United States, where approximately 250,000 new lung cancer cases are diagnosed annually, this translates to approximately 2,500 to 5,000 new ROS1-positive NSCLC diagnoses per year. Globally, Nuvalent and GSK estimate approximately 50,000 new diagnoses annually.

The ROS1-positive NSCLC population has several distinguishing epidemiological features. The median age at diagnosis is younger than for other NSCLC subtypes, often in the 40s to 50s. Women are represented at higher rates than in unselected NSCLC. Most patients are never-smokers or former light smokers. The tumors are predominantly adenocarcinoma histology, and brain metastases are common both at initial presentation and during the course of treatment, occurring in 30 to 45% of patients at some point in their disease course.

These epidemiological features matter clinically. A younger, otherwise healthy patient diagnosed with ROS1-positive NSCLC has a long potential treatment horizon ahead of them, which means the durability of each line of therapy matters more than in a frailer, older patient. It also means that CNS disease management is a central concern across the treatment timeline, not a late-stage complication.

The ROS1 Kinase and Why It Drives Lung Cancer

ROS1 (ROS proto-oncogene 1) is a receptor tyrosine kinase expressed in multiple tissues during development but with limited expression in most normal adult tissues. Its natural ligand and physiological signaling functions are not fully characterized. What is known is that chromosomal rearrangements involving ROS1, in which the ROS1 kinase domain fuses to the promoter and partial coding sequence of a partner gene, create constitutively active chimeric oncoproteins that drive uncontrolled cell proliferation.

Over 20 ROS1 fusion partners have been identified in NSCLC, with CD74-ROS1 being among the most common. All fusion partners produce the same functional consequence: constitutive activation of the ROS1 kinase domain, which signals continuously through the same downstream pathways as the RET and ALK kinases (RAS/MAPK, PI3K/AKT, JAK/STAT), driving tumor growth and survival.

The structural similarity between ROS1 and ALK (approximately 77% kinase domain amino acid identity) is clinically relevant: several ALK inhibitors, particularly crizotinib and lorlatinib, have significant ROS1 inhibitory activity and are approved for ROS1-positive NSCLC alongside their ALK indications. This shared structural profile was the historical basis for applying ALK inhibitors to ROS1-positive disease, before ROS1-specific and ROS1/RET co-targeting inhibitors were developed.

The structural similarity between ROS1 and the TRK family (TRKA, TRKB, TRKC) is the source of a distinct tolerability challenge. Earlier-generation brain-penetrant dual inhibitors that cover both ROS1 and TRK kinases (particularly entrectinib and repotrectinib) produce neurological adverse events from CNS TRK inhibition: cognitive effects, dizziness, paresthesias, and ataxia. These toxicities are often dose-limiting and have been a meaningful contributor to treatment discontinuation in clinical practice.

What Makes Zidesamtinib a Next-Generation Approach

Zidesamtinib was engineered by Nuvalent with three specific design objectives aimed at the clinical shortcomings of existing ROS1 inhibitors:

1. Activity against resistance mutations, particularly G2032R

The most common acquired resistance mutation in ROS1-positive NSCLC is G2032R, a “solvent front” mutation in the ROS1 kinase domain at amino acid position 2032. This mutation alters the geometry of the kinase active site in a way that physically impedes the binding of many first- and second-generation ROS1 inhibitors. G2032R resistance is observed in a significant proportion of patients who progress on crizotinib, entrectinib, and other earlier-generation agents.

Zidesamtinib was designed with a molecular conformation that maintains potent binding to the G2032R-mutant kinase despite the altered active site geometry. The ARROS-1 data confirmed this pharmacological design goal: patients with G2032R-mutant ROS1-positive NSCLC achieved a 54% ORR, comparable to the overall 44% ORR in the full efficacy population, demonstrating that the drug maintains activity at the resistance mutation that has historically been the most difficult to address.

2. CNS penetration

Brain metastases in ROS1-positive NSCLC are common and clinically significant. In patients with CNS disease, the drug’s ability to penetrate the blood-brain barrier determines whether brain metastases are addressed alongside systemic disease or whether the CNS becomes a sanctuary site for disease progression.

Zidesamtinib was designed with molecular properties optimized for blood-brain barrier penetration: molecular weight, lipophilicity, and efflux transporter (P-glycoprotein) substrate profile were all considered in the drug’s structure. In ARROS-1, among patients with measurable brain metastases, the intracranial ORR was 48%, with complete intracranial responses in 20% of evaluable patients. A 20% complete intracranial response rate in a previously treated population is a strong CNS efficacy signal.

3. ROS1 selectivity over TRK kinases

The structural similarity between ROS1 and TRK kinases creates a design challenge: inhibitors that are potent against ROS1 often have collateral TRK inhibitory activity. In the CNS, where TRK signaling supports neuronal function, this TRK inhibition produces the neurological adverse events (cognitive effects, dizziness, ataxia) that characterize some existing brain-penetrant options.

Zidesamtinib was designed with selectivity favoring ROS1 over TRK kinases, exploiting subtle structural differences in the ROS1 versus TRK active sites. In the ARROS-1 safety data, adverse event-related dose reductions occurred in only 10% of patients and treatment discontinuations due to adverse events in only 2%, a very favorable tolerability profile for an oncology drug in a previously treated population. The avoidance of TRK-related CNS adverse events is a key contributor to this favorable tolerability.

The ARROS-1 Trial: Full Data

Design

ARROS-1 (NCT05118789) is a global, multicenter, Phase 1/2, single-arm, open-label, multi-cohort basket trial evaluating zidesamtinib in patients with advanced ROS1-positive NSCLC and other ROS1-positive solid tumors. The trial is ongoing; the approval was based on a prespecified interim analysis of the previously-treated ROS1-positive NSCLC cohort.

The efficacy population included 117 adult patients with locally advanced or metastatic ROS1-positive NSCLC who had received at least one prior ROS1 TKI, with or without prior platinum-based chemotherapy or immunotherapy. The cohort was split:

59 patients with one prior ROS1 TKI (less heavily pretreated)
58 patients with two or more prior ROS1 TKIs, including patients who had specifically received lorlatinib, repotrectinib, and/or taletrectinib (the most potent existing options)

Efficacy results

Endpoint	Full efficacy population (n=117)	One prior ROS1 TKI (n=59)	Two or more prior ROS1 TKIs (n=58)
Overall response rate	44%	51%	38%
Responders in response at 6 months	Favorable (reported consistent with 12- and 18-month data)	—	—
Responders in response at 12 months	78%	—	—
Responders in response at 18 months	62%	—	—
ORR in G2032R resistance mutation subgroup	54%	—	—
Intracranial ORR (patients with measurable brain metastases)	48%	—	—
Complete intracranial response rate	20%	—	—

Source: ARROS-1 FDA approval summary. FDA.gov. July 22, 2026. AJMC July 2026 clinical data. NCT05118789.

The 44% ORR in 117 previously treated patients spanning one to more than two prior ROS1 TKIs is a clinically meaningful result for a post-TKI setting where available cytotoxic alternatives typically produce response rates of 15 to 25%. The durability finding, that 78% of responders remained in response at one year, distinguishes zidesamtinib from conventional chemotherapy in this setting and is consistent with the deep, durable responses that characterize well-matched targeted oncology therapies.

The 51% ORR after one prior ROS1 TKI versus 38% after two or more prior TKIs reflects the expected gradient of response with increasing prior therapy, but the 38% rate in heavily pretreated patients who have already received lorlatinib, repotrectinib, or taletrectinib is itself notable. These are the most potent currently available ROS1 inhibitors, and maintaining a meaningful response rate after them is a meaningful demonstration of zidesamtinib’s differentiated activity.

The G2032R subgroup ORR of 54% is the most important resistance mutation-specific finding, confirming that the drug’s pharmacological design goal of maintaining activity against the most common ROS1 resistance mutation was achieved in the clinic.

Dr. Alexander Drilon of Memorial Sloan Kettering Cancer Center, a principal investigator of ARROS-1, noted that despite advances in treatment, resistance mutations, disease progression in the brain, and treatment-related adverse events continue to create challenges for patients, and that the responses observed in ARROS-1, including in heavily pretreated patients, represent meaningful progress for people living with this disease.

Tolerability

The tolerability profile from ARROS-1 is among the most favorable observed for any ROS1-targeted therapy in this treatment setting:

Adverse event-related dose reductions: 10%
Treatment discontinuations due to adverse events: 2%

The most common adverse reactions occurring in at least 15% of patients in the pooled safety population of 446 patients (which includes the full ARROS-1 treated population beyond the 117-patient efficacy population) were not individually reported in the available press release and will be detailed in the full prescribing information. The generally favorable tolerability reflects the ROS1-selective design and the absence of significant TRK off-target activity.

The ROS1-Positive NSCLC Treatment Landscape After July 2026

ROS1-positive NSCLC now has an increasingly complex treatment landscape, with multiple approved options across lines of therapy:

Drug	Company	ROS1 indication	FDA approval	CNS activity	Resistance coverage
Xalkori (crizotinib)	Pfizer	ROS1-positive NSCLC, first-line	March 2016	Limited (poor CNS penetration)	Limited
Rozlytrek (entrectinib)	Roche/Genentech	ROS1-positive NSCLC with or without CNS involvement	August 2019	Good (CNS activity)	Limited G2032R activity; TRK off-target CNS effects
Lorlatinib (Lorbrena)	Pfizer	ROS1-positive NSCLC, any line	January 2022	Good (brain-penetrant)	Some resistance mutation coverage; TRK off-target effects
Augtyro (repotrectinib)	BMS	ROS1-positive NSCLC, any line	November 2023	Good	Improved G2032R coverage; TRK off-target effects possible
Taletrectinib (Enhertu)	AnHeart/Eli Lilly	ROS1-positive NSCLC	Approved	Moderate CNS activity	Some resistance coverage
Jideytro (zidesamtinib)	GSK/Nuvalent	ROS1-positive NSCLC, after prior ROS1 TKI	July 22, 2026	Good (engineered CNS penetration)	G2032R: 54% ORR; TRK-selective sparing

Zidesamtinib is the only approved agent specifically indicated for the post-prior-ROS1-TKI setting. All other approved ROS1 inhibitors are first-line options or are approved regardless of prior therapy. The approved indication for zidesamtinib is specifically patients who have received at least one prior ROS1 TKI, positioning it as the designated second-line-and-beyond option.

ARROS-1 is also evaluating zidesamtinib in the first-line setting for patients who have not yet received a ROS1 TKI. If that cohort produces compelling results, a first-line indication could follow, potentially positioning zidesamtinib across the full treatment continuum.

Safety: What the Prescribing Information Covers

The full adverse reaction profile will be detailed in the complete prescribing information for Jideytro. Based on available data from ARROS-1 and the pooled safety population of 446 patients:

Most common adverse reactions (at least 15%): The specific adverse reactions and their frequencies were not individually listed in the available press releases and will be published in the full prescribing information. The favorable overall tolerability profile (dose reductions 10%, discontinuations 2%) indicates that the adverse reaction profile is manageable.

Warnings and precautions from the prescribing information (based on FDA summary):

Warning	Details	Clinical guidance
Interstitial lung disease/pneumonitis	Reported with ROS1 inhibitor class; potentially serious	Monitor for new or worsening respiratory symptoms; hold for suspected pneumonitis; permanently discontinue for confirmed severe events
Hepatotoxicity	Liver enzyme elevations observed	Monitor liver function tests at baseline and periodically; dose modification for significant elevation
Hypertension	Observed with kinase inhibitors	Monitor blood pressure; antihypertensive therapy as needed
QT interval prolongation	Kinase inhibitor class effect	ECG monitoring in patients with risk factors; electrolyte monitoring and correction
Hemorrhagic events	Monitor	Withhold for significant hemorrhage
Hypersensitivity	Reported	Manage per prescribing information
Tumor lysis syndrome	Risk in rapidly proliferating tumors	Hydration and laboratory monitoring
Impaired wound healing	Kinase inhibitor class effect	Withhold before and after elective surgery per prescribing information timing guidance
Hypothyroidism	Monitor thyroid function	Replace thyroid hormone as clinically indicated
Embryo-fetal toxicity	Zidesamtinib can cause fetal harm	Effective contraception during treatment and for specified period after last dose

Required Testing: ROS1 Positivity Must Be Confirmed

The approved indication requires ROS1-positive disease detected by an FDA-approved test. ROS1 testing should be part of the standard comprehensive molecular profiling that is now recommended for all newly diagnosed advanced NSCLC patients.

Fluorescence in situ hybridization (FISH) and next-generation sequencing (NGS)-based RNA and DNA panels are the most commonly used ROS1 detection methods. RNA-based sequencing is particularly important for ROS1 fusion detection because the diverse range of fusion partners and intronic breakpoints can be missed by DNA-only sequencing approaches. Major approved NGS platforms including FoundationOne CDx are validated for ROS1 fusion detection.

At disease progression on a prior ROS1 TKI, molecular re-testing can characterize acquired resistance mechanisms including specific resistance mutations (such as G2032R), which may guide selection among available post-progression options. Liquid biopsy (cell-free DNA) can detect some resistance mutations from blood with a less invasive approach than repeat tissue biopsy and is available through several approved platforms.

Corporate Context: Nuvalent, GSK, and What Comes Next

Jideytro is GSK’s first approved lung cancer medicine, and its approval reflects the strategic acquisition of Nuvalent Inc., the biotech that developed zidesamtinib. Nuvalent was founded on the premise that existing targeted kinase inhibitors for thoracic oncology left significant clinical gaps related to CNS penetration, resistance mutations, and off-target tolerability challenges, and that next-generation selective inhibitors engineered to address these specific failure modes could meaningfully improve outcomes.

GSK’s acquisition of Nuvalent brought not only zidesamtinib but also:

Neladalkib (NVL-655): an ALK-selective inhibitor under FDA review with a target action date of November 27, 2026, for ALK-altered NSCLC
NVL-330: an investigational HER2-selective inhibitor for HER2-altered NSCLC, in earlier-stage development

If neladalkib receives approval in November 2026 as expected, GSK will hold two next-generation precision oncology approvals in NSCLC within six months, establishing a meaningful footprint in thoracic oncology that did not exist before the Nuvalent acquisition.

Janet Freeman-Daily, Co-Founder and President of The ROS1ders, the leading patient advocacy organization for ROS1-positive cancer patients, noted that the ROS1-positive community is deeply invested in advancing care with treatments that are effective and tolerable, and that this approval represents an important advance for people in need.

For related HED coverage on targeted kinase inhibitor approvals in lung cancer and related precision oncology, see our post on Retevmo (selpercatinib) converting from accelerated to traditional approval for RET fusion-positive solid tumors and our post on Padcev (enfortumab vedotin) receiving its first perioperative MIBC approval regardless of cisplatin eligibility.

For patients and families navigating a ROS1-positive NSCLC diagnosis, The ROS1ders (theROS1ders.org) is the leading patient-founded organization dedicated specifically to this molecular subtype. The LUNGevity Foundation (lungevity.org; 1-800-LUNG-USA) and the GO2 Foundation for Lung Cancer maintain current resources on molecular testing, treatment options, and clinical trials.

Sources

FDA approval announcement: FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer. FDA.gov. July 22, 2026. Full announcement at FDA.gov. Wikipedia

GSK approval press release: GSK announces the US FDA approval of Jideytro (zidesamtinib) for previously treated ROS1-positive non-small cell lung cancer. PRNewswire. July 22, 2026. Full press release.

GSK news release (first lung cancer approval, ahead of PDUFA): Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer. gsk.com. July 22, 2026.

Drugs.com approval news: FDA Approves Jideytro (zidesamtinib) for Previously Treated ROS1-Positive Non-Small Cell Lung Cancer. drugs.com. July 22, 2026.

AJMC (full ORR/DOR breakdown, subgroup data, tolerability rates): FDA Approves Zidesamtinib as New Option for Resistant ROS1+ NSCLC. ajmc.com. July 2026. Full article.

Oncology News Central (ARROS-1 data, Dr. Drilon quote): FDA Approves Zidesamtinib (Jideytro) for ROS1-Positive Non-Small Cell Lung Cancer. oncologynewscentral.com. July 2026. Full article.

HMP Global Oncology (ORR 44%, durability at 12 and 18 months, first-line investigation context): FDA Approves Zidesamtinib for Previously Treated ROS1-Positive Non-Small Cell Lung Cancer. hmpgloballearningnetwork.com. July 2026. Full article.

OncoDaily (GSK first lung cancer approval, neladalkib pipeline, ROS1ders quote, 50,000 global cases): FDA Approves Zidesamtinib (Jideytro) for ROS1-Positive NSCLC. oncodaily.com. July 2026. Full article. Oncology News Central

Cancer Therapy Advisor (ARROS-1 population detail, trial support summary): FDA Approves Jideytro for Previously Treated ROS1+ NSCLC. cancertherapyadvisor.com. July 2026.

ARROS-1 trial registration: NCT05118789. ClinicalTrials.gov.

Jideytro prescribing information (full PI): JIDEYTRO (zidesamtinib) Prescribing Information. Nuvalent/GSK. 2026.

Jideytro approval history: Jideytro FDA Approval History. drugs.com.

NSCLC and molecular oncology overview: Non-Small Cell Lung Cancer. StatPearls. NCBI.

Crizotinib ROS1 approval: FDA approves crizotinib for ROS1-positive NSCLC. FDA.gov.

Entrectinib ROS1 approval: FDA approves entrectinib for ROS1-positive NSCLC. FDA.gov.

Patient resources: The ROS1ders: theROS1ders.org | LUNGevity Foundation: 1-800-LUNG-USA | GO2 Foundation for Lung Cancer | Free to Breathe | GSK Jideytro patient support

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Jideytro (zidesamtinib) received accelerated approval based on overall response rate and duration of response; continued approval may depend on verification and description of clinical benefit in a confirmatory trial. ROS1-positive status must be confirmed by an FDA-approved test before initiating treatment. Treatment decisions for ROS1-positive NSCLC following prior TKI therapy should be made in close collaboration with a board-certified medical oncologist with expertise in thoracic oncology and molecular-targeted therapy.

Retevmo Received Accelerated Approval for RET Fusion-Positive Solid Tumors in 2022 on Response Rate Data. On July 14, 2026, the FDA Confirmed the Clinical Benefit Was Real. Here Is What That Conversion Means.

July 29, 2026

The essentials: On July 14, 2026, the FDA granted traditional (full) approval to Retevmo (selpercatinib, Eli Lilly and Company) for adult and pediatric patients aged 2 years and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. This is a regulatory conversion from accelerated to traditional approval. It does not change the indication, the population, or the drug. What changed is the evidentiary threshold: accelerated approval was granted in 2022 based on overall response rate and duration of response as surrogate endpoints. Traditional approval requires confirmatory evidence demonstrating actual clinical benefit. The conversion confirms that the response rates observed in LIBRETTO-001 represent genuine clinical benefit rather than a surrogate that might not translate to meaningful outcomes. Timeline of the tissue-agnostic indication: accelerated approval for adult patients: September 21, 2022. Pediatric extension (accelerated approval for ages 2 and older): May 29, 2024. Traditional (full) approval covering both adults and children aged 2 and older: July 14, 2026. Primary evidence base (tissue-agnostic, non-NSCLC/non-thyroid solid tumors): LIBRETTO-001 (NCT03157128), multicenter, open-label, multi-cohort Phase 1/2 trial. Efficacy analysis set for traditional approval: 75 patients with RET fusion-positive solid tumors other than NSCLC and thyroid cancer. ORR: 47% (95% CI 35% to 59%). Median DOR: 24.5 months (95% CI 11.2 to 49.1). Pediatric evidence: LIBRETTO-121 (NCT03899792), demonstrating responses in congenital infantile fibrosarcoma, spindle cell sarcoma, and RET fusion-positive thyroid cancer. Supported by: established traditional approval data in NSCLC (LIBRETTO-001 NSCLC cohort, original May 2020 approval) and thyroid cancer (traditional approval in medullary thyroid cancer May 2020; RET fusion-positive thyroid cancer traditional approval 2022). What this means for prescribing: no change in the indication, patient eligibility, required RET testing, or dosing. The conversion to traditional approval removes the post-marketing requirement to verify clinical benefit in a confirmatory trial, because that verification has been provided.

The accelerated approval program is one of the FDA’s most powerful tools for getting effective drugs to patients with serious diseases faster. But it comes with a condition: the drug is approved based on a surrogate endpoint (typically tumor response rate, a measure of whether the tumor shrinks) that is reasonably likely to predict clinical benefit, and continued approval depends on completing a confirmatory trial that demonstrates the actual clinical benefit, whether patients live longer, function better, or have improved quality of life.

When a drug converts from accelerated to traditional approval, it means the confirmatory standard has been met. The FDA has reviewed the totality of evidence and concluded that the benefit originally inferred from surrogate response data is, in fact, real and established. The drug’s position in therapy is strengthened. The post-marketing obligation to verify is fulfilled. The label revision reflects a regulatory maturation, not a discovery.

For Retevmo (selpercatinib, Eli Lilly), this conversion arrived on July 14, 2026, for its tissue-agnostic indication covering RET fusion-positive solid tumors other than the NSCLC and thyroid cancer indications that already held full traditional approval. The drug had been treating patients under accelerated approval in this broader solid tumor population since September 2022. The 47% response rate and 24.5-month median duration of response in the LIBRETTO-001 non-NSCLC/non-thyroid cohort, combined with accumulated clinical experience and responses observed in pediatric patients across rare histologies in LIBRETTO-121, provided the confirmatory evidence base the FDA required.

This post covers what RET gene fusions are and why they matter across cancer types, how selpercatinib works as a selective RET inhibitor, what the complete Retevmo approval history looks like, what the LIBRETTO-001 and LIBRETTO-121 data show, what the regulatory distinction between accelerated and traditional approval means in practice, and what the conversion means for the clinicians and patients who have been using this drug.

What RET Is and Why a Gene Fusion Changes Everything

RET (Rearranged during Transfection) is a proto-oncogene encoding a receptor tyrosine kinase expressed in cells derived from the neural crest, including thyroid parafollicular cells (C cells), renal collecting duct cells, and neurons of the enteric nervous system. In normal cells, the RET kinase requires its ligand (glial cell line-derived neurotrophic factor, GDNF, and related proteins) to activate. Ligand binding triggers receptor dimerization and autophosphorylation, initiating downstream signaling through RAS/MAPK, PI3K/AKT/mTOR, and JAK/STAT pathways that regulate cell growth and survival.

Two types of oncogenic RET alterations drive human cancers: activating point mutations, which constitutively activate RET without requiring ligand binding, and gene fusions, in which chromosomal rearrangements fuse the RET kinase domain to the promoter and partial coding sequence of a partner gene.

RET gene fusions create chimeric proteins in which the kinase domain of RET is constitutively active, continuously signaling for cell proliferation and survival regardless of ligand availability. The fusion partner determines the specific structural features of the chimeric protein (including its dimerization properties and intracellular localization), but in all cases the downstream consequence is uncontrolled kinase activity driving tumor growth.

RET fusions are found across multiple tumor types:

Non-small cell lung cancer (approximately 1 to 2% of NSCLC): the most common solid tumor context; typically KIF5B-RET or CCDC6-RET fusions
Thyroid cancer: highly prevalent in papillary thyroid cancer (approximately 10 to 20% of cases) and relevant in other thyroid malignancies
Pancreatic cancer, colorectal cancer, salivary gland tumors, ovarian cancer, breast cancer, and multiple other histologies: lower individual prevalence but collectively encompassing thousands of patients annually

The tissue-agnostic indication covers this last category: any advanced solid tumor with a confirmed RET gene fusion, regardless of the cancer type in which it occurs, provided the patient has received prior systemic therapy or has no satisfactory alternative treatment options.

The tissue-agnostic regulatory framework reflects a broader shift in oncology toward molecular characterization of cancer over purely anatomic characterization. A RET fusion-positive pancreatic cancer and a RET fusion-positive NSCLC are different diseases in terms of their tissue of origin, their natural history, and their treatment history, but they share the molecular driver that makes them susceptible to RET inhibition. The shared molecular vulnerability justifies a shared approval across tumor types.

How Selpercatinib Works: Selective RET Inhibition

Selpercatinib is an oral, highly selective RET kinase inhibitor designed to potently inhibit both wild-type RET and the common oncogenic RET alterations (fusions and point mutations including RET M918T, the most common mutation in medullary thyroid cancer) while minimizing activity against off-target kinases.

The selectivity design philosophy distinguishes selpercatinib from earlier multi-kinase inhibitors (such as cabozantinib and vandetanib) that had incidental RET activity alongside activity against VEGFR, MET, and other kinases. Those earlier agents’ off-target activity contributed to high rates of adverse events, particularly cardiovascular and dermatological toxicities, and limited the depth and duration of RET-specific therapeutic benefit achievable in clinical practice.

Selpercatinib occupies the ATP-binding pocket of the RET kinase domain in a way that locks the enzyme in an inactive conformation. The drug is also designed to address known resistance mutations: at concentrations achievable in the clinic, it maintains activity against several RET mutations that confer resistance to earlier-generation RET inhibitors, including V804M and V804L (the “gatekeeper” mutations).

The high selectivity translates into an adverse event profile that differs from multi-kinase inhibitors. The most common adverse reactions in LIBRETTO-001 (occurring in 25% or more of the full safety population, n=796) were edema, diarrhea, fatigue, dry mouth, hypertension, abdominal pain, constipation, rash, nausea, and headache. These are largely manageable with dose modification and supportive care, and the rates of severe (grade 3 or 4) events are substantially lower than with the older multi-kinase inhibitors used in RET-altered thyroid cancer.

Retevmo’s Full Approval History: A Cumulative Story

Understanding the July 2026 traditional approval requires context for Retevmo’s complete regulatory trajectory. The drug now holds multiple distinct approved indications accumulated over six years.

Indication	Approval type	Date	Trial basis
RET fusion-positive NSCLC (adults)	Accelerated	May 8, 2020	LIBRETTO-001 NSCLC cohort
RET-mutant medullary thyroid cancer (adults)	Accelerated	May 8, 2020	LIBRETTO-001 MTC cohort
RET fusion-positive thyroid cancer (adults)	Accelerated	May 8, 2020	LIBRETTO-001 thyroid cohort
RET fusion-positive NSCLC (adults)	Traditional (full)	March 25, 2022	LIBRETTO-431 Phase 3 versus chemo
RET-mutant MTC and RET fusion-positive thyroid cancer (adults and pediatric ages 12 and older)	Traditional (full)	October 19, 2022	LIBRETTO-001 confirmed data
RET fusion-positive solid tumors, all types (adults)	Accelerated	September 21, 2022	LIBRETTO-001 non-NSCLC/non-thyroid ORR/DOR
RET-mutant MTC and RET fusion-positive thyroid cancer (pediatric ages 2 and older)	Accelerated	May 29, 2024	LIBRETTO-121 pediatric data
RET fusion-positive solid tumors, all types (adults and pediatric ages 2 and older)	Traditional (full)	July 14, 2026	LIBRETTO-001 confirmed; LIBRETTO-121 supported

The July 2026 action completes the regulatory maturation of the tissue-agnostic indication and extends full traditional approval to the pediatric population (ages 2 and older) that had previously held only accelerated approval.

The Evidence Base: LIBRETTO-001 and LIBRETTO-121

LIBRETTO-001: The backbone of the tissue-agnostic indication

LIBRETTO-001 (NCT03157128) is an international, non-randomized, open-label, multi-cohort Phase 1/2 basket trial evaluating selpercatinib across all RET-altered solid tumors. The trial enrolled both RET fusion-positive and RET-mutant cancers across multiple tumor types and is the primary evidence source for most of Retevmo’s approved indications.

The efficacy analysis supporting the traditional approval conversion for the tissue-agnostic indication focused on 75 patients with RET fusion-positive solid tumors excluding NSCLC and thyroid cancer (the tumor types with separate, fully established approval pathways). This population included cancers of the pancreas, colon, rectum, salivary gland, ovary, breast, and other sites, all unified by the presence of a confirmed RET gene fusion.

Efficacy endpoint	Result
Population (non-NSCLC, non-thyroid RET fusion-positive solid tumors)	n=75
Overall response rate (ORR)	47% (95% CI 35% to 59%)
Complete response rate	Included in the 47% ORR
Median duration of response (DOR)	24.5 months (95% CI 11.2 to 49.1)

Source: LIBRETTO-001. NCT03157128. FDA traditional approval summary July 14, 2026.

A 47% ORR and 24.5-month median DOR in a pan-tumor, pretreated population with diverse histologies is a clinically meaningful and durable response. The median DOR of nearly 2 years means that among the patients who responded, approximately half maintained that response beyond 24 months. In the context of heavily pretreated advanced solid tumors, which typically show short-duration responses to available cytotoxic chemotherapy, this durability distinguishes the targeted RET inhibitor approach from standard cytotoxic alternatives.

The supporting efficacy evidence from the NSCLC and thyroid cancer cohorts in LIBRETTO-001, both of which carry traditional approval, provides additional confirmation that selpercatinib’s anti-tumor activity is a real, consistent pharmacological phenomenon rather than a statistical artifact of small-cohort data.

LIBRETTO-121: The pediatric evidence base

LIBRETTO-121 (NCT03899792) is a multicenter, open-label, multi-cohort trial evaluating selpercatinib specifically in pediatric and young adult patients with RET-altered cancers. The trial evaluated patients with locally advanced refractory RET fusion-positive solid tumors who were unresponsive to available therapies or had no standard systemic curative therapy.

The evidence from LIBRETTO-121 supporting the July 2026 traditional approval included:

One patient with congenital infantile fibrosarcoma: response observed
One patient with spindle cell sarcoma: response observed
Patients with RET fusion-positive thyroid cancer: responses observed

Congenital infantile fibrosarcoma and spindle cell sarcoma are rare pediatric tumors that carry ETV6-NTRK3 or other fusions in many cases, but the subset with RET fusions represents an ultra-rare population with very limited treatment options. A documented response in even a single patient with a rare pediatric sarcoma histology is clinically meaningful in a disease where treatment options are severely constrained.

The pediatric dosing framework for selpercatinib in LIBRETTO-121 includes weight-based dosing for children under 50 kg and adult dosing (160 mg twice daily) for patients at or above 50 kg or aged 12 and older meeting weight criteria. The prescribing information specifies dosing tables by weight for the pediatric population.

The Accelerated to Traditional Approval Conversion: What It Means and Why It Matters

Accelerated approval is a regulatory pathway created to make drugs available earlier for serious conditions with unmet medical need, based on surrogate endpoints that are “reasonably likely to predict” clinical benefit. Response rate is the most commonly used surrogate: if a tumor shrinks, the inference is that the patient will likely benefit clinically, even if survival data are not yet mature.

The limitation of accelerated approval is exactly that: it is based on an inference. A tumor can shrink and still not provide meaningful clinical benefit if the response is short, if the toxicity is prohibitive, or if the shrinkage does not translate into longer survival or better function. These are the cases where confirmatory trials sometimes reveal that the surrogate did not predict the expected clinical benefit, and the drug’s accelerated approval is subsequently withdrawn.

The conversion to traditional approval is the opposite event: it means the FDA has reviewed additional evidence demonstrating that the drug delivers genuine clinical benefit. For selpercatinib, the combination of the extended response durations observed in LIBRETTO-001 (median DOR of 24.5 months across the diverse non-NSCLC/non-thyroid cohort), the fully established traditional approval in NSCLC and thyroid cancer, and the pediatric response data in LIBRETTO-121 together provided the evidentiary confirmation required.

The practical implications of the conversion for patients and prescribers:

The indication does not change. The patient population, dosing, and required testing are identical before and after the conversion.

The regulatory confidence in the drug’s benefit is strengthened. Traditional approval removes the qualifier from the label indicating that continued approval may depend on a confirmatory trial. The clinical benefit is established.

The post-marketing verification requirement is fulfilled. Under accelerated approval, sponsors are legally required to conduct and submit confirmatory trial data. That obligation is discharged when traditional approval is granted.

Payer coverage is sometimes affected. Some commercial payers treat accelerated-approval drugs with greater scrutiny in prior authorization decisions, viewing them as having a higher evidentiary uncertainty. Traditional approval can support broader formulary access and simpler authorization pathways in some systems.

RET Testing: A Required Prerequisite

The tissue-agnostic indication for Retevmo requires RET gene fusion detection using an FDA-approved test. This testing requirement is embedded in the indication language: “locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test.”

For oncologists managing patients with advanced solid tumors: comprehensive genomic profiling (CGP) panels, which assess for RET fusions alongside hundreds of other clinically relevant alterations in a single assay, are the most efficient approach to RET testing in practice. Major approved CGP tests include Foundation Medicine’s FoundationOne CDx and Liquid CDx platforms, MSKCC’s MSK-IMPACT, and others. RNA-based sequencing is particularly important for RET fusion detection because DNA-based sequencing may miss some intronic fusion breakpoints; laboratories offering solid tumor profiling should ideally include RNA-based detection for fusion genes.

Patients whose tumors have not previously undergone molecular profiling and who are progressing on first-line therapy should be considered for testing at the earliest opportunity, because tissue requirements for a repeat biopsy may limit testing access later in the disease course. Cell-free DNA (liquid biopsy) is also available and can detect RET fusions from a blood draw, though with lower sensitivity than tissue testing for some rare fusion partners.

Safety: What the Prescribing Information Covers

The safety profile of selpercatinib from LIBRETTO-001 is well-characterized across the approximately 796-patient full safety population with advanced solid tumors. The July 14, 2026 conversion does not change the safety profile or the warnings; it confirms the established benefit-risk assessment.

Most common adverse reactions (25% or more in the full safety population): edema, diarrhea, fatigue, dry mouth, hypertension, abdominal pain, constipation, rash, nausea, and headache.

Most common grade 3 or 4 laboratory abnormalities (5% or more): decreased lymphocytes, increased ALT, increased AST, decreased sodium, and decreased calcium.

Key warnings and precautions:

Warning	Rate/detail	Management
Hepatotoxicity	ALT or AST elevation; monitor before initiating and periodically	Monitor liver enzymes; dose interrupt or discontinue for significant elevation
ILD/pneumonitis	Potentially fatal	Monitor for pulmonary symptoms; hold for grade 2; permanently discontinue for grade 3 or 4
Hypertension	Grade 3 or higher in approximately 20%	Monitor blood pressure; antihypertensive medications as needed; dose modification for uncontrolled hypertension
QT interval prolongation	Grade 3 or higher in approximately 5%	ECG at baseline and periodically; electrolyte monitoring and replacement
Hemorrhagic events	Monitor	Withhold for grade 3 or higher bleeding; discuss with prescribing information for resumption
Hypersensitivity	Reported	Manage per prescribing information; may require corticosteroids
Tumor lysis syndrome	Particularly in rapidly proliferating tumors	Monitor laboratory values; hydration
Impaired wound healing	Withhold before and after surgery	See prescribing information for timing guidance around elective procedures
Hypothyroidism	Monitor TSH periodically	Replace thyroid hormone as clinically indicated
Embryo-fetal toxicity	Selpercatinib can cause fetal harm	Effective contraception during treatment and for specified time after last dose
Slipped capital femoral epiphysis (pediatric)	Monitor for hip or knee pain in pediatric patients	A specific pediatric warning added with the 2024 pediatric expansion

The pediatric-specific warning for slipped capital femoral epiphysis (SCFE), a disruption of the growth plate at the femoral head, was added to the prescribing information with the 2024 pediatric expansion and remains in place with the 2026 traditional approval. Pediatric patients receiving selpercatinib should be monitored for hip or knee pain, and any such complaint should prompt orthopedic evaluation.

Retevmo’s Current Complete Indication Coverage

After July 14, 2026, Retevmo (selpercatinib) holds the following approved indications:

Indication	Population	Approval status
RET fusion-positive NSCLC	Adults	Traditional (full)
RET-mutant medullary thyroid cancer	Adults and pediatric ages 2 and older	Traditional (full)
RET fusion-positive thyroid cancer	Adults and pediatric ages 2 and older	Traditional (full)
RET fusion-positive solid tumors (any type)	Adults and pediatric ages 2 and older	Traditional (full), July 14, 2026

All indications now hold traditional approval. Retevmo has no remaining accelerated approval indications. The regulatory maturation of the drug is complete across its full clinical scope.

What This Means for Oncologists and Patients

For oncologists managing patients with advanced solid tumors

The practical implication for clinical practice is modest because the indication, the patient population, and the drug are unchanged. What the traditional approval provides is regulatory confirmation of clinical benefit, which strengthens the position of selpercatinib in treatment guidelines and may support broader formulary access in payer systems that treat accelerated-approval drugs differently.

For patients currently receiving selpercatinib under the prior accelerated approval: nothing changes about their treatment. The drug they are taking is the same; the benefit they are receiving is now confirmed rather than inferred.

For oncologists identifying new patients with RET fusion-positive solid tumors (outside of NSCLC and thyroid cancer): the traditional approval removes any label-language qualifier about provisional status. The evidence base is established. The indication is full.

The response rate of 47% and median DOR of 24.5 months represent the expected clinical outcomes in a heavily pretreated pan-tumor population. Individual patient outcomes will vary based on tumor histology, prior treatment burden, performance status, and specific RET fusion partner, but these numbers provide a reasonable framework for pre-treatment counseling.

For patients with rare RET fusion-positive cancers

The tissue-agnostic nature of this indication remains one of its most important features for patients. A patient with RET fusion-positive pancreatic cancer or colon cancer does not have a separate lung cancer drug or a thyroid cancer drug being offered off-label. They have a drug approved specifically for their cancer type, based on the molecular driver their tumor carries, regardless of where in the body the tumor originated. That clarity matters for insurance coverage, for informed consent, and for the patient’s understanding of why this specific drug was recommended.

The full traditional approval now reinforces that position. For patients who were told in 2022 or 2023 that they were receiving a drug under accelerated approval pending confirmatory data, the July 2026 update means that confirmatory standard has been met. The benefit is established.

For related HED coverage on precision oncology and targeted kinase inhibitor approvals, see our post on Revtorpyk (gedatolisib) becoming the first approved targeted therapy for PIK3CA wild-type HR+/HER2- breast cancer and our post on daraxonrasib (RMC-6236) generating a standing ovation at ASCO 2026 for its Phase 3 results in KRAS-driven pancreatic cancer.

Sources

FDA traditional approval announcement: FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors. FDA.gov. July 14, 2026. Full announcement at FDA.gov. Eli Lilly and Company

CancerNetwork coverage (trial support overview): FDA Traditionally Approves Selpercatinib in RET+ Solid Tumors. cancernetwork.com. July 2026.

OncLive (ORR 47% and DOR 24.5 months data): FDA Awards Traditional Approval to Selpercatinib for RET+ Advanced Solid Tumors. onclive.com. July 2026.

Healio (n=75 population, LIBRETTO-001 cohort detail): FDA grants traditional approval to Retevmo for RET fusion-positive solid tumors. healio.com. July 2026.

CURE (patient-focused conversion explanation, LIBRETTO-121 histologies): FDA Grants Traditional Approval to Retevmo for RET Fusion-Positive Solid Tumors. curetoday.com. July 2026.

ASCO Post (complete indication language, LIBRETTO-121 context): FDA Grants Traditional Approval to Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive Solid Tumors. ascopost.com. July 2026.

Oncology Nursing News (regulatory conversion context): FDA Grants Traditional Approval to Selpercatinib for RET-Fusion Solid Tumors. oncnursingnews.com. July 2026.

Lilly accelerated approval press release (September 2022): FDA Approves Lilly’s Retevmo (selpercatinib), the First and Only RET Inhibitor for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion. Eli Lilly. September 21, 2022.

LIBRETTO-001 FDA review article (PMC): FDA accelerated approval summary for selpercatinib RET fusion-positive solid tumors (2022). PMC10524590.

LIBRETTO-001 trial registration: NCT03157128. ClinicalTrials.gov.

LIBRETTO-121 trial registration: NCT03899792. ClinicalTrials.gov.

Drugs.com approval news: FDA Grants Traditional Approval to Retevmo (selpercatinib) for Locally Advanced or Metastatic RET Fusion-Positive Solid Tumors. drugs.com. July 14, 2026.

Retevmo prescribing information: RETEVMO (selpercatinib) Prescribing Information. Eli Lilly and Company. 2026.

Retevmo approval history: Retevmo FDA Approval History. drugs.com.

Patient resources: LUNGevity Foundation: RET+ resources | Thyroid Cancer Alliance | RET Research Foundation | ClinicalTrials.gov: search selpercatinib | Lilly Cares patient support for Retevmo

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. The July 14, 2026 traditional approval of Retevmo (selpercatinib) for RET fusion-positive solid tumors reflects a regulatory conversion from accelerated to traditional approval; the indication, population, dosing, and required testing are unchanged. RET gene fusion testing using an FDA-approved test is required before initiating treatment. Decisions about selpercatinib therapy should be made in close collaboration with a board-certified medical oncologist experienced in molecular-targeted therapy and familiar with the tumor type in question.

Leqembi Has Changed What Is Possible in Early Alzheimer’s Disease. Until Now, Every Dose Required a Clinic Visit and an IV Line. That Changed on July 13, 2026.

July 28, 2026

The essentials: On July 13, 2026, the FDA approved a supplemental Biologics License Application for Leqembi Iqlik (lecanemab-irmb, Eisai and Biogen) as a once-weekly subcutaneous injection for treatment initiation in adults with early Alzheimer’s disease. This is the world’s first anti-amyloid therapy that can be started at home, without a clinic visit, and administered by the patient or a caregiver in approximately 15 seconds per injection. What this approval adds: Leqembi Iqlik was previously approved (August 2025) for subcutaneous maintenance dosing following 18 months of IV treatment. The July 13, 2026 approval extends SC use to the initiation phase, meaning the entire treatment course can now be managed subcutaneously from the first dose. No IV infusion is required at any point for patients who choose the SC formulation. The approved initiation regimen: 500 mg subcutaneous once weekly, delivered as two simultaneous 250 mg injections, each administered in approximately 15 seconds, via a pre-filled autoinjector. After completing the initiation phase (18 months of SC or IV dosing), patients transition to maintenance dosing at 360 mg SC once weekly. The evidentiary basis: sub-studies within the Phase 3 Clarity AD long-term extension (LTE) demonstrating that once-weekly SC administration achieves pharmacokinetic exposure equivalent to the approved biweekly IV regimen, with similar clinical and biomarker (amyloid removal) benefits. ARIA-E (amyloid-related imaging abnormalities, edema type) rates with SC administration are expected to be comparable to IV. The underlying efficacy data: the Phase 3 Clarity AD trial (n=1,795, 18 months, double-blind, randomized, placebo-controlled) showed 27% slowing of clinical decline on CDR-SB versus placebo (treatment difference minus 0.45; 95% CI minus 0.67 to minus 0.23; p=0.00005). All key secondary endpoints met. Four-year open-label extension data shows the benefit deepening over time: CDR-SB benefit versus ADNI-matched controls grew from 0.52 points at 18 months to 1.01 at 36 months and 1.75 at 48 months. Real-world data from the LEADER study (AAIC 2026, July 2026): over 75% of early AD patients remained stable and nearly 7% improved over an average of 17 months of lecanemab treatment in clinical practice. U.S. commercial launch of Leqembi Iqlik as initiation dose: planned for late August 2026. Leqembi is currently approved in 53 countries. Leqembi Iqlik is the first and only anti-amyloid treatment in the world to offer at-home dosing from the beginning of treatment through maintenance.

Alzheimer’s disease affects approximately 7 million Americans today and is projected to affect nearly 13 million by 2050. It is the only disease in the top 10 causes of death in the United States without a therapy that prevents it, stops it, or reverses it. The disease modifies everything, the person living with it, the family surrounding them, the daily structure of home life, the ability to work, to drive, to recognize the people who matter most.

The January 2023 accelerated approval and July 2023 full traditional approval of Leqembi (lecanemab-irmb, Eisai/Biogen) represented the first time a drug had demonstrated statistically significant, clinically meaningful slowing of Alzheimer’s disease progression in a Phase 3 trial with sufficient safety profile to support full approval. The Phase 3 Clarity AD data were not a marginal finding: 27% slowing of clinical decline measured by the CDR-SB, beginning as early as 6 months of treatment, growing over time, sustained through four years of open-label extension. This was not the drug that reverses Alzheimer’s disease. But it was proof, for the first time in the disease’s clinical history, that the underlying biological process could be meaningfully slowed.

What it was not, until now, was accessible in the most practical sense. Every lecanemab dose required a biweekly trip to an infusion center. For a patient with mild cognitive impairment or mild Alzheimer’s dementia, managing regular clinic visits was manageable. Over time, as disease progresses, or for patients in rural areas, or for those whose caregiver situation makes regular infusion center visits logistically difficult, this requirement becomes an accumulating burden. And the infusion reactions that occurred in 26% of IV-treated patients in Clarity AD added another layer of clinical management to every visit.

Leqembi Iqlik’s July 13, 2026 approval as an initiation-dose subcutaneous treatment removes that burden from the first dose. A 15-second subcutaneous injection at home replaces a biweekly infusion clinic visit. For patients who want it, and for whom home administration is appropriate, the treatment that slows Alzheimer’s disease is now something that can happen at the kitchen table rather than in a healthcare facility. That is not a trivial change.

What Alzheimer’s Disease Is and Why the Disease Stage Matters

Alzheimer’s disease is a progressive neurodegenerative disease and the most common cause of dementia. It is characterized pathologically by the accumulation of amyloid beta plaques and neurofibrillary tangles of tau protein in the brain, beginning years or decades before clinical symptoms appear, and progressing through stages of cognitive impairment that ultimately result in the inability to perform basic daily functions.

The disease is understood to follow a continuum:

Preclinical Alzheimer’s disease: Amyloid accumulation detectable by PET scan or CSF analysis but no cognitive symptoms. This is the earliest detectable stage, before the disease has clinically manifested.

Mild cognitive impairment (MCI) due to Alzheimer’s disease: Subtle but measurable cognitive changes, below the threshold for dementia, with confirmed amyloid pathology. Activities of daily living are largely preserved. Patients may notice memory lapses, word-finding difficulties, or difficulty with complex planning, but remain independent.

Mild Alzheimer’s dementia: Cognitive impairment that interferes with daily functioning, though patients retain significant independence. This is the stage at which symptoms are first clearly apparent to family members and often when a diagnosis is formally established.

Leqembi (and Leqembi Iqlik) is approved for early Alzheimer’s disease, which encompasses both MCI due to Alzheimer’s and mild Alzheimer’s dementia. The approval requires confirmation of amyloid pathology before initiating treatment, either by amyloid PET scan or CSF analysis showing abnormal amyloid levels. This confirmation is not optional: lecanemab’s mechanism of action is directed at amyloid, and the clinical evidence was generated exclusively in amyloid-confirmed patients. Treating without confirmed amyloid would be treating without evidence that the drug’s target is present.

The restriction to early stages is biologically appropriate and clinically important. The disease-modifying mechanism of lecanemab addresses the amyloid pathology that drives neurodegeneration. By the time a patient reaches moderate or severe dementia, the downstream consequences of amyloid accumulation, significant neuronal loss, synapse loss, and tau tangle burden, are already extensive. Clearing amyloid at that stage provides less opportunity for clinical benefit. The window for anti-amyloid therapy is earlier, before irreversible neuronal damage has accumulated.

The Amyloid Hypothesis and How Lecanemab Works

Amyloid beta is a small peptide generated by cleavage of the amyloid precursor protein (APP) by beta-secretase and gamma-secretase enzymes. In normal aging, amyloid beta is produced and cleared in balance. In Alzheimer’s disease, this balance is disrupted: amyloid beta accumulates, misfolds, and aggregates into progressively larger and more toxic forms, from monomers to oligomers to protofibrils and eventually to the insoluble fibrillar plaques that appear in the brains of patients with the disease.

The amyloid cascade hypothesis holds that this accumulation is not merely a biomarker of Alzheimer’s disease but a key early driver of the downstream pathological cascade, including tau phosphorylation, neuroinflammation, synaptic dysfunction, and neuronal death. The hypothesis has generated decades of scientific debate, and the failures of numerous amyloid-targeting drugs in clinical trials have repeatedly raised questions about its validity. The Clarity AD results, showing that clearing amyloid produces measurable slowing of clinical decline, provide the strongest clinical evidence to date that the hypothesis is at least partially correct in the early disease setting.

Lecanemab is a humanized IgG1 monoclonal antibody that targets aggregated forms of amyloid beta, with particularly high affinity for soluble amyloid protofibrils, which are thought to be among the most neurotoxic forms of the protein. The binding specificity for aggregated amyloid (protofibrils and fibrils) rather than monomeric amyloid is a key pharmacological feature. By engaging the aggregated forms most associated with toxicity, lecanemab is thought to clear them through several mechanisms: direct antibody-mediated dissolution of aggregates, Fc-receptor-mediated microglial phagocytosis of opsonized amyloid complexes, and inhibition of further fibril formation.

The pharmacodynamic evidence from Clarity AD confirms robust amyloid clearance: patients treated with lecanemab showed near-complete clearance of amyloid from PET-measurable brain regions by 18 months. This amyloid removal from the brain, measured in centiloids on PET imaging, was one of the key secondary endpoints and showed highly statistically significant differences versus placebo across all brain regions examined.

How Leqembi Iqlik Is Different: The Subcutaneous Formulation Story

The development of a subcutaneous formulation for lecanemab required solving a pharmaceutical challenge that applies to all large monoclonal antibodies: how to deliver an effective therapeutic dose through the skin, where the absorption rate and volume limitations differ substantially from intravenous administration.

The approved SC formulation uses a concentrated lecanemab solution delivered via pre-filled autoinjector at 500 mg per 2 mL injection volume for initiation dosing (two 250 mg autoinjectors per dose) and 360 mg for maintenance. The formulation does not include hyaluronidase, unlike the SC pembrolizumab formulation (Keytruda Qlex) discussed in a previous HED post. Lecanemab’s SC delivery achieves pharmacokinetically equivalent exposure to IV dosing through the concentration and volume of the SC formulation itself, without enzymatic disruption of the subcutaneous matrix.

The pharmacokinetic equivalence to IV was demonstrated through sub-studies in the Clarity AD long-term extension (LTE). These studies evaluated multiple SC dosing regimens and established that once-weekly SC administration produces area under the curve (AUC) and steady-state trough concentrations equivalent to the approved biweekly IV regimen of 10 mg/kg. The amyloid removal on PET imaging in LTE participants who switched from IV to SC maintenance dosing was maintained, providing biomarker evidence that the SC route produces clinically equivalent amyloid clearance.

The autoinjector device is designed for patient or caregiver self-administration. Each injection delivers the dose in approximately 15 seconds. For the 500 mg initiation dose, two injections are given simultaneously or in close sequence at each weekly dosing occasion. Injection sites include the abdomen and thigh.

The most significant clinical implication of the SC initiation approval is the elimination of infusion reactions as a clinical concern at treatment start. In Clarity AD with IV dosing, infusion reactions occurred in 26.4% of lecanemab-treated patients, concentrated in the first dose (75% occurred on day 1). These reactions, predominantly mild to moderate, required premedication protocols, monitoring time, and occasional infusion rate modifications. The SC route eliminates infusion reactions from the ARIA and infusion management framework.

The Clarity AD Evidence Base: What the Foundational Trial Data Shows

The efficacy and safety of lecanemab rest on Phase 3 Clarity AD (NCT03887455), the pivotal global randomized trial that supported full traditional FDA approval in July 2023 and all subsequent regulatory approvals globally.

Clarity AD design and population

Clarity AD enrolled 1,795 adults aged 50 to 90 years with confirmed amyloid pathology (by PET or CSF) and clinical diagnosis of either MCI due to Alzheimer’s disease or mild Alzheimer’s dementia. Baseline CDR-SB score indicated early disease (mean approximately 3.2 on a 0 to 18 scale). Patients were randomized 1:1 to lecanemab 10 mg/kg IV every 2 weeks or placebo for 18 months. 95% of completers enrolled in the open-label extension.

Primary and key secondary endpoints at 18 months

Endpoint	Lecanemab	Placebo	Result
CDR-SB change from baseline (primary)	1.21	1.66	Difference minus 0.45 (95% CI minus 0.67 to minus 0.23); p=0.00005; 27% slowing
Amyloid PET (centiloids, key secondary)	Near-complete clearance	Accumulation	p less than 0.001
ADAS-Cog14 (key secondary)	Less decline	More decline	p less than 0.001
ADCOMS (key secondary)	Less decline	More decline	p less than 0.001
ADCS-MCI-ADL (key secondary)	Less decline	More decline	p less than 0.001
Earliest significant CDR-SB separation	6 months	—	p less than 0.01

Source: van Dyck CH et al. Lecanemab in Early Alzheimer’s Disease. NEJM. 2023;388(1):9-21. doi:10.1056/NEJMoa2212948.

The 27% slowing of clinical decline is measured on the CDR-SB, the Clinical Dementia Rating Sum of Boxes, a clinician-administered scale assessing six domains: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated 0 to 3 and the scores are summed for a total of 0 to 18. A lower score reflects better function. The treatment difference of 0.45 points at 18 months, on a scale where a change from 0.5 to 1 in any domain reflects a meaningful shift in independence, represents measurable preservation of function across the early disease population.

Long-term open-label extension data: the benefit deepens

The Clarity AD OLE, with four years of data, shows the clinical benefit of sustained lecanemab treatment growing over time compared to a matched control cohort from the Alzheimer’s Disease Neuroimaging Initiative (ADNI):

Timepoint	CDR-SB benefit versus ADNI-matched controls
18 months (end of core study)	0.52 points
36 months (18 months of OLE)	1.01 points
48 months (30 months of OLE)	1.75 points

Source: Clarity AD OLE 48-month data. PMC12725329.

This growing absolute benefit over time is consistent with the hypothesis that early removal of amyloid pathology interrupts the downstream disease cascade in a way that produces compounding benefit: the longer treatment continues, the more neurological damage is prevented compared to the untreated trajectory.

The OLE data also showed that 95% of Clarity AD completers chose to enroll in the open-label extension, a patient choice rate that reflects the acceptability of continued treatment and confidence in the drug’s benefit profile among both patients and their treating physicians.

LEADER real-world data: the clinical practice picture

The LEADER study, Leqembi’s real-world evidence program, presented data at the Alzheimer’s Association International Conference (AAIC) in July 2026 showing that in clinical practice:

Over 75% of early Alzheimer’s patients enrolled in the study remained stable and nearly 7% improved over an average of 17 months of treatment. Eisai

This real-world data is complementary to the controlled trial results and addresses the question of whether the Clarity AD findings translate to the broader clinical population. The stability rate in clinical practice, in patients selected by treating physicians rather than a research protocol, provides some reassurance that the trial results are not artifactual of a highly selected trial population.

The Leqembi Iqlik Dosing Framework: What the Full SC Schedule Looks Like

The approval of SC initiation dosing creates a complete at-home treatment pathway for the first time:

Phase	Formulation	Dose	Frequency	Duration	Setting
Initiation (SC)	Leqembi Iqlik	500 mg (two 250 mg injections)	Once weekly	18 months	Home (patient or caregiver)
Initiation (IV alternative)	Leqembi	10 mg/kg	Every 2 weeks	18 months	Infusion center
Maintenance (SC)	Leqembi Iqlik	360 mg	Once weekly	Ongoing	Home (patient or caregiver)

Patients and physicians can choose between the SC and IV initiation routes. The clinical data support equivalent efficacy and biomarker outcomes for both routes; the choice is a shared decision based on patient preference, caregiver capacity, infusion center access, and the individual clinical context.

For patients who initiate with IV and want to transition to SC maintenance, the August 2025 maintenance approval supports that pathway. For patients who prefer to start at home from dose one, the July 2026 initiation approval enables that pathway. The result is flexibility that was not available at any point in the drug’s first three years of commercial availability.

Safety: What Patients, Caregivers, and Prescribers Need to Understand

The safety considerations for lecanemab center on ARIA (amyloid-related imaging abnormalities), which are an on-target effect of anti-amyloid antibody therapy reflecting the vascular and parenchymal response to amyloid removal from the brain.

ARIA: what it is and how it is managed

ARIA occurs in two forms. ARIA-E involves cerebral edema or sulcal effusion visible on FLAIR MRI sequences, reflecting blood-brain barrier disruption and edema at sites of amyloid clearance. ARIA-H involves cerebral microhemorrhages, superficial siderosis, or macrohemorrhages, reflecting small vascular bleeds associated with amyloid clearance from vessel walls.

In Clarity AD:

ARIA-E: 12.6% (lecanemab) versus 1.7% (placebo). Symptomatic ARIA-E: 2.8% versus 0.0%
ARIA-H: 17.3% (lecanemab) versus 9.0% (placebo). Symptomatic ARIA-H: 0.7% versus 0.2%

The large majority of ARIA events were asymptomatic and detected on protocol MRI monitoring. Symptomatic ARIA events produced headache, confusion, dizziness, or visual disturbances in a minority of those detected radiographically. Most ARIA events resolved spontaneously or with temporary treatment interruption.

ApoE4 carrier status substantially affects ARIA risk: homozygous ApoE4 carriers (approximately 2 to 3% of the population) had ARIA rates approximately 3-fold higher than non-carriers. ApoE4 genotyping before treatment initiation is recommended in the prescribing information to inform the risk-benefit discussion.

ARIA monitoring requirements

MRI monitoring before initiating treatment, before the 5th, 7th, and 14th infusions (at approximately 3, 6, and 12 months with IV dosing), and as clinically indicated is required per the prescribing information. The monitoring schedule for SC initiation dosing aligns with similar timepoints. ARIA detection before it becomes symptomatic allows dose holds to support resolution, which is the primary management approach.

The ARIA context for SC administration

The SC formulation is expected to produce ARIA rates comparable to IV administration, based on the pharmacokinetic equivalence and the established relationship between amyloid clearance (which is equivalent between routes) and ARIA incidence. This does not eliminate ARIA risk; it means the risk profile is similar to what has been established with IV dosing. The elimination of infusion reactions with SC administration improves one aspect of the safety experience without affecting the ARIA monitoring requirements.

Boxed warnings

Leqembi (and Leqembi Iqlik) carries a boxed warning for ARIA, including serious and life-threatening events. Patients on anticoagulants, or with additional risk factors for bleeding, may have higher ARIA-H risk and should be evaluated carefully before initiating treatment. The use of tissue plasminogen activator (tPA) for stroke in lecanemab-treated patients requires careful clinical judgment given the potential for increased hemorrhagic risk in ARIA-affected individuals.

The Meaning of This Approval Beyond the Label

The approval of lecanemab as an at-home self-administered treatment from the first dose is not a minor administrative update to an existing drug. It is a conceptual shift in what disease-modifying Alzheimer’s therapy looks like as a lived experience.

Every other element of Alzheimer’s disease management, the cognitive and behavioral symptoms, the functional decline, the caregiver burden, the loss of independence, happens at home, in daily life. Until this approval, the only disease-modifying therapy available required a patient and caregiver to organize their lives around biweekly clinic visits for infusions that could last several hours. The subcutaneous initiation approval brings the disease-modifying treatment into the same setting where the disease itself is experienced.

For early Alzheimer’s patients who retain sufficient independence and cognitive function to engage meaningfully with their own care, a treatment that can be self-administered at home is one that they can participate in as an active health decision rather than as a healthcare system dependent. That distinction matters to patients, to caregivers, and to the long-term sustainability of treatment adherence.

The LEADER real-world data, showing 75% stability and 7% improvement at an average of 17 months, is the early evidence that this is working outside of trial conditions. It is not definitive; it is not placebo-controlled; but it is a signal from clinical practice that the Clarity AD trial results are not confined to the controlled research environment.

For patients and families living with early Alzheimer’s disease who want to understand whether lecanemab or Leqembi Iqlik may be appropriate: the conversation begins with a neurologist who can evaluate cognitive status, confirm amyloid pathology, assess ApoE4 status, review anticoagulant and other medications, and discuss the specific risk-benefit profile in the context of the individual patient’s disease stage and overall health.

The Alzheimer’s Association (alz.org; 24-hour helpline 1-800-272-3900) and the Alzheimer’s Drug Discovery Foundation maintain current information on treatment options, clinical trials, and caregiver resources.

Sources

FDA approval announcement: FDA approves first at-home starting dose for Alzheimer’s disease treatment. FDA.gov. July 13, 2026.

Eisai and Biogen press release: FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease. GlobeNewswire. July 13, 2026.

Biogen investor news: FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease. investors.biogen.com. July 13, 2026.

BioArctic press release: FDA approves Leqembi Iqlik (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer’s disease. bioarctic.com. July 13, 2026.

Drugs.com approval news: FDA Approves Leqembi Iqlik (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease. drugs.com. July 13, 2026.

Psychiatry Advisor (SC formulation clinical context, home administration framing): Lecanemab SC Starting Regimen Approved for Early Alzheimer Disease. psychiatryadvisor.com. July 2026.

Healio (LEADER real-world data, AAIC 2026 reference): FDA approves subcutaneous Leqembi for initiation. healio.com. July 2026.

Clarity AD primary NEJM publication: van Dyck CH et al. Lecanemab in Early Alzheimer’s Disease. NEJM. 2023;388(1):9-21. doi:10.1056/NEJMoa2212948.

Clarity AD topline press release (Biogen): LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT. investors.biogen.com. September 2022.

Clarity AD full results (Eisai/CTAD 2022): Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity AD Study. eisai.com. November 2022.

Clarity AD OLE 48-month data (PMC): The Lecanemab Clarity AD Open-Label Extension in Early Alzheimer’s Disease: Initial Findings From the 48-Month Analysis. PMC12725329.

Clarity AD OLE 4-year AAIC 2025 data (BioArctic): Latest data presented at AAIC 2025 reinforces lecanemab’s clinical effect. bioarctic.com. July 2025.

SC maintenance approval (August 2025, Biogen): FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing. investors.biogen.com. August 2025.

Amyloid biology in Alzheimer’s disease: Amyloid Beta and Alzheimer’s Disease. PMC7232739.

Leqembi original full FDA approval (July 2023): FDA grants traditional approval to Alzheimer’s disease treatment. FDA.gov.

NIA Alzheimer’s disease overview: Alzheimer’s Disease Fact Sheet. NIA.

Leqembi prescribing information: LEQEMBI (lecanemab-irmb) and LEQEMBI IQLIK Prescribing Information. Eisai Co., Ltd. 2026.

Leqembi approval history: Leqembi FDA Approval History. drugs.com.

Patient resources: Alzheimer’s Association 24-hour helpline: 1-800-272-3900 | Alzheimer’s Drug Discovery Foundation | Eisai Leqembi patient support | BrightFocus Foundation Alzheimer’s resources | ClinicalTrials.gov: search lecanemab

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Leqembi (lecanemab-irmb) and Leqembi Iqlik carry a boxed warning for amyloid-related imaging abnormalities (ARIA), including serious and life-threatening events. Treatment requires confirmation of amyloid pathology before initiating, baseline and periodic MRI monitoring during treatment, and assessment of ApoE4 genotype and anticoagulant use given their effect on ARIA risk. All treatment decisions for early Alzheimer’s disease, including the choice between SC and IV formulations, should be made in close collaboration with a board-certified neurologist or geriatric psychiatrist experienced in Alzheimer’s disease management.

For 25 Years, Cisplatin-Based Chemotherapy Before Bladder Removal Was the Only Regimen Shown to Improve Survival in Muscle-Invasive Bladder Cancer. A New Phase 3 Trial Just Surpassed It.

July 24, 2026

The essentials: On July 10, 2026, the FDA approved Padcev (enfortumab vedotin-ejfv, Astellas Pharma/Pfizer) plus Keytruda (pembrolizumab, Merck) or Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph, Merck) as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility. This is the first platinum-free perioperative regimen approved for all adults with MIBC who are candidates for cystectomy. Two trials supported this combined label coverage. For cisplatin-ineligible patients: Phase 3 KEYNOTE-905/EV-303 (NCT03924895), which supported the November 21, 2025 approval in the cisplatin-ineligible population. pCR 57.1% versus 8.6% (surgery alone; p less than 0.001); statistically significant EFS and OS improvement. For cisplatin-eligible patients: Phase 3 KEYNOTE-B15/EV-304 (NCT04700124), n=808, presented at ASCO GU 2026 and published in JCO, supporting the July 10, 2026 expansion. Primary endpoint: event-free survival (EFS) by BICR. Median EFS: not reached (EV plus pembro) versus 48.5 months (gemcitabine plus cisplatin); HR 0.53 (95% CI 0.41 to 0.70). 47% reduction in risk of an EFS event. pCR: 55.8% versus 32.5%; estimated difference 23.4 percentage points (95% CI 16.7 to 29.8; p less than 0.0001). OS: HR 0.65 (95% CI 0.48 to 0.89; p=0.0029). All three endpoints met. This is the first regimen to beat standard cisplatin-based neoadjuvant chemotherapy in cisplatin-eligible MIBC since platinum-based neoadjuvant therapy was established as standard nearly 25 years ago. The regimen covers the full treatment sequence: 4 cycles of neoadjuvant EV plus pembrolizumab, radical cystectomy with pelvic lymph node dissection, then 5 additional adjuvant cycles of EV plus continued pembrolizumab. Grade 3 or higher adverse events: 75.7% (EV plus pembro) versus 67.2% (gemcitabine plus cisplatin). No new safety signals; consistent with established profile. Key context: approximately half of all MIBC patients are cisplatin-ineligible. The November 2025 approval addressed them. The July 2026 approval addresses the other half, who are eligible for cisplatin but now have a superior platinum-free alternative.

Bladder cancer is the fourth most common cancer in men in the United States and is diagnosed in approximately 84,000 Americans per year. The majority of bladder cancers are non-muscle-invasive at diagnosis and are managed with local resection and intravesical therapy. But when cancer invades the muscular wall of the bladder, the clinical calculus changes fundamentally. Muscle-invasive bladder cancer (MIBC) carries a 5-year overall survival rate of approximately 50 to 60% with optimal treatment, meaning that even with the best available care, roughly half of patients will die of the disease within five years.

For nearly 25 years, the best available care in the neoadjuvant setting meant one thing: cisplatin-based chemotherapy before surgery. The combination of gemcitabine plus cisplatin administered before radical cystectomy produces pathologic complete response (pCR, meaning no residual tumor at surgery) in approximately 30 to 40% of patients and improves survival compared to surgery alone. That survival benefit, established in meta-analyses and multiple randomized trials, made neoadjuvant cisplatin the standard of care and kept it there for more than two decades.

The problem: approximately half of patients with MIBC cannot receive cisplatin. Kidney function decline, hearing loss, neuropathy, and performance status limitations all contribute to cisplatin ineligibility in a patient population that skews older and commonly has significant comorbidities. For these patients, surgery alone had been the standard, with all the survival disadvantage that comes from not having neoadjuvant systemic therapy.

Padcev (enfortumab vedotin-ejfv) plus Keytruda (pembrolizumab) has now closed both gaps. The November 2025 approval for cisplatin-ineligible patients, based on KEYNOTE-905/EV-303, gave that neglected population their first perioperative systemic therapy option. The July 10, 2026 approval, based on KEYNOTE-B15/EV-304, extends the same regimen to cisplatin-eligible patients, where it did not just match cisplatin but surpassed it: median EFS not reached with EV plus pembrolizumab versus 48.5 months with gemcitabine plus cisplatin, pCR rate 55.8% versus 32.5%, and an overall survival advantage. All three primary and key secondary endpoints met in a 808-patient randomized Phase 3 trial.

As Dr. Matthew Galsky of the Icahn School of Medicine at Mount Sinai, who presented the KEYNOTE-B15 data at ASCO GU 2026, put it: this is a pivotal moment. For the first time since cisplatin-based neoadjuvant therapy was shown to improve outcomes in patients with MIBC almost 25 years ago, a non-platinum-based regimen has surpassed it.

What Muscle-Invasive Bladder Cancer Is and Why Surgery Alone Is Not Enough

Bladder cancer originates in the urothelium, the transitional epithelial lining of the urinary tract. Non-muscle-invasive bladder cancer (stages Ta, T1, and carcinoma in situ) involves only the superficial layers and can be managed with transurethral resection and intravesical agents. Muscle-invasive disease (stage T2 or higher) has penetrated the detrusor muscle of the bladder wall, dramatically increasing metastatic risk and fundamentally changing treatment strategy.

MIBC is staged using the TNM system. Stage T2 invades the inner half of the muscle; T3 extends through the muscle into perivesical fat; T4 invades adjacent structures including the prostate, uterus, or pelvic wall. Lymph node status (N0/N1) is assessed at surgery. All patients with resectable MIBC without distant metastasis are candidates for radical cystectomy with pelvic lymph node dissection as the definitive surgical approach.

Radical cystectomy is curative in approximately 60 to 70% of patients with organ-confined (T2) disease but in only about 25 to 35% of patients with T3 to T4 or node-positive disease. The primary driver of recurrence and death is occult micrometastatic disease that is present but not detectable at the time of surgery. Systemic therapy before surgery (neoadjuvant) attacks this micrometastatic burden while the tumor is still accessible and the patient has not yet undergone the physiological stress of a major operation.

The concept of pathologic complete response is important in MIBC: patients who have no residual tumor at the time of cystectomy (pCR, or ypT0N0) after neoadjuvant therapy have substantially better long-term outcomes than those with residual disease. A pCR rate of 55.8% in KEYNOTE-B15 means that more than half of cisplatin-eligible MIBC patients treated with perioperative EV plus pembrolizumab had no viable tumor left at surgery, compared with approximately 1 in 3 patients on standard cisplatin-based chemotherapy.

What Enfortumab Vedotin Is: The Nectin-4 ADC Mechanism

Enfortumab vedotin-ejfv (Padcev) is an antibody-drug conjugate (ADC) that targets Nectin-4, a cell adhesion molecule that is highly expressed in urothelial carcinoma and in a variety of other cancer types, while having more limited expression in normal adult tissues. This differential expression creates a therapeutic window for tumor-directed drug delivery.

The three components of enfortumab vedotin:

The antibody: anti-Nectin-4. A fully human monoclonal antibody that binds with high affinity to Nectin-4 on the surface of urothelial cancer cells and is internalized through receptor-mediated endocytosis.

The linker: protease-cleavable. A maleimide-based linker that is cleaved by cathepsins in the acidic lysosomal environment of the internalized cell, releasing the cytotoxic payload selectively inside the tumor cell. The linker also allows a bystander killing effect: free payload diffuses from the targeted cell to adjacent cancer cells, even those with lower Nectin-4 expression.

The payload: MMAE (monomethyl auristatin E). A potent microtubule-disrupting agent that binds to tubulin and prevents polymerization, triggering G2/M cell cycle arrest and apoptosis. MMAE is approximately 100 to 1,000 times more potent than conventional chemotherapy on a per-molecule basis, which is why the ADC delivery format can produce activity at relatively low doses compared to systemic MMAE administration.

Nectin-4 is expressed in more than 97% of urothelial carcinomas at moderate to high levels, making it one of the most broadly applicable ADC targets in any solid tumor type. This near-universal expression means that patient selection by Nectin-4 testing is not currently required: essentially all urothelial cancer patients are likely to have Nectin-4-expressing tumors.

The Two-Trial Evidence Base: KEYNOTE-905 and KEYNOTE-B15

The July 10, 2026 approval covers all MIBC patients regardless of cisplatin eligibility, resting on two separate Phase 3 trials that together cover the complete MIBC population.

KEYNOTE-905/EV-303: The cisplatin-ineligible population (November 2025 approval)

KEYNOTE-905/EV-303 (NCT03924895) enrolled 344 patients with MIBC who were ineligible for or declined cisplatin-based chemotherapy, randomized 1:1 to neoadjuvant EV plus pembrolizumab followed by cystectomy followed by adjuvant EV plus pembrolizumab, or immediate cystectomy alone.

Endpoint	EV plus pembrolizumab	Surgery alone	Result
pCR (ypT0N0)	57.1%	8.6%	p less than 0.001
EFS	Statistically significant improvement	Reference	Prespecified threshold met
OS	Statistically significant improvement	Reference	Prespecified threshold met

Source: KEYNOTE-905/EV-303. NCT03924895.

The 57.1% pCR rate in a cisplatin-ineligible population that had no approved perioperative systemic therapy option before this trial was the most striking finding from KEYNOTE-905. The November 2025 FDA approval made EV plus pembrolizumab the first perioperative regimen available to this half of the MIBC population.

KEYNOTE-B15/EV-304: The cisplatin-eligible population (July 2026 approval)

KEYNOTE-B15/EV-304 (NCT04700124) enrolled 808 patients with previously untreated MIBC who were eligible for cisplatin-based therapy and candidates for radical cystectomy with pelvic lymph node dissection. Patients required central pathology and imaging confirmation of clinical stage cT2 to T4aN0M0 or T1 to T4aN1M0 disease. They were randomized 1:1 to:

EV plus pembrolizumab arm (n=405): 4 cycles of neoadjuvant EV 1.25 mg/kg on days 1 and 8 plus pembrolizumab 200 mg on day 1, every 3 weeks, followed by radical cystectomy plus PLND, then 5 additional cycles of adjuvant EV plus 13 additional cycles of adjuvant pembrolizumab (or pembrolizumab dosed 400 mg every 6 weeks for 7 cycles).

Gemcitabine plus cisplatin arm (n=403): 4 cycles of neoadjuvant gemcitabine 1,000 mg/m2 on days 1 and 8 plus cisplatin 70 mg/m2 on day 1, every 3 weeks, followed by radical cystectomy plus PLND, then observation.

The primary endpoint was EFS by blinded independent central review. Key secondary endpoints included pCR by central pathologist review and OS. The data were presented at the 2026 ASCO GU Symposium in San Francisco and published in the Journal of Clinical Oncology.

Endpoint	EV plus pembrolizumab	Gemcitabine plus cisplatin	Result
Median EFS (primary, BICR)	Not reached	48.5 months	HR 0.53 (95% CI 0.41 to 0.70)
EFS risk reduction	47%	Reference	—
pCR rate (ypT0N0)	55.8%	32.5%	Difference 23.4 pp (95% CI 16.7 to 29.8); p less than 0.0001
OS (key secondary)	Improvement	Reference	HR 0.65 (95% CI 0.48 to 0.89); p=0.0029
Grade 3 or higher AEs	75.7%	67.2%	Numerically higher with EV plus pembro

Source: Galsky MD et al. KEYNOTE-B15/EV-304, JCO ASCO 2026 LBA630. doi:10.1200/JCO.2026.44.7_suppl.LBA630. NCT04700124.

The primary endpoint finding of a 47% reduction in EFS risk, with median EFS not yet reached in the EV plus pembrolizumab arm versus 48.5 months in the cisplatin-based chemotherapy arm, is one of the most compelling perioperative oncology datasets in bladder cancer history. The EFS result was statistically significant and clinically substantial, meeting the primary endpoint convincingly.

The pCR data further anchors the magnitude of the benefit: 55.8% of cisplatin-eligible patients treated with EV plus pembrolizumab had no residual viable tumor at cystectomy, compared with 32.5% on standard gemcitabine plus cisplatin. A 23-percentage-point improvement in pCR is a large absolute difference in a surgically curable disease where pCR is strongly associated with long-term disease-free survival.

The OS benefit (HR 0.65, p=0.0029) is particularly significant. Overall survival advantages in the neoadjuvant setting in bladder cancer have historically required large meta-analyses to establish with the available single-trial data. Demonstrating a statistically significant OS advantage in a single 808-patient trial reflects the genuine magnitude of the EV plus pembrolizumab benefit over cisplatin-based standard of care.

The Complete Treatment Sequence: What Perioperative Means in Practice

The approved regimen covers three sequential phases for patients eligible for cystectomy, and understanding the full treatment timeline is essential for patient counseling and multidisciplinary care coordination.

Phase 1 — Neoadjuvant (before surgery), 4 cycles (12 weeks):

Enfortumab vedotin 1.25 mg/kg (maximum 125 mg for patients at or above 100 kg) IV on days 1 and 8 of each 21-day cycle
Pembrolizumab 200 mg IV on day 1 every 3 weeks, or 400 mg IV every 6 weeks; or Keytruda Qlex subcutaneous on corresponding schedule
4 total neoadjuvant cycles

Surgery: Radical cystectomy with pelvic lymph node dissection, performed after completing the 4 neoadjuvant cycles.

Phase 2 — Adjuvant (after surgery), continuation:

Enfortumab vedotin continues for 5 additional cycles (same dosing as neoadjuvant)
Pembrolizumab continues: 200 mg IV every 3 weeks for 13 total adjuvant cycles (approximately 39 weeks), or 400 mg every 6 weeks for 7 adjuvant cycles; or Keytruda Qlex equivalents

The total treatment duration is approximately 12 weeks neoadjuvant plus the adjuvant phase, which extends approximately a year post-surgery for the full pembrolizumab course. This is a longer treatment commitment than neoadjuvant chemotherapy alone (which has no adjuvant component beyond surveillance), and the logistics of 18 months of combined therapy require careful coordination between the medical oncologist, urologic oncologist, and the patient’s support systems.

A notable feature of the EV-304 trial is that 262 of 405 EV-plus-pembrolizumab patients started the adjuvant phase and 208 completed it, reflecting real-world dropout rates from the surgical pathway and treatment tolerance over a prolonged regimen. Understanding that not all patients who start neoadjuvant treatment will complete the full intended adjuvant course is important for setting expectations in clinical practice.

The Cisplatin-Ineligibility Problem This Approval Resolves

Understanding why “regardless of cisplatin eligibility” matters requires understanding why approximately half of MIBC patients cannot receive cisplatin to begin with.

Cisplatin nephrotoxicity is the primary limiting factor. Standard cisplatin eligibility criteria require GFR at or above 50 to 60 mL/min/1.73m2 depending on the institutional protocol. Bladder cancer skews toward older adults and is associated with smoking-related comorbidities including cardiovascular and renal disease; many patients have renal function below this threshold at diagnosis. Other cisplatin eligibility barriers include hearing loss (cisplatin is ototoxic), peripheral neuropathy, Eastern Cooperative Oncology Group performance status of 2 or higher, and New York Heart Association class 3 or 4 heart failure.

Before KEYNOTE-905, cisplatin-ineligible patients with MIBC had no approved perioperative systemic therapy option at all. They went directly to surgery without neoadjuvant treatment, accepting the survival disadvantage that came from operating on disease that neoadjuvant therapy might have downstaged or eliminated. KEYNOTE-905 gave this population their first approved option. KEYNOTE-B15 then went further, demonstrating that even patients who are eligible for cisplatin are better served by the ADC plus checkpoint inhibitor combination.

The combined impact of both trials and both approvals means that MIBC patients in 2026 have a single effective perioperative regimen that is appropriate regardless of their renal function, hearing status, or other cisplatin eligibility criteria. The treatment algorithm has simplified: if a patient is a candidate for cystectomy, EV plus pembrolizumab is an appropriate perioperative treatment. The question of whether they can tolerate cisplatin is no longer the gating question for neoadjuvant therapy access.

Safety: What the KEYNOTE-B15 Profile Shows

The safety profile of EV plus pembrolizumab in KEYNOTE-B15 was consistent with the established safety experience from prior trials, with no new safety signals identified. The grade 3 or higher adverse event rate was 75.7% in the EV plus pembrolizumab arm versus 67.2% in the gemcitabine plus cisplatin arm, a numerically higher rate that requires clinical context.

Enfortumab vedotin’s adverse event profile reflects both the MMAE payload and on-target skin effects from Nectin-4 expression in the epidermis:

Boxed warnings for Padcev (enfortumab vedotin-ejfv):

Skin reactions: Severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported, some with fatal outcomes. Skin reactions are one of the most clinically significant toxicities unique to enfortumab vedotin. Patients should be monitored for new or worsening skin reactions. Grade 3 skin reactions require treatment interruption; Stevens-Johnson syndrome or TEN require permanent discontinuation.

Hyperglycemia: Clinically significant hyperglycemia, including new-onset diabetes and diabetic ketoacidosis, has occurred. Monitor blood glucose before each infusion. Withhold for glucose greater than 250 mg/dL.

Additional warnings and precautions:

Safety item	Details	Clinical guidance
Peripheral neuropathy	Sensory and motor neuropathy from MMAE mechanism; grade 3 or higher in approximately 5 to 10% in trials	Monitor for neuropathy symptoms before each cycle; dose modification for grade 2 or higher
Pneumonitis	Interstitial lung disease reported; potentially fatal	Monitor for respiratory symptoms; grade 2 or higher requires treatment interruption
Ocular toxicity	Dry eye, blurred vision, keratitis	Ophthalmologic evaluation if symptomatic
Embryo-fetal toxicity	MMAE can cause fetal harm	Effective contraception required during treatment and for specified periods after last dose
Pembrolizumab immune-mediated adverse events	Full immune-related AE profile (pneumonitis, colitis, hepatitis, endocrinopathies, nephritis)	Standard pembrolizumab immune-related AE monitoring and management applies

The safety profile across the neoadjuvant and adjuvant EV plus pembrolizumab combination represents the superimposition of the two drugs’ individual toxicity profiles. Oncology teams experienced in managing ADC skin and neuropathy toxicities, and in managing checkpoint inhibitor immune-mediated adverse events, will find the combination manageable with established protocols. Teams less experienced with either drug class may benefit from multidisciplinary support, particularly for severe skin reactions and immune-mediated toxicities.

Padcev’s Complete Indication Picture After July 2026

Indication	Setting	Approval date
Locally advanced or metastatic urothelial cancer (with pembrolizumab)	First-line, cisplatin-ineligible	December 2023
Locally advanced or metastatic urothelial cancer (with pembrolizumab)	First-line, regardless of cisplatin eligibility	April 2024
Locally advanced or metastatic urothelial cancer (monotherapy)	Previously treated with platinum and PD-1/L1 inhibitor	December 2019/2021
MIBC, neoadjuvant plus adjuvant (with pembrolizumab)	Perioperative, cisplatin-ineligible	November 21, 2025
MIBC, neoadjuvant plus adjuvant (with pembrolizumab)	Perioperative, regardless of cisplatin eligibility	July 10, 2026

What This Means for Patients and Multidisciplinary Bladder Cancer Teams

For patients with newly diagnosed MIBC who are candidates for cystectomy

This approval means that for the first time, a single perioperative treatment regimen is appropriate and approved for all MIBC patients regardless of cisplatin eligibility. Patients who were previously told they could not receive chemotherapy before surgery because of kidney function, hearing, or other cisplatin barriers now have an effective neoadjuvant option.

For patients who are cisplatin-eligible, the KEYNOTE-B15 data make a compelling case that EV plus pembrolizumab should be considered as the preferred perioperative approach over gemcitabine plus cisplatin, based on superior EFS, pCR, and OS. Clinical practice changes of this magnitude take time to be incorporated into guidelines and routine care, and the conversation with patients should honestly present the KEYNOTE-B15 data alongside the established cisplatin-based evidence. The higher grade 3 or higher AE rate with EV plus pembrolizumab (75.7% versus 67.2%) and the specific skin and neuropathy toxicity profile are relevant factors for shared decision-making.

For patients whose surgeons and medical oncologists are now coordinating a perioperative regimen: the critical addition to the care pathway is pre-surgical integration of the neoadjuvant cycles, which now include 12 weeks of combination therapy before cystectomy, followed by surgical planning, and then the adjuvant phase. Patients should understand the full duration of treatment commitment before beginning.

For urologic oncologists and medical oncologists

KEYNOTE-B15 establishes EV plus pembrolizumab as a perioperative option that is superior to the standard gemcitabine plus cisplatin regimen in cisplatin-eligible MIBC on all three key endpoints: EFS, pCR, and OS. Dr. Christopher Hoimes of Duke Cancer Institute, a principal investigator for EV-304, described the data as supporting EV plus pembrolizumab as a novel treatment option and potential standard of care for MIBC patients regardless of cisplatin eligibility.

Incorporating this into multidisciplinary tumor board discussions and treatment protocols requires coordination between urology, medical oncology, and supportive care teams, particularly given the skin reaction boxed warning and the monitoring requirements for neuropathy, hyperglycemia, and immune-mediated adverse events. Subspecialty dermatology access and ophthalmology evaluation pathways should be integrated into the perioperative care plan for patients starting EV.

For related HED coverage on bladder cancer and checkpoint inhibitor combination approvals, see our post on Keytruda Qlex receiving its new first-line TNBC indication alongside Trodelvy and our post on Revtorpyk (gedatolisib) becoming the first targeted therapy for PIK3CA wild-type HR+/HER2- breast cancer.

For patients and families navigating a muscle-invasive bladder cancer diagnosis, the Bladder Cancer Advocacy Network (bcan.org; 1-888-901-BCAN) and the American Cancer Society’s Bladder Cancer resource page maintain current treatment information and patient support resources.

Sources

FDA approval announcement: FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer. FDA.gov. July 10, 2026.

Pfizer/Astellas press release: U.S. FDA Approves PADCEV plus Keytruda as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility. Pfizer Inc. July 10, 2026.

Astellas press release: U.S. FDA Approves PADCEV plus Keytruda as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility. newsroom.astellas.com. July 10, 2026.

Drugs.com approval news: U.S. FDA Approves Padcev plus Keytruda or Keytruda Qlex as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility. drugs.com. July 10, 2026.

KEYNOTE-B15/EV-304 JCO ASCO 2026 primary abstract: Galsky MD et al. Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab for participants with MIBC who are eligible for cisplatin: randomized, open-label, phase 3 KEYNOTE-B15 study. JCO ASCO 2026 LBA630. doi:10.1200/JCO.2026.44.7_suppl.LBA630.

KEYNOTE-B15 trial registration: NCT04700124. ClinicalTrials.gov.

OncLive (EFS primary endpoint data, all three endpoints met): Perioperative Enfortumab Vedotin/Pembrolizumab Meets EFS, OS, pCR End Points in Cisplatin-Eligible MIBC. onclive.com. July 2026.

Targeted Oncology (median EFS not reached versus 48.5 months): Enfortumab Vedotin/Pembrolizumab Redefines Neoadjuvant Therapy for MIBC. targetedonc.com. June 2026.

GU Oncology Now (HR 0.53 EFS, Dr. Galsky quote): EV/Pembro Improved EFS, OS in Cisplatin-Eligible MIBC. guoncologynow.com. March 2026.

Cancer Therapy Advisor (pCR 55.8% vs 32.5%, OS HR 0.65 exact data): ASCO GU 2026: Are Combinatorial Therapies the Future Standard of Care in RCC and MIBC? cancertherapyadvisor.com. February 2026.

Urology Times (full trial design detail, Dr. Galsky presentation context): KEYNOTE-B15: EV/pembro sets new benchmark before cystectomy in MIBC. urologytimes.com. 2026.

Pharmacy Times (cisplatin ineligibility context, global MIBC epidemiology): Phase 3 Data Back a New Perioperative Standard for Cisplatin-Eligible Muscle-Invasive Bladder Cancer. pharmacytimes.com. June 2026.

UroToday (Dr. Hoimes investigator quote, Pfizer/Astellas/Merck collaboration context): U.S. FDA Approves PADCEV plus Keytruda as Neoadjuvant and Adjuvant Treatment for MIBC Regardless of Cisplatin Eligibility. urotoday.com. July 2026.

KEYNOTE-905/EV-303 prior approval (November 2025): FDA approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer (cisplatin-ineligible). FDA.gov. November 21, 2025.

KEYNOTE-905 trial registration: NCT03924895. ClinicalTrials.gov.

Bladder cancer overview: Bladder Cancer. StatPearls. NCBI.

Padcev prescribing information: PADCEV (enfortumab vedotin-ejfv) Prescribing Information. Astellas Pharma US, Inc. 2026.

Padcev approval history: Padcev FDA Approval History. drugs.com.

Patient resources: Bladder Cancer Advocacy Network: 1-888-901-BCAN | American Cancer Society Bladder Cancer resources | Pfizer Padcev patient support | ClinicalTrials.gov: search bladder cancer enfortumab

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Padcev (enfortumab vedotin-ejfv) carries a boxed warning for severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis, and for hyperglycemia. The perioperative regimen combining Padcev and Keytruda requires coordinated care across medical oncology and urologic oncology, with monitoring for enfortumab vedotin-specific toxicities and pembrolizumab immune-mediated adverse events. Treatment decisions for muscle-invasive bladder cancer, including the choice of perioperative regimen and surgical approach, should be made through a multidisciplinary team including a urologic oncologist and a medical oncologist experienced in urothelial carcinoma.

Seasonal Allergic Rhinitis in School-Age Children Is One of the Most Undertreated Conditions in Pediatrics. Ryaltris Just Became the First Fixed-Dose Antihistamine-Steroid Nasal Spray Approved for Children as Young as Six.

July 23, 2026

The essentials: On July 7, 2026, the FDA expanded the approval of Ryaltris (olopatadine hydrochloride 665 mcg and mometasone furoate 25 mcg nasal spray, Glenmark Pharmaceuticals) to include children aged 6 to less than 12 years with seasonal allergic rhinitis (SAR). The prior lower age limit was 12 years. Ryaltris is now approved for adults and pediatric patients aged 6 and older, making it the first fixed-dose antihistamine-corticosteroid nasal spray approved for this age group in the United States. What Ryaltris is: a fixed-dose combination (FDC) nasal spray containing olopatadine hydrochloride (an antihistamine, H1 receptor antagonist) at 665 mcg per spray and mometasone furoate (a corticosteroid) at 25 mcg per spray. Two sprays per nostril are used for the adult dose; for children aged 6 to 11, one spray per nostril twice daily is the approved pediatric dose. The two active ingredients address both the histamine-mediated and inflammatory components of SAR simultaneously in a single device. The clinical basis for the age expansion: Phase 3, randomized, double-blind, placebo-controlled trial, n=446, children aged 6 to less than 12 years with seasonal allergic rhinitis. Dosing: one spray in each nostril twice daily for 14 days. Primary endpoint: change from baseline in average AM and PM patient-reported 12-hour reflective Total Nasal Symptom Score (rTNSS) over the 14-day period. Result: statistically significant improvement in average AM and PM rTNSS versus placebo (p=0.001). Trial completion rate: 96.6% (431 of 446 patients). TEAEs: 10.4% (Ryaltris) versus 12.0% (placebo), comparable between arms. Most common TEAEs: dysgeusia 1.3% versus 0.0% placebo; headache 1.3% versus 0.5%; epistaxis 0.9% versus 2.3% (nosebleed rate actually lower with Ryaltris than placebo). The pediatric findings were consistent with the clinical trial experience in the more than 4,000 adults and adolescents studied in the Ryaltris Phase 3 program. Primary publication: Prenner BM et al. Ann Allergy Asthma Immunol. 2022. doi:10.1016/j.anai.2022.07.029. Key safety warnings: potential reduction in pediatric growth velocity with intranasal corticosteroid use; immunosuppression risks (consistent with corticosteroid class); epistaxis; nasal ulceration; septal perforation; hypersensitivity.

Seasonal allergic rhinitis is, by prevalence, one of the most common chronic conditions affecting school-age children in the United States. Estimates consistently place the prevalence at 10 to 15% of children aged 6 to 11 years, with up to 40% of all children affected by some form of allergic rhinitis across their school years. The condition is responsible for missed school days, reduced academic performance, impaired sleep, and daytime fatigue that affects every aspect of a child’s functioning during allergy season. Pediatric allergists and primary care physicians who manage these children have solid options for their older adolescent patients; the treatment toolkit for the 6-to-11 age group has been meaningfully more limited.

The standard treatment approach for pediatric SAR has historically combined a non-sedating antihistamine (oral or intranasal) with an intranasal corticosteroid, each addressing different aspects of the allergic response. This two-medication approach is effective but creates adherence challenges: two devices, two dosing regimens, and for a school-age child managing medications, more complexity than a single product requires.

Ryaltris (Glenmark Pharmaceuticals) was approved in January 2022 as the first fixed-dose combination of an antihistamine (olopatadine) and a corticosteroid (mometasone furoate) in a single nasal spray for SAR. The July 7, 2026 expansion to children aged 6 to 11 is supported by Phase 3 data specifically generated in this population, not extrapolated from adult data, and demonstrates that the same fixed-dose combination approach is effective and well-tolerated at the reduced one-spray-per-nostril pediatric dose.

What Seasonal Allergic Rhinitis Is and Why It Matters in Children

Seasonal allergic rhinitis is an IgE-mediated hypersensitivity response to seasonal aeroallergens, most commonly tree pollen (spring), grass pollen (late spring and summer), and weed pollen including ragweed (late summer and fall). When a sensitized individual inhales these allergens, they bind to IgE antibodies on mast cells in the nasal mucosa. The mast cells degranulate, releasing histamine and other preformed mediators that produce the immediate symptoms of allergic rhinitis: sneezing, nasal itching, rhinorrhea, and watery eyes. A late-phase inflammatory response follows hours later, driven by eosinophils, basophils, and T cells, producing nasal congestion, mucosal edema, and the persistent stuffiness that dominates many patients’ experience of allergy season.

The four nasal symptoms scored in the rTNSS, nasal congestion, rhinorrhea, nasal itching, and sneezing, capture both the histamine-mediated immediate response and the inflammatory late-phase response, which is why a drug that addresses only one pathway (antihistamine only, or corticosteroid only) may not address all four symptoms adequately.

In children aged 6 to 11, SAR is not a minor inconvenience. Studies of SAR’s impact on school-age children consistently document:

Sleep disruption from nighttime nasal congestion, with consequent daytime fatigue and difficulty concentrating. Poor school performance during peak allergy season, with documented effects on standardized testing scores in allergic versus non-allergic children during high-pollen days. Reduced participation in outdoor activities and physical education. Behavioral effects including irritability and reduced quality of life, reported by both children and their caregivers. Comorbidity with asthma, which is more likely to be poorly controlled in children with untreated or undertreated allergic rhinitis, through the unified airway model.

Effective treatment of SAR in this age group is therefore not cosmetic or optional. It has direct implications for academic function, physical activity, sleep, and asthma control.

How Ryaltris Works: The Two-Mechanism Fixed-Dose Combination

Ryaltris addresses SAR through the complementary mechanisms of its two active ingredients, delivered simultaneously in a single nasal spray device.

Olopatadine hydrochloride 665 mcg: the antihistamine component

Olopatadine is a selective, relatively non-sedating H1 receptor antagonist that blocks histamine from binding to H1 receptors on nasal mucosal cells. When histamine is blocked at the H1 receptor, the immediate allergic response, sneezing, nasal itching, and rhinorrhea, is substantially reduced. Olopatadine also has mast cell-stabilizing properties, inhibiting the release of mediators from mast cells and thereby reducing both the immediate and the late-phase components of the allergic response.

Intranasal olopatadine at 665 mcg is a higher dose than what was available in prior intranasal antihistamine products (azelastine, for example, is available at much lower per-spray concentrations but with a distinct pharmacological profile). The 665 mcg dose was selected through the Ryaltris development program to optimize the antihistamine contribution to the fixed-dose combination.

Mometasone furoate 25 mcg: the corticosteroid component

Mometasone furoate is a synthetic corticosteroid with high intranasal activity and very low systemic bioavailability when administered intranasally. Less than 1% of an intranasal mometasone dose reaches the systemic circulation, which is one of the reasons intranasal corticosteroids are considered safe for long-term use in allergic rhinitis at labeled doses.

Corticosteroids reduce allergic inflammation through broad suppression of the inflammatory gene expression cascade: they reduce the production of cytokines, chemokines, and arachidonic acid-derived mediators from eosinophils, mast cells, and T cells in the nasal mucosa. This suppression of the late-phase inflammatory response addresses nasal congestion, a symptom that antihistamines alone do not adequately control, because congestion is driven primarily by inflammatory vasodilation and edema rather than by histamine directly.

Why combining both in one spray is more than convenience

The clinical rationale for fixed-dose combination therapy in SAR is not merely adherence convenience. The two active mechanisms are complementary, not redundant: the antihistamine addresses the immediate histamine-mediated response while the corticosteroid addresses the late-phase inflammatory response. Clinical studies of SAR treatment consistently show that patients on combination antihistamine plus corticosteroid therapy achieve better symptom control than those on either monotherapy, particularly for the congestion symptom that antihistamines address inadequately. The Ryaltris Phase 3 pivotal program in adults and adolescents directly compared Ryaltris to both component monotherapies (olopatadine-only and mometasone-only nasal sprays), demonstrating superiority over each monotherapy.

Delivering both in a single device adds the practical benefit of a simplified regimen. For a school-age child who needs to use a nasal spray twice daily, the difference between one device and two devices is meaningful for adherence and for the practical management of a medication routine across a school day.

The Phase 3 Pediatric Trial: What the Data Shows

Design

The Phase 3 pediatric trial was a randomized, double-blind, placebo-controlled parallel-group study enrolling 446 children aged 6 to less than 12 years with a documented history of seasonal allergic rhinitis and a positive skin prick test to a relevant seasonal allergen. Patients were required to have a nasal symptom score at screening consistent with at least moderate disease. Participants were randomized approximately 1:1 to Ryaltris one spray per nostril twice daily or placebo nasal spray for 14 days.

The primary endpoint was the change from baseline in average morning (AM) and evening (PM) patient-reported 12-hour reflective Total Nasal Symptom Score (rTNSS) over the 14-day treatment period. The rTNSS is the sum of patient-rated severity (0 to 3 scale for each) across four nasal symptoms: nasal congestion, rhinorrhea, nasal itching, and sneezing, for a maximum score of 12. The reflective score captures symptoms over the prior 12 hours, covering the full day’s experience across both AM and PM assessment points.

A pediatric-adapted quality of life questionnaire was used as a secondary endpoint, appropriate for the younger age group.

Results

Endpoint	Ryaltris	Placebo	Result
Primary: mean change from baseline in average AM/PM rTNSS	Statistically significant improvement	Reference	p=0.001
Trial completion rate	—	—	96.6% (431 of 446)
TEAEs	10.4%	12.0%	Comparable; lower rate with Ryaltris
Dysgeusia (taste disturbance)	1.3%	0.0%	Higher with Ryaltris (class effect of olopatadine)
Headache	1.3%	0.5%	Slight numeric difference
Epistaxis (nosebleed)	0.9%	2.3%	Lower with Ryaltris than placebo
Quality of life (secondary)	Positive impact	Reference	Consistent with symptom improvement

Source: Prenner BM et al. Olopatadine/mometasone furoate nasal spray in pediatric patients aged 6 to less than 12 years with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2022. doi:10.1016/j.anai.2022.07.029.

The primary endpoint result (statistically significant rTNSS improvement, p=0.001) confirms that the fixed-dose combination produces meaningful reduction in the four core nasal symptoms in children aged 6 to 11. The effect is described as clinically meaningful and statistically significant, consistent with the language from the adult and adolescent pivotal trials.

The safety profile is notably favorable. The total TEAE rate was actually lower with Ryaltris (10.4%) than with placebo (12.0%), which is unusual and reflects that the active treatment may reduce some symptom-related adverse events (nosebleed rate was 0.9% with Ryaltris versus 2.3% with placebo, likely because better allergen symptom control reduces nasal mucosal trauma from excessive nose-blowing and sneezing). Dysgeusia, the most characteristic adverse effect of intranasal olopatadine from its pharmacological bitter taste profile, occurred in 1.3% of active-treated children, consistent with the known tolerability profile.

The 96.6% trial completion rate in 6-to-11-year-olds over a 14-day double-blind treatment period is also noteworthy: it reflects high acceptability of the nasal spray device and administration regimen in this age group, suggesting the once-or-twice-daily spray routine is practical in pediatric clinical practice.

Dosing: The Pediatric Dose Is Different From the Adult Dose

This distinction is important for prescribing accuracy and for family counseling.

Population	Dose	Frequency	Route
Adults and adolescents aged 12 and older	2 sprays per nostril	Twice daily	Intranasal
Children aged 6 to less than 12	1 spray per nostril	Twice daily	Intranasal

Children aged 6 to 11 receive one spray per nostril (rather than the two-spray adult dose) twice daily. At the 665 mcg/25 mcg per spray concentration, this delivers 665 mcg olopatadine and 25 mcg mometasone furoate per nostril per dose, or a total of 1,330 mcg olopatadine and 50 mcg mometasone per dosing event across both nostrils. The dose differentiation was built into the clinical trial design specifically for the pediatric age group.

Families and prescribers should be clear that a child using a caregiver’s Ryaltris prescription intended for an adult would receive double the labeled pediatric dose. This is a practical counseling point: prescriptions for children in this age group should specify the one-spray-per-nostril dose clearly, and shared medication between family members using different doses should be avoided.

Safety: What Prescribers and Families Need to Know

The Ryaltris safety profile in the pediatric population was consistent with the established adult profile, with the additional pediatric-specific considerations that apply to all intranasal corticosteroid products in children.

Potential reduction in growth velocity: Intranasal corticosteroids, including mometasone furoate, have the potential to reduce growth velocity in pediatric patients. This is a class effect of systemic and topically-absorbed corticosteroids. At the doses used in Ryaltris, intranasal mometasone has very low systemic bioavailability (less than 1%), and long-term studies with mometasone furoate nasal spray at licensed doses have not demonstrated clinically significant effects on growth velocity or hypothalamic-pituitary-adrenal axis function. However, the prescribing information includes a standard precaution to monitor growth in pediatric patients on any intranasal corticosteroid-containing product with prolonged use, and to use the minimum effective dose.

Systemic corticosteroid warnings: The prescribing information carries standard warnings regarding: immunosuppression with possible exacerbation of existing infections (patients with active or latent infections should be monitored); hypercorticism and adrenal suppression with misuse (exceeding recommended doses or using occlusive dressings over intranasal corticosteroids); and hypersensitivity reactions.

Local nasal effects: Epistaxis, nasal ulcerations, septal perforation, and impaired wound healing are warnings for all intranasal corticosteroid products. These are uncommon at standard doses but warrant monitoring, particularly with prolonged use. As noted in the trial data, epistaxis occurred at a lower rate with Ryaltris than with placebo in the pediatric trial (0.9% versus 2.3%), likely reflecting better symptom control rather than any specific protective effect.

Contraindication: Ryaltris is contraindicated in patients with known hypersensitivity to mometasone furoate, olopatadine, or any component of the formulation.

Dysgeusia: The mild bitter taste that some patients experience from intranasal olopatadine (occurring in 1.3% of pediatric trial participants) is a recognized class characteristic of some intranasal antihistamines. It is not harmful, typically brief, and rarely leads to discontinuation. Advising children that a mild taste sensation after nasal spray use is normal can reduce parent anxiety about this symptom.

The Ryaltris Indication Picture After July 2026

Indication	Patient population	Approval date
Seasonal allergic rhinitis	Adults and pediatric patients aged 12 and older	January 13, 2022
Seasonal allergic rhinitis	Children aged 6 to less than 12	July 7, 2026

Where Ryaltris Fits in the Pediatric SAR Treatment Landscape

Seasonal allergic rhinitis in children aged 6 to 11 has several approved treatment options, and understanding where Ryaltris fits requires situating it against the alternatives.

Oral second-generation antihistamines (cetirizine, loratadine, fexofenadine, levocetirizine, desloratadine): approved for children as young as 2 to 6 years depending on the product. Effective for sneezing, itching, and rhinorrhea; less effective for nasal congestion. Convenient (once-daily oral dosing) but do not provide anti-inflammatory coverage for the late-phase response.

Intranasal corticosteroids alone (fluticasone propionate, mometasone furoate, budesonide, triamcinolone acetonide): approved for children as young as 2 to 6 years depending on the product. Effective for all four nasal symptoms including congestion; require 1 to 2 weeks to reach full effect; excellent safety profile with very low systemic bioavailability.

Intranasal antihistamines alone (azelastine, olopatadine): faster onset of action than intranasal corticosteroids; effective for immediate symptoms; the most common adverse effect is dysgeusia.

Fixed-dose combination (Ryaltris): now the first FDC of antihistamine plus corticosteroid approved in a single nasal spray for children aged 6 to 11. Addresses both pathways simultaneously; backed by dedicated pediatric Phase 3 data; one device simplifies the regimen.

For children whose symptoms are mild and who respond adequately to a once-daily oral antihistamine or intranasal corticosteroid monotherapy, there is no clinical imperative to switch to a fixed-dose combination. For children with moderate-to-severe SAR who have inadequate control on monotherapy, or for children starting treatment who are likely to need both antihistamine and corticosteroid coverage, Ryaltris now provides a pediatric-labeled fixed-dose option backed by dedicated trial data in this age group.

Marc Kikuchi, President and Business Head, North America at Glenmark, noted that the approval expands access to Ryaltris for younger children with seasonal allergic rhinitis and allows closer engagement with healthcare professionals and patients as Glenmark assumes direct commercialization of Ryaltris in the United States, which it took over on April 1, 2026.

For related HED coverage on pediatric allergic disease and respiratory treatments, see our post on Skyrizi (risankizumab-rzaa) becoming the first IL-23 inhibitor approved for pediatric plaque psoriasis and psoriatic arthritis in children aged 6 and older and our post on Zoryve (roflumilast) cream 0.3% extending plaque psoriasis treatment to children as young as age 2.

Sources

Glenmark FDA approval press release: Glenmark Receives U.S. FDA Approval to Expand the Use of Ryaltris Nasal Spray for Children Aged 6 to Less Than 12 Years. Glenmark Specialty S.A. July 21, 2026.

Drugs.com approval news: Glenmark Receives U.S. FDA Approval to Expand the Use of Ryaltris Nasal Spray for Children Aged 6 to Less Than 12 Years. drugs.com. July 21, 2026.

HCPLive clinical summary (safety warnings, dosing, FDA expansion date): FDA Approves Ryaltris for Children Aged 6 to 11 With Seasonal Allergic Rhinitis. hcplive.com. July 2026.

Healio (publication reference, Annals of Allergy): FDA expands Ryaltris approval to include children aged 6 to 11 years. healio.com. July 2026.

Medical Dialogues (Marc Kikuchi quote, direct commercialization context): USFDA Approves Expanded Pediatric Use of Glenmark’s RYALTRIS Nasal Spray. medicaldialogues.in. July 2026.

Pulmonology Advisor (rTNSS endpoint, p=0.001, TEAE data, Dr. Rahman quote): Ryaltris Safe, Effective for Pediatric Patients in Seasonal Allergic Rhinitis Trial. pulmonologyadvisor.com.

BioSpace (original Phase 3 pediatric data announcement, primary endpoint result, TEAE rates): Glenmark Pharmaceuticals Announces Results from a Phase 3 Study of Ryaltris in Patients Aged 6 to Under 12 Years. biospace.com. May 8, 2019.

Prenner BM et al. Annals primary publication: Prenner BM et al. Efficacy and safety of olopatadine/mometasone furoate nasal spray in pediatric patients 6 to less than 12 years old with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2022. doi:10.1016/j.anai.2022.07.029.

Canada Regulatory Decision Summary (rTNSS range from adult pivotal trials context): Regulatory Decision Summary for Ryaltris. Health Canada HPFB.

Ryaltris HCP website (adult rTNSS details): About Ryaltris. us.ryaltris.com.

Ryaltris original FDA approval (January 13, 2022): FDA approves Ryaltris (mometasone furoate and olopatadine hydrochloride) nasal spray. FDA.gov.

Ryaltris approval history: Ryaltris FDA Approval History. drugs.com.

Seasonal allergic rhinitis overview: Allergic Rhinitis. StatPearls. NCBI.

Ryaltris prescribing information: RYALTRIS (olopatadine hydrochloride and mometasone furoate) Prescribing Information. Glenmark Pharmaceuticals. 2026.

Patient resources: American Academy of Allergy, Asthma and Immunology: aaaai.org | Asthma and Allergy Foundation of America: aafa.org | Glenmark Ryaltris patient information

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Ryaltris (mometasone furoate and olopatadine hydrochloride) contains an intranasal corticosteroid; pediatric patients on this product should be monitored for growth velocity with long-term use. The pediatric dose (1 spray per nostril twice daily) differs from the adult dose (2 sprays per nostril twice daily) and must be prescribed and communicated accurately. Treatment decisions for seasonal allergic rhinitis in children should be made in consultation with a qualified healthcare provider, such as a board-certified allergist or pediatrician.

Von Willebrand Disease Is the Most Common Inherited Bleeding Disorder in the World. In Young Children With Severe Disease, Prophylactic Treatment Has Lacked Any FDA-Approved Option Until Now.

July 22, 2026

The essentials: On July 2, 2026, the FDA approved expanded use of Wilate (von Willebrand Factor/Coagulation Factor VIII Complex Human, Octapharma) for routine prophylaxis to reduce the frequency of bleeding episodes in pediatric patients with von Willebrand disease (VWD) who are younger than 6 years of age. The prior lower age limit for the prophylaxis indication was 6 years. This makes Wilate the first and only VWF concentrate approved for prophylactic treatment across all ages and all types of VWD, from early childhood through adulthood. What this approval is: a label expansion for an established, approved product adding the under-6 prophylaxis indication. Wilate has been approved since December 2009, with the prophylaxis indication for adults and children aged 6 and older added in December 2023. The July 2, 2026 action fills the youngest pediatric gap. The WIL-33 trial: Phase 3 open-label, multicenter, international trial (NCT04953884), 12 patients, median age 2.0 years (range 1.0 to 5.0), all with severe VWD (VWF:RCo below 20%). VWD types: type 2 (4 patients; 3 type 2A, 1 type 2B); type 3 (8 patients). Dosing: 30 to 50 IU/kg administered intravenously 2 to 3 times per week over 12 months. Primary endpoint: total annualized bleeding rate (TABR) during prophylaxis. Results: mean TABR 4.6 (standard deviation 6.1) in the full analysis set; 2.7 (SD 1.8) in the per-protocol robustness set. Mean spontaneous ABR 0.9 (SD 1.2), indicating very low spontaneous bleeding on prophylaxis. 98.2% of all 56 bleeding episodes during prophylaxis were minor in nature. 95.6% of treated bleeding episodes required only 1 infusion to control. Pharmacokinetics: VWF:RCo half-life 11.7 hours, within expected ranges for this age group. No thrombotic events or FVIII accumulation. ABR comparison across age groups in the prescribing information: 4.6 (younger than 6 years) versus 3.73 (6 to 12 years) versus 4.28 (12 to younger than 17 years), showing consistency across the full pediatric range. The approval fulfills FDA postmarketing requirement number 1 established following the December 2023 prophylaxis approval. This is also the first prospective, dedicated clinical trial of VWF prophylaxis in children under 6 years worldwide: prior to WIL-33, practice guidance for this age group was extrapolated from very small case series and adult data.

Von Willebrand disease is frequently described as the most common inherited bleeding disorder in the world, and the description is accurate. Affecting an estimated 1 in 100 to 1 in 1,000 people depending on the diagnostic threshold used, VWD is far more prevalent than hemophilia. Yet it is substantially less visible in the public discourse, receives less research funding in proportion to its disease burden, and is diagnosed and managed less systematically, particularly at the severe end of the spectrum where the clinical consequences are most significant.

For children with severe VWD, the bleeding risk is real and starts early. Nosebleeds that last hours. Bruising from minor contact. Mucosal bleeding that does not stop without intervention. In VWD type 3, the most severe form, joint bleeds can occur and cause the same progressive joint damage seen in hemophilia. The youngest children face these risks at a time when they are developmentally most active, most prone to minor trauma, and least able to communicate pain or bleeding symptoms to caregivers.

Evidence-based guidelines have recommended prophylactic VWF replacement therapy for patients with severe, frequent bleeds since this approach was demonstrated to reduce bleeding rates substantially in older patients and adults. But until July 2, 2026, pediatric hematologists managing children younger than 6 years with severe VWD had no FDA-approved option for routine prophylaxis. They were extrapolating from older patient data, using off-label approaches, or treating on-demand only: waiting for a bleed to occur before intervening rather than preventing it.

Wilate (Octapharma) is now approved for this purpose. The Phase 3 WIL-33 trial, the first dedicated prospective global trial of VWF prophylaxis specifically in children under 6 years, enrolled 12 children with a median age of 2 years and demonstrated that prophylaxis was safe, well-tolerated, and associated with low bleeding rates across all VWD types. The spontaneous bleeding rate was 0.9 events per year on average, 98.2% of all bleeds during prophylaxis were minor, and no thrombotic events occurred.

What Von Willebrand Disease Is: The Disease and the Protein

Von Willebrand factor (VWF) is a large multimeric glycoprotein produced by endothelial cells and megakaryocytes and stored in Weibel-Palade bodies in the vascular endothelium and in platelet alpha granules. It serves two essential functions in hemostasis. The first is platelet adhesion: when a blood vessel is injured, VWF binds to exposed subendothelial collagen and then captures circulating platelets via the platelet surface receptor GPIb-IX-V, enabling primary platelet plug formation. The second is FVIII stabilization: VWF circulates in the blood as a carrier protein for coagulation factor VIII, protecting it from premature degradation and concentrating it at sites of vascular injury where coagulation is needed.

Von Willebrand disease results from quantitative deficiency or qualitative dysfunction of VWF. The consequences of VWF deficiency are impaired platelet adhesion (reduced primary hemostasis) and reduced FVIII levels (impaired secondary coagulation), together producing a bleeding tendency that ranges from mild to severe.

VWD is classified into three main types:

Type 1 (approximately 60 to 80% of cases): Partial quantitative deficiency of VWF, with structurally normal protein but reduced levels. Typically mild, often not requiring regular treatment.

Type 2 (approximately 15 to 30% of cases): Qualitative abnormality of VWF, with normal or near-normal quantities but dysfunctional protein. Divided into subtypes: type 2A (reduced high-molecular-weight multimers), type 2B (enhanced binding to platelet GPIb, which paradoxically depletes VWF and platelets), type 2M (reduced platelet-dependent function without loss of multimers), and type 2N (reduced binding affinity for FVIII).

Type 3 (approximately 1 to 5% of cases): Severe quantitative deficiency of VWF, with virtual absence of the protein and correspondingly very low FVIII levels. This is the most severe form, producing significant spontaneous mucosal bleeding, joint bleeding, and surgical bleeding risk. The WIL-33 trial enrolled primarily type 3 patients (8 of 12) with 4 type 2 patients, reflecting the clinical priority of treating the highest-risk children.

The clinical features of VWD reflect its primary hemostatic defect: mucosal bleeding is the dominant symptom. Nosebleeds that are prolonged, difficult to control, and recurrent. Gum bleeding. Easy bruising disproportionate to the trauma that caused it. In females with VWD, heavy menstrual bleeding is often the presenting complaint. Gastrointestinal bleeding. Postoperative bleeding. In type 3 and some type 2 subtypes, joint bleeding (hemarthrosis) occurs and can cause the same progressive arthropathy seen in hemophilia A and B.

VWD affects approximately 3.2 million Americans at some level of severity, though most have mild type 1 disease. Approximately 20,000 to 40,000 people in the United States have type 3 or severe type 2 disease requiring regular treatment. The disease occurs across all racial and ethnic groups and affects males and females approximately equally, though females are more often diagnosed because of heavy menstrual bleeding bringing them to medical attention.

Why Prophylaxis Matters: The Case for Prevention Over On-Demand Treatment

The management of severe VWD has historically followed one of two approaches: on-demand treatment, in which VWF-containing product is administered only when a bleeding episode occurs or is anticipated, or prophylactic treatment, in which VWF is administered regularly to maintain hemostatic function and prevent bleeds from occurring in the first place.

The evidence supporting prophylaxis over on-demand treatment in severe VWD is well-established for adults and older children. The prior pivotal trial program for Wilate’s prophylaxis indication (WIL-31, which supported the December 2023 approval for ages 6 and older) showed an 84% reduction in mean total annualized bleeding rate when patients switched from on-demand to prophylactic treatment. This magnitude of benefit is consistent with what has been shown for hemophilia prophylaxis: preventing bleeds prevents the cumulative damage from repeated tissue injury.

For young children specifically, the case for early prophylaxis carries additional weight. Repeated mucosal bleeding events, even minor ones, cause pain, family anxiety, and healthcare utilization from infancy. More significantly, joint bleeding in type 3 VWD begins accumulating damage from the first events, and joint damage in childhood is progressive and irreversible. Starting prophylaxis before a pattern of bleeding-related complications develops, rather than after, is the logical application of the same principle that moved hemophilia management from on-demand to prophylaxis in the 1980s and 1990s.

As Dr. Akshat Jain, MD, MPH, principal investigator of the WIL-33 trial, noted: prior research into prophylactic treatment for VWD has been very limited in this age group. Now there is pharmacokinetic data and clinical evidence to confirm that VWF prophylaxis is safe, effective, and well-tolerated in pediatric patients with VWD, including children younger than 6 years of age.

Why treating VWD under age 6 has been so underdeveloped VWD in young children presents a compound challenge for clinical research. The disease is less visible than hemophilia, receives less funding, and its heterogeneity across types makes population-level study design complex. The youngest children, particularly those under 6, are also the hardest to enroll in clinical trials: they require pediatric-specific pharmacokinetic studies with appropriate dosing, they cannot report symptoms reliably, and their caregivers face significant logistical burdens in trial participation. The WIL-33 trial is, by the account of its investigators, the first prospective, dedicated global clinical trial of VWF prophylaxis specifically in children under 6 years with severe VWD. Previous practice guidance in this age range relied on extrapolation from adult and older pediatric data, small case series, and individual center experience. This evidentiary gap was the basis for the FDA’s postmarketing requirement number 1 established in 2023, requiring Octapharma to conduct and submit WIL-33 data. The July 2, 2026 approval reflects the completion of that commitment.

What Wilate Is: The Product and Its Mechanism

Wilate is a plasma-derived combination product containing von Willebrand factor and coagulation factor VIII, both derived from human plasma and manufactured by Octapharma using a proprietary purification process that includes two dedicated viral inactivation steps (solvent/detergent treatment and dry heat treatment at 100°C for 2 hours) and nanofiltration for pathogen safety.

The combination of VWF and FVIII in a single product reflects the biological relationship between the two proteins. VWF carries FVIII in the circulation and protects it from premature clearance. In VWF-deficient patients, FVIII levels are also reduced (especially in type 3 VWD), because FVIII is rapidly degraded without its VWF carrier. Replacing VWF alone ultimately stabilizes endogenous and exogenous FVIII; replacing both together in a single dose addresses the immediate hemostatic deficiency more completely.

The 1:1 ratio of VWF:RCo to FVIII in Wilate’s formulation is designed to reflect the physiological ratio of these proteins in circulation, providing balanced hemostatic support without excessive FVIII accumulation over time.

The product’s full indication coverage after July 2026

Indication	Patient population	Approval date
On-demand treatment and control of bleeding episodes (VWD)	Adults and pediatric patients, all ages	December 4, 2009
Perioperative management of bleeding (VWD)	Adults and pediatric patients, all ages	August 13, 2015
Routine prophylaxis to reduce frequency of bleeding episodes (VWD)	Adults and pediatric patients aged 6 and older	December 1, 2023
On-demand treatment and control of bleeding episodes (hemophilia A)	Adults and patients aged 12 and older	October 8, 2019
Routine prophylaxis for bleeding episodes (hemophilia A)	Adults and patients aged 12 and older	October 8, 2019
Routine prophylaxis to reduce frequency of bleeding episodes (VWD)	Pediatric patients younger than 6 years	July 2, 2026

The WIL-33 Trial: Full Data

Design

WIL-33 (NCT04953884) was a Phase 3, open-label, prospective, non-controlled, international, multicenter trial evaluating efficacy, pharmacokinetics, immunogenicity, and safety of Wilate prophylaxis in children younger than 6 years with severe VWD, defined as VWF ristocetin cofactor activity (VWF:RCo) below 20%. This is a clinically relevant threshold: VWF:RCo below 20% identifies the most severely affected patients, including virtually all type 3 patients and the most clinically significant type 2 subtypes.

The 12 enrolled patients had a median age of 2.0 years (range 1.0 to 5.0 years), making this a genuinely very young cohort. Eight patients had type 3 VWD and four had type 2 VWD (3 type 2A and 1 type 2B). This distribution reflects the clinical priority: type 3 VWD carries the most severe bleeding risk and the most compelling need for prophylaxis.

Wilate was administered intravenously at 30 to 50 IU/kg, two to three times per week, for 12 months. The primary endpoint was the total annualized bleeding rate (TABR) during prophylaxis, capturing spontaneous, traumatic, and other bleeds occurring between the first prophylactic dose and study completion.

Efficacy results

Endpoint	Full analysis set (n=12)	Per-protocol robustness set (n=9)
Mean total ABR (TABR)	4.6 (SD 6.1)	2.7 (SD 1.8)
Mean TABR, type 2 VWD	2.1 (SD 1.0)	2.0 (SD 1.1)
Mean TABR, type 3 VWD	5.8 (SD 7.2)	3.4 (SD 2.2)
Mean spontaneous ABR	0.9 (SD 1.2)	1.0 (SD 1.3)
Total bleeding episodes during prophylaxis	56	—
Episodes classified as minor	98.2% (55 of 56)	—
Treated bleeding episodes requiring only 1 infusion	95.6% (43 of 45)	—
Median weekly prophylactic dose	100 IU/kg (range 63 to 311, FAS); 92 IU/kg (range 63 to 130, PPR)	—

Source: WIL-33 ASH 2025 abstract. Blood. 2025;146(Supplement 1):4855. NCT04953884.

The primary finding is a mean TABR of 4.6 in the full analysis set, falling to 2.7 in the per-protocol population that excluded patients with dosing deviations. The spontaneous ABR of 0.9 is particularly meaningful: spontaneous bleeds (those occurring without identifiable trauma or provocation) are the most clinically significant bleeding category in VWD, reflecting the adequacy of hemostatic protection during daily life. A mean of fewer than one spontaneous bleed per year in children aged 1 to 5 with severe VWD represents effective prophylactic coverage.

An important contextual note: 22 of the 56 total bleeding episodes (39%) occurred in a single patient whose bleeds were attributed to allergic rhinitis rather than hemostatic failure. Allergic rhinitis causes mucosal inflammation that can trigger or exacerbate nosebleeds in VWD patients even on adequate prophylaxis. When this one patient’s unusual contribution to the total bleed count is considered, the underlying prophylaxis performance across the rest of the cohort is even more favorable.

The per-protocol robustness set (n=9, excluding 3 patients with dosing deviations), with a mean TABR of 2.7 and type 3-specific rate of 3.4, likely represents the most informative dataset for predicting outcomes in a clinical practice setting where adherence to the recommended dosing protocol is achieved.

Pharmacokinetics

The mean VWF:RCo half-life in children under 6 was 11.7 hours, within the expected range established from data in older patients and adults and consistent with the pharmacokinetic modeling used to support the 2 to 3 times weekly dosing schedule. No clinically meaningful differences in pharmacokinetic parameters from older age groups were identified, supporting the extrapolation of the established dosing guidance to this youngest patient population.

Comparison across age groups

One of the most informative elements of the approved prescribing information is the cross-age ABR comparison:

Age group	Total ABR during prophylaxis
Younger than 6 years (WIL-33)	4.6
6 to 12 years (WIL-31 pediatric cohort)	3.73
12 to younger than 17 years (WIL-31 adolescent cohort)	4.28

The consistency of the ABR values across age groups in the pediatric range is clinically reassuring: children under 6 on prophylaxis have bleeding rates comparable to older children on the same treatment. The slightly higher absolute ABR in the youngest group likely reflects their developmental stage (more minor trauma from active play and toddler activity) and the contribution of the single rhinitis patient, rather than a true pharmacodynamic age effect.

Safety

Wilate was well-tolerated in the WIL-33 population. No thrombotic events occurred. No FVIII accumulation was observed, consistent with the physiological 1:1 VWF:FVIII ratio in the product. No inhibitor formation (neutralizing antibodies against VWF or FVIII) was detected in the study period, though inhibitor development remains a potential risk of any VWF-containing product requiring ongoing monitoring.

One patient discontinued prematurely due to adverse events that were not classified as treatment-emergent, and this patient was excluded from the per-protocol analysis set. The specific nature of these events is not described in the available publications.

Safety: What the Prescribing Information Covers

Wilate’s safety profile is well-characterized across its 17-year history of use since 2009, and the warnings applicable to the under-6 prophylaxis indication are consistent with the established class-level risks of plasma-derived VWF/FVIII concentrates.

Hypersensitivity and anaphylaxis: Serious hypersensitivity reactions, including anaphylaxis, can occur with Wilate and with plasma-derived coagulation products generally. Type 2B VWD patients are particularly noted in the prescribing information because VWF infusion can cause platelet aggregation and thrombocytopenia in this subtype through enhanced binding of infused VWF to platelet GPIb. Close monitoring and platelet counts during treatment initiation are recommended for type 2B patients.

Thromboembolic events: Thrombosis has been reported with VWF-containing products, particularly in patients with additional thrombotic risk factors or when products are used at high doses in perioperative settings. No thrombotic events occurred in WIL-33, but monitoring for signs and symptoms of thrombosis remains a prescribing information requirement.

FVIII monitoring: Because Wilate contains FVIII in addition to VWF, plasma FVIII activity should be monitored, particularly during high-dose or prolonged use, to avoid supra-physiological FVIII levels that could increase thrombotic risk. In the WIL-33 pediatric prophylaxis setting at the recommended 30 to 50 IU/kg doses, FVIII accumulation was not observed.

Inhibitor development: Development of neutralizing antibodies (inhibitors) against VWF or FVIII can occur with any plasma-derived or recombinant coagulation factor product, though it is less common with VWF products than with factor concentrates used in hemophilia. Immunogenicity monitoring was conducted in WIL-33 and no inhibitors were detected.

Plasma-derived product risk: As with any product derived from human plasma, despite multiple viral inactivation and reduction steps, the theoretical risk of transmission of blood-borne infectious agents cannot be entirely eliminated. Patients and families should be counseled about this risk, which is considered very low given the manufacturing safeguards.

What This Means for Pediatric Hematologists and Families

For pediatric hematologists

The practical implication of this approval is straightforward: children younger than 6 years with severe VWD (types 2 or 3) who have a documented history of frequent or severe bleeding episodes now have an FDA-approved option for routine prophylaxis. The WIL-33 dosing guidance, 30 to 50 IU/kg administered intravenously 2 to 3 times per week, is consistent with what has been used in older patients and can be initiated under the existing Wilate label without the need for off-label justification.

The small sample size of WIL-33 (n=12) is the most important interpretive limitation. The trial was designed and sized as a dedicated pediatric PK and safety study, not a large-scale efficacy trial. The bleeding rate data support efficacy at a clinical level, but the confidence intervals around the mean TABR are wide given the sample size, and the contribution of one outlier patient to total bleed count is substantial. Clinical practice should incorporate this context when counseling families about expected outcomes.

The cross-age ABR consistency in the prescribing information, showing comparable values across pediatric age groups, is the most practically useful data point for framing treatment expectations: children under 6 on Wilate prophylaxis achieve bleeding control comparable to older children on the same regimen.

For patients with type 2B VWD specifically, the enhanced VWF-platelet interaction that characterizes this subtype warrants careful monitoring during treatment initiation, including platelet counts, consistent with the prescribing information.

For families

If your child is younger than 6 and has been diagnosed with severe VWD (type 2 or type 3) and experiences frequent or significant bleeding episodes, Wilate prophylaxis is now an FDA-approved option. The discussion with your child’s pediatric hematologist about whether prophylaxis is appropriate should include your child’s bleeding history, the frequency and severity of episodes, and whether the venous access and infusion frequency (2 to 3 times weekly by intravenous infusion) are practical given your child’s age and individual circumstances.

For very young children requiring regular IV infusions, central venous access devices (port-a-cath or implanted port) are sometimes considered to facilitate consistent treatment. This is a decision made by the treating hematologist in consultation with the family, weighing the benefits of reliable venous access against the procedural and infection risks of central line placement.

Patient support resources for VWD families include the National Hemophilia Foundation (hemophilia.org; 1-800-42-HANDI), which provides information on both hemophilia and VWD across all ages, and the VWD Connect Foundation, which focuses specifically on the VWD community.

For related HED coverage on rare pediatric hematologic disease and gene therapy, see our post on Casgevy (exagamglogene autotemcel) expanding to patients as young as age 2 with sickle cell disease and transfusion-dependent beta thalassemia and our post on Hympavzi (marstacimab-hncq) becoming available to children aged 6 to 11 and to patients with hemophilia inhibitors.

Sources

Octapharma FDA approval press release: Octapharma USA Announces Expanded FDA Approval of wilate for von Willebrand Disease Prophylaxis in Children Younger Than 6 Years. PRNewswire. July 8, 2026.

BioSpace press release: Octapharma USA Announces Expanded FDA Approval of wilate for von Willebrand Disease Prophylaxis in Children Younger Than 6 Years. biospace.com. July 8, 2026.

Drugs.com approval news: Octapharma USA Announces Expanded FDA Approval of Wilate for von Willebrand Disease Prophylaxis in Children Younger Than 6 Years. drugs.com. July 8, 2026.

BioPharm International (PMR context, safety summary): FDA Approves Expanded Use of Wilate for Von Willebrand Disease Prophylaxis in Children Under Age 6. biopharminternational.com. July 2026.

AJMC (first dedicated prospective trial context, Dr. Jain and Nielsen quotes): FDA Expands Approval for VWD Prophylaxis in Children Younger Than 6. ajmc.com. July 2026.

Hematology Advisor (WIL-33 full data table, ABR breakdown by type, spontaneous ABR): FDA Expands Wilate Approval for VWD Prophylaxis in Children Under 6. hematologyadvisor.com. July 2026.

Hematology Advisor (WIL-33 interim data, first prospective trial): First Prospective Global Trial Demonstrates Benefit of VWF Prophylaxis in Young Children With Severe VWD. hematologyadvisor.com. December 2025.

Pharmacy Times (cross-age ABR comparison data from PI, treated episode infusion data): FDA Expands Wilate Approval for Routine Prophylaxis in Children Younger Than 6 With von Willebrand Disease. pharmacytimes.com. July 2026.

Pharmacally (PMR fulfillment detail): FDA Expands WILATE Prophylaxis Approval to Children Under 6 With von Willebrand Disease. pharmacally.com. July 2026.

Healio (Dr. Kaushal expansion statement): FDA expands Casgevy approval to children 2 years and older with sickle cell disease. healio.com.

WIL-33 ASH 2025 abstract (Blood): Plasma-derived VWF/FVIII prophylaxis in children under 6 with VWD: First results from WIL-33. Blood. 2025;146(Supplement 1):4855. doi:10.1182/blood-2025-219636.

WIL-33 trial registration: NCT04953884. ClinicalTrials.gov.

VWD overview: Von Willebrand Disease. StatPearls. NCBI.

CDC VWD facts: Von Willebrand Disease Data and Statistics. CDC.

Original Wilate FDA approval (December 2009): FDA Approves Wilate, the First Replacement Therapy Developed Specifically for Von Willebrand Disease. Octapharma. December 2009.

Wilate prescribing information: WILATE Prescribing Information. Octapharma. 2026.

Wilate approval history: Wilate FDA Approval History. drugs.com.

Patient resources: National Hemophilia Foundation: 1-800-42-HANDI | VWD Connect Foundation | Octapharma Wilate patient information

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. The WIL-33 trial enrolled 12 patients; the relatively small sample size should be considered when interpreting bleeding rate estimates and their precision. Decisions about initiating routine prophylaxis with Wilate in children younger than 6 years with von Willebrand disease should be made in consultation with a board-certified pediatric hematologist with expertise in bleeding disorders, taking into account the individual child’s VWD type, bleeding history, and the practical considerations of regular intravenous infusion in young children.

The World’s First CRISPR Gene Therapy Was Approved in 2023 for Patients 12 and Older. On July 1, 2026, It Became Available to Children as Young as Age Two. Here Is What That Means.

July 21, 2026

The essentials: On July 1, 2026, the FDA granted supplemental approval to Casgevy (exagamglogene autotemcel, Vertex Pharmaceuticals and CRISPR Therapeutics) for patients aged 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT). The prior lower age limit was 12 years. Casgevy is now the first gene therapy approved for young children with SCD and the first CRISPR-based gene editing therapy to reach patients as young as age 2 in either condition. This expansion makes approximately 5,500 additional children in the United States newly eligible for this one-time therapy. What Casgevy is: an autologous CRISPR/Cas9 genome-edited hematopoietic stem cell-based gene therapy that edits the patient’s own CD34-positive stem cells ex vivo to reactivate fetal hemoglobin (HbF) production. The edited cells are infused back into the patient in a single dose following myeloablative conditioning. Fetal hemoglobin, which does not sickle and is not affected by beta-thalassemia mutations, compensates for the defective adult hemoglobin and prevents the downstream complications of both diseases. The evidence base for the age expansion rests on two distinct evidentiary components: for children aged 5 to younger than 12 years: Phase 3 CLIMB-151 (NCT05329649 for SCD) and Phase 3 CLIMB-141 (for TDT), with clinical trial data presented at EHA 2026 and simultaneously published in the New England Journal of Medicine. CLIMB-151 SCD cohort (ages 5 to 11, n=11 dosed): 100% of patients (8 of 8) with sufficient follow-up achieved VF12 (freedom from VOCs for at least 12 consecutive months); mean VOC-free duration 19.0 months (range 13.2 to 30.1 months). CLIMB-141 TDT cohort (ages 5 to 11, n=15 dosed): 100% of patients (8 of 8) with sufficient follow-up achieved TI12 (transfusion independence for at least 12 consecutive months while maintaining weighted average hemoglobin at or above 9 g/dL); mean transfusion-free duration 23.4 months (range 13.3 to 28.5 months). For children aged 2 to younger than 5 years: approval based on product characteristics and extrapolated clinical study data; CLIMB-141 and CLIMB-151 are ongoing for this youngest cohort. Long-term adult/adolescent data (CLIMB-121/CLIMB-111/CLIMB-131 as of April 2025): SCD: 100% of patients (45 of 45) achieved VF12; mean VOC-free duration 35.3 months (range 12.9 to 67.7 months). TDT: 98.2% of patients (55 of 56) achieved TI12; mean transfusion-free duration 41.4 months (range 13 to 72.3 months). Safety in children ages 5 to 11: consistent with myeloablative conditioning and autologous transplant as established in older patients. Most common grade 3 or 4 non-laboratory adverse reactions: mucositis and febrile neutropenia (SCD and TDT); decreased appetite (TDT). One death in the CLIMB-141 TDT cohort from severe veno-occlusive disease attributed to busulfan conditioning, not to Casgevy.

Sickle cell disease and transfusion-dependent beta thalassemia are diseases that begin damaging the body in early childhood. The sickling crises that define SCD can begin as early as the first year of life. The transfusion burden of TDT typically starts before age two. Organ damage, stroke risk, growth delay, developmental disruption, and the cumulative physical and psychological toll of years of medical management all accumulate from the earliest years onward.

For a one-time curative gene therapy, the question of when to treat matters profoundly. Treating a child at age eight who has already spent years hospitalized with pain crises and organ damage prevents further damage but cannot reverse what has already occurred. Treating a child at age two, before years of disease burden have accumulated, offers the possibility of a genuinely different life trajectory rather than a rescue from an already-damaged one.

When the FDA first approved Casgevy in December 2023 as the world’s first CRISPR-based gene therapy, the lower age limit was 12 years. That was appropriate given the evidence available at the time. But it left the children most vulnerable to early-onset disease complications, those under 12, without access to a therapy that might prevent those complications before they developed.

The July 1, 2026 supplemental approval, expanding Casgevy to patients aged 2 and older, is supported by Phase 3 data in children aged 5 to 11 showing the same complete response rates in SCD and TDT that have been observed in adults and adolescents. In the CLIMB-151 SCD trial, every child with sufficient follow-up was free from vaso-occlusive crises. In CLIMB-141 for TDT, every child with sufficient follow-up achieved transfusion independence. And the long-term data in adults and adolescents continues to show durable fetal hemoglobin expression and disease-free survival approaching six years in some patients.

What Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Are

Sickle cell disease

Sickle cell disease is caused by a point mutation in the HBB gene encoding the beta-globin subunit of hemoglobin. The most common and severe form, sickle cell anemia (HbSS), results from homozygous inheritance of the HbS allele. The abnormal HbS hemoglobin polymerizes when deoxygenated, deforming red blood cells into the rigid, crescent-shaped “sickle” morphology that gives the disease its name.

These sickled cells have a much shorter lifespan than normal red cells (10 to 20 days versus 120 days), causing chronic hemolytic anemia. They are also rigid and adhesive, obstructing blood flow in small vessels and triggering the vaso-occlusive crises (VOCs) that are the hallmark of severe SCD. A vaso-occlusive crisis is a period of intense pain caused by ischemia in the affected tissue. Episodes last hours to days, frequently require hospitalization and opioid analgesia, and represent the leading cause of emergency department visits and hospitalizations for patients with SCD.

The cumulative damage from repeated VOCs is devastating. Strokes occur in approximately 11% of children with SCD before age 20 without preventive treatment. Pulmonary hypertension, kidney disease, avascular necrosis of the joints, chronic pain, and progressive organ failure accumulate over years and decades. Life expectancy, though improved by modern management, is shortened by 20 to 30 years compared to the general population.

Approximately 100,000 Americans are affected by SCD, with the disease disproportionately impacting people of African descent. Approximately 1 in 365 Black Americans is born with SCD. The disease is also prevalent in Hispanic, Mediterranean, Middle Eastern, and South Asian populations. In the U.S., newborn screening detects SCD at birth, meaning the diagnosis is typically established in infancy.

Transfusion-dependent beta thalassemia

Beta thalassemia results from mutations in the HBB gene that reduce or eliminate beta-globin production. In transfusion-dependent beta thalassemia (the most severe form, also called thalassemia major), both copies of the HBB gene are severely affected, resulting in near-total absence of normal adult hemoglobin. Red blood cells are small, fragile, and short-lived. Without intervention, the resulting severe anemia is life-threatening.

The standard treatment for TDT is lifelong regular blood transfusions, typically every 3 to 5 weeks, to maintain hemoglobin levels adequate for normal function. These transfusions come with their own burden: over years and decades, iron accumulates in tissues from transfused red blood cells, causing iron overload that damages the heart, liver, and endocrine organs. Iron chelation therapy is required alongside transfusions to manage this accumulation. The combined burden of regular transfusions, chelation therapy, and monitoring defines the life of a child with TDT from the first years onward.

Approximately 1,000 Americans have TDT, with substantially higher global prevalence in the Mediterranean basin, the Middle East, and South and Southeast Asia.

Why early treatment matters more than it might seem

The case for treating SCD and TDT as early as possible is straightforward. These are not diseases that begin causing harm in adolescence. A child with severe SCD is at risk for stroke from the first years of life. A child with TDT begins accumulating iron overload from the first transfusions. The organ damage that reduces life expectancy and quality of life is cumulative. Every year of exposure to the underlying disease, without disease modification, represents irreversible damage.

The prior lower age limit of 12 years for Casgevy meant that a child diagnosed with SCD at birth would not be eligible for this one-time curative therapy until 12 years of disease burden had accumulated. For a therapy that can potentially eliminate VOCs and transfusion dependence with a single treatment, treating earlier means preventing more cumulative harm.

How CRISPR/Cas9 Gene Editing Works in Casgevy: The Science

Casgevy is the first approved therapeutic use of CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9) technology in humans. Understanding what it does requires understanding why the target it edits matters.

The fetal hemoglobin solution

Adult human hemoglobin consists of two alpha-globin and two beta-globin chains. The beta-globin gene is the site of mutation in both SCD and TDT. During fetal development, the body produces a different form of hemoglobin: fetal hemoglobin (HbF), which uses gamma-globin chains instead of beta-globin. HbF is the oxygen-carrying hemoglobin of the fetus and newborn; it is gradually replaced by adult hemoglobin (HbA) during the first year of life as the gamma-globin genes are switched off.

HbF does not sickle. The alpha-gamma chains of HbF do not polymerize in response to deoxygenation the way HbS chains do. And HbF compensates for absent or deficient beta-globin in TDT, because its gamma-globin chains pair with alpha-globin to form functional hemoglobin molecules. People who retain elevated HbF production into adult life due to a genetic variant called hereditary persistence of fetal hemoglobin (HPFH) are protected from sickle cell disease symptoms even when they carry the HbS allele.

The therapeutic insight behind Casgevy is to reactivate HbF production by editing the gene that normally switches it off. The primary switch for HbF silencing in adult life is a transcriptional repressor called BCL11A. BCL11A binds to an erythroid enhancer region and suppresses gamma-globin gene expression, reducing HbF to the low levels seen in most adults. Deleting or disrupting this BCL11A erythroid enhancer through CRISPR editing allows gamma-globin expression to resume and HbF to accumulate in adult red cells.

The ex vivo editing process

The gene editing in Casgevy does not occur inside the patient. It occurs in the manufacturing laboratory, and the process follows a sequence of steps:

Mobilization and collection: The patient receives growth factor medications (G-CSF and plerixafor) to mobilize hematopoietic stem and progenitor cells (HSPCs) from the bone marrow into the peripheral blood, where they are collected by apheresis.

Ex vivo CRISPR/Cas9 editing: The collected CD34-positive HSPCs are taken to a manufacturing facility where CRISPR/Cas9 components are delivered into the cells. The Cas9 protein, guided by a specifically designed guide RNA, creates a targeted double-strand DNA break at the BCL11A erythroid enhancer sequence. The cells’ natural DNA repair mechanism introduces small insertions or deletions at the cut site, disrupting the enhancer function and relieving BCL11A-mediated HbF repression. The editing is verified for efficiency and safety before the product is released.

Myeloablative conditioning: Before reinfusion, the patient undergoes full myeloablative conditioning, typically high-dose busulfan chemotherapy, to clear the bone marrow and create space for the edited cells to engraft. This conditioning is the primary source of short-term treatment-related toxicity, not the gene editing itself.

Single-dose infusion: The edited cells are returned to the patient in a single intravenous infusion. They travel to the bone marrow, engraft, and begin producing red blood cells expressing high levels of HbF. As the edited cell population expands, HbF levels rise, sickling is prevented, and transfusion requirements fall.

The editing is permanent. Because the modified HSPCs continue to self-renew and produce HbF-expressing red blood cells for life, the effect is lifelong, not temporary. This is why Casgevy is described as a one-time treatment rather than an ongoing therapy.

The Clinical Evidence: What the CLIMB Trials Show

The Casgevy clinical program is called CLIMB (CRISPR Therapeutics and Vertex-authored studies in blood diseases). The evidence base for the July 2026 age expansion comes from two distinct bodies of data.

Adult and adolescent data (ages 12 to 35): the established foundation

The long-term dataset from the pivotal CLIMB-111 (TDT) and CLIMB-121 (SCD) trials, with ongoing follow-up in the CLIMB-131 long-term extension study, provides the most mature evidence base for Casgevy’s durability.

As of April 2025, the most recent data cutoff reported:

SCD (CLIMB-121/CLIMB-131): 100% of patients (45 of 45) achieved VF12, defined as freedom from severe VOCs for at least 12 consecutive months. The mean duration of VOC-free status was 35.3 months (range 12.9 to 67.7 months). The longest-treated patients have now been VOC-free for more than 5 years.

TDT (CLIMB-111/CLIMB-131): 98.2% of patients (55 of 56) achieved TI12, defined as transfusion independence for at least 12 consecutive months while maintaining weighted average hemoglobin at or above 9 g/dL. The mean duration of transfusion independence was 41.4 months (range 13 to 72.3 months). One patient did not achieve TI12 due to disease-related complications unrelated to the gene therapy product.

These durability data, showing sustained HbF expression and disease-free status approaching six years in some adults, are the foundation on which the pediatric expansion rests.

CLIMB-151 (SCD, ages 5 to 11): the primary new evidence

CLIMB-151 (NCT05329649) is an ongoing Phase 3 open-label trial evaluating Casgevy in patients aged 2 to 11 years with SCD and recurrent VOCs. The approval for ages 5 to younger than 12 with SCD was based on data from this trial, as presented at the European Hematology Association Congress in June 2026 and simultaneously published in the New England Journal of Medicine.

Outcome	CLIMB-151 (SCD, ages 5 to 11)
Patients dosed	11
Patients achieving VF12 (sufficient follow-up)	8 of 8 (100%)
All patients free from any VOC after infusion	Yes (0 VOC events across all 11 patients post-infusion)
Mean VOC-free duration among VF12 achievers	19.0 months (range 13.2 to 30.1 months)
Consistency with adult/adolescent profile	Confirmed

Source: CLIMB-151 data, EHA 2026 and NEJM June 2026. NCT05329649.

Every child with sufficient follow-up was free from vaso-occlusive crises for at least a year, and no child experienced any VOC at any point after Casgevy infusion. The complete response rate is consistent with the 100% VF12 rate observed in adults and adolescents, confirming that the mechanism operates as effectively in younger children.

CLIMB-141 (TDT, ages 5 to 11): the TDT pediatric evidence

CLIMB-141 is the parallel trial for TDT in the 2 to 11 age range. The most recent interim data (EHA 2026) enrolled 15 children, of whom 8 had sufficient follow-up to assess TI12.

Outcome	CLIMB-141 (TDT, ages 5 to 11)
Patients dosed	15
Patients achieving TI12 (sufficient follow-up)	8 of 8 (100%)
All TI12 achievers maintained transfusion independence throughout follow-up	Yes
Mean transfusion-free duration among TI12 achievers	23.4 months (range 13.3 to 28.5 months)

Source: CLIMB-141 interim data, EHA 2026 and NEJM June 2026.

Again, the 100% primary endpoint achievement rate in children is consistent with the 98.2% TI12 rate observed in adults and adolescents.

Ages 2 to younger than 5: the extrapolation basis

For the youngest children in the expanded indication (ages 2 to younger than 5), the FDA approved Casgevy based on product characteristics and extrapolated clinical study data, not on completed efficacy data from this specific age group. CLIMB-141 and CLIMB-151 are continuing to enroll and dose children aged 2 to 4, and clinical trial data from this cohort will be forthcoming. The extrapolation approach is appropriate when the biological mechanism is age-independent (the BCL11A enhancer disruption and HbF reactivation operate the same way in a 3-year-old’s stem cells as in a 15-year-old’s), and when pharmacokinetic and safety data support equivalent treatment in the younger age range.

This extrapolation for ages 2 to 4 is the most important interpretive nuance in this approval for clinicians counseling families. The therapy is approved, the mechanism is sound, and the 5-to-11 data strongly support efficacy across the pediatric range. But formal efficacy data specifically in the 2-to-4 age group are not yet available and will emerge from the ongoing trials.

The Treatment Process: What Families Need to Know Before Deciding

The decision to pursue Casgevy is among the most consequential a family of a child with SCD or TDT will face, and it is genuinely complex. This is not a medication taken daily or a treatment given in an outpatient clinic. It is a months-long medical process with significant procedural risks alongside transformative potential.

The treatment timeline

The full Casgevy treatment process, from initial preparation to recovery, typically spans 6 to 12 months and involves the following phases:

Preparation and eligibility evaluation (weeks to months before treatment): Comprehensive baseline assessment including organ function, prior treatment history, infectious disease screening (hepatitis B, hepatitis C, HIV), and confirmation that the patient is clinically stable and appropriate for myeloablative conditioning. Prior hydroxyurea use is required before Casgevy treatment in SCD. Patients cannot have received prior allogeneic HSCT.

Cell collection (mobilization and apheresis): Growth factors are administered to mobilize HSPCs into the bloodstream; cells are then collected by apheresis. Multiple collection sessions may be required.

Manufacturing (4 to 6 months, approximately): The collected cells are shipped to Vertex/CRISPR Therapeutics’ manufacturing facility where CRISPR editing occurs. Quality testing verifies editing efficiency, sterility, and product release criteria. This step takes several months and cannot be accelerated, meaning the timing of the overall process is largely determined by manufacturing.

Myeloablative conditioning: High-dose busulfan is administered to destroy the patient’s existing bone marrow. This is the most medically intense phase of the treatment, requiring inpatient hospitalization and carrying risks including mucositis, febrile neutropenia, veno-occlusive disease of the liver, and other conditioning-related toxicities.

Casgevy infusion: The edited cells are returned as a single intravenous infusion. Engraftment takes several weeks, during which the patient is vulnerable to infection and requires intensive inpatient supportive care.

Recovery and monitoring: Patients are monitored for engraftment, HbF levels, and safety outcomes over months following infusion. All patients are enrolled in CLIMB-131, the 15-year long-term follow-up study, which is a post-marketing commitment to characterize long-term safety including any potential oncogenic risk from the CRISPR editing or lentiviral vector integration (Casgevy uses CRISPR rather than a lentiviral vector, but insertional mutagenesis from off-target editing remains a theoretical risk requiring long-term surveillance).

The risk that requires honest discussion: VOD from busulfan

Among the most clinically significant safety findings in the CLIMB-141 TDT pediatric trial was one death, in a child with TDT who developed severe veno-occlusive disease (VOD) of the liver from busulfan conditioning. This death was attributed to the conditioning regimen rather than to Casgevy itself, and VOD is a known risk of busulfan-based myeloablative conditioning. But the event underscores that the myeloablative conditioning required before Casgevy infusion carries real and serious risks, separate from any risks attributable to the gene editing.

Families and clinicians considering Casgevy for young children must have an explicit discussion about the risks of the conditioning regimen. VOD prophylaxis with ursodiol and careful busulfan pharmacokinetic monitoring (to individualize dosing and reduce over-exposure) are standard at experienced transplant centers and reduce but do not eliminate the risk. The treatment should be undertaken at centers with dedicated expertise in myeloablative conditioning and pediatric hematopoietic stem cell transplantation.

Who Is Newly Eligible: Approximately 5,500 Additional U.S. Children

Vertex estimates that approximately 5,500 additional children in the United States are now eligible for Casgevy following the age expansion. These are children aged 2 to 11 with:

SCD with recurrent VOCs: the indication requires a documented history of recurrent severe vaso-occlusive crises. Specific thresholds (typically at least 2 protocol-defined severe VOCs in the preceding 2 years) apply and are specified in the prescribing information.

Transfusion-dependent beta thalassemia: the indication covers patients requiring regular red blood cell transfusions to maintain adequate hemoglobin for normal function.

Both indications carry additional eligibility requirements including negative hepatitis B, hepatitis C, and HIV screening; no prior allogeneic HSCT; clinical stability appropriate for myeloablative conditioning; and for SCD, prior or documented intolerance to hydroxyurea.

Access and the cost reality

Casgevy carries a list price of approximately $2.2 million per treatment. This is a one-time cost for a one-time treatment, and cost-effectiveness modeling that accounts for avoided hospitalizations, transfusions, chelation therapy, and long-term organ damage supports the economic case for the price at a population level. But the logistics of prior authorization, payer coverage, and access to qualified treatment centers create real-world barriers that do not dissolve because the therapy is clinically compelling.

For families navigating coverage, Vertex’s patient support program and the Sickle Cell Disease Association of America and Cooley’s Anemia Foundation both maintain access resources. Medicaid covers Casgevy in most states for eligible patients, which is significant given the disproportionate enrollment of SCD patients in Medicaid programs.

The therapy is available exclusively at authorized treatment centers. Finding a qualified center experienced in both pediatric stem cell transplantation and gene therapy is a prerequisite for access. Vertex maintains a directory of authorized treatment centers on casgevy.com.

Dr. Megha Kaushal, acting deputy director of the Office of Therapeutic Products at FDA’s Center for Biologics Evaluation and Research, noted that these disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways. The FDA’s approval, she said, provides pediatric patients as young as age 2 with access to a critical additional treatment option.

For related HED coverage on CRISPR gene therapy and rare pediatric blood diseases, see our post on KRESLADI (marnetegragene autotemcel), the first gene therapy for severe Leukocyte Adhesion Deficiency Type I and our coverage of Tregzi, the first precision-engineered cell therapy for allogeneic stem cell transplantation approved for blood cancers.

For families living with SCD or TDT, the Sickle Cell Disease Association of America (sicklecelldisease.org; 1-800-421-8453) and the Thalassemia International Federation maintain current patient resources, treatment center directories, and peer support networks. In the United States, Cooley’s Anemia Foundation (thalassemia.org; 1-800-522-7222) provides comprehensive TDT support.

Sources

FDA supplemental approval announcement: FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease. FDA.gov. July 1, 2026.

Vertex FDA approval press release: Vertex Announces US FDA Approval for Expanded Use of CASGEVY for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia. BusinessWire. July 1, 2026.

Vertex newsroom: Vertex Announces US FDA Approval for Expanded Use of CASGEVY. news.vrtx.com. July 1, 2026.

Drugs.com approval news: Vertex Announces FDA Approval for Expanded Use of Casgevy for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia. drugs.com. July 1, 2026.

CLIMB-151 and CLIMB-141 EHA 2026 and NEJM publication (ages 5 to 11): Vertex Presents New Data on CASGEVY, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress. Vertex/BusinessWire. June 10, 2026.

CLIMB-151 and CLIMB-141 ASH 2025 (ages 5 to 11, first-ever pediatric data): Vertex Presents New Data on CASGEVY, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting. Vertex/BusinessWire. December 6, 2025.

CLIMB-151 trial registration (SCD ages 2 to 11): NCT05329649. ClinicalTrials.gov.

CLIMB-131 long-term follow-up trial registration: NCT04208529. ClinicalTrials.gov.

HCPLive (first CRISPR therapy for ages 2+ context): FDA Expands Exa-Cel Gene Therapy Approval to Children 2 Years and Up With SCD or beta-Thalassemia. hcplive.com. July 2026.

Pharmacy Times (VF12 ages 5 to 11 complete data, busulfan VOD death detail): FDA Expands Casgevy Approval to Children as Young as 2 Years With Sickle Cell Disease or Transfusion-Dependent beta-Thalassemia. pharmacytimes.com. July 2026.

Clinical Advisor and Hematology Advisor (age 2 to 4 extrapolation clarification): Gene Therapy Casgevy Approved for Younger SCD and TDT Patients. clinicaladvisor.com. July 2026.

Healio (Dr. Kaushal FDA quote): FDA expands Casgevy approval to children 2 years and older with sickle cell disease. healio.com. July 2026.

Casgevy original December 2023 FDA approval: FDA approves exagamglogene autotemcel for sickle cell disease. FDA.gov.

CRISPR/Cas9 mechanism overview: CRISPR/Cas9 Gene Editing Technology. PMC6107701.

SCD overview: Sickle Cell Disease. StatPearls. NCBI.

Beta thalassemia overview: Beta Thalassemia. StatPearls. NCBI.

SCD data: CDC Sickle Cell Disease Data.

Casgevy prescribing information: CASGEVY (exagamglogene autotemcel) Prescribing Information. Vertex Pharmaceuticals. 2026.

Casgevy approval history: Casgevy FDA Approval History. drugs.com.

Patient resources: Sickle Cell Disease Association of America: 1-800-421-8453 | Cooley’s Anemia Foundation: 1-800-522-7222 | Thalassemia International Federation | Vertex Casgevy patient support | National Heart, Lung, and Blood Institute: Sickle Cell Disease

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Casgevy (exagamglogene autotemcel) is a complex gene therapy requiring myeloablative conditioning and administration at specialized authorized treatment centers. The approval for children aged 2 to younger than 5 years is based on product characteristics and extrapolated data; direct efficacy data in this youngest cohort are forthcoming from ongoing trials. The treatment carries serious risks including those related to myeloablative conditioning. All decisions about gene therapy for sickle cell disease or transfusion-dependent beta thalassemia must be made in close collaboration with a board-certified hematologist and a center with expertise in pediatric hematopoietic stem cell transplantation and gene therapy.

PCSK9 Inhibitors Have Been Among the Most Effective Cholesterol Drugs Ever Developed. They Have Also Required Injections Every Two to Four Weeks. Lipfendra Is the First One That Is Just a Pill.

July 20, 2026

The essentials: On July 16, 2026, the FDA approved Lipfendra (enlicitide, Merck) 20 mg tablets as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Lipfendra is the first FDA-approved oral PCSK9 inhibitor in history. Every other approved PCSK9 inhibitor is administered by subcutaneous injection (evolocumab/Repatha, alirocumab/Praluent) or intravenous infusion (inclisiran/Leqvio). What enlicitide is: a novel macrocyclic peptide that binds directly to PCSK9 and prevents it from binding to LDL receptors on liver cells, allowing more LDL receptors to remain on the cell surface and remove more LDL-C from the blood. The macrocyclic peptide format is what enables oral bioavailability that conventional peptide PCSK9 inhibitors cannot achieve. Dosing: 20 mg once daily by mouth. No food restriction, no injection, no clinic visit required for administration. The clinical basis: two pivotal Phase 3 trials. CORALreef Lipids (NCT05952856, n=2,912, adults with hypercholesterolemia at elevated ASCVD risk on stable statin therapy): placebo-adjusted LDL-C reduction of 55.8% at week 24 (95% CI minus 60.9 to minus 50.7; p less than 0.001); reduction sustained at 47.6 percentage points versus placebo at week 52. 70.3% of patients achieved LDL-C below 70 mg/dL with at least 50% reduction; 67.5% achieved LDL-C below 55 mg/dL with at least 50% reduction. Broad lipid benefits: non-HDL-C down 53.4 percentage points; apolipoprotein B (ApoB) down 50.3 percentage points; lipoprotein(a) down 28.2 percentage points (median) versus placebo at week 24. CORALreef HeFH (NCT05952869, n=303, adults with HeFH on stable statin therapy): placebo-adjusted LDL-C reduction of 59% at week 24. Mean baseline LDL-C 119 mg/dL. Safety: in CORALreef Lipids, adverse event frequency was similar between enlicitide and placebo. In CORALreef HeFH, the most common adverse reactions occurring at higher frequencies than placebo were diarrhea (7% versus 2%) and dizziness (9% versus 4%). Adherence in both trials: 97% adherence to study intervention; 96% adherence to dosing instructions, among the highest adherence rates reported in any cardiovascular outcomes trial program. The critical unanswered question: cardiovascular outcomes. Does LDL-C lowering with enlicitide reduce heart attacks, strokes, and cardiovascular death? The large CORALreef Outcomes trial (NCT06008756, over 14,500 patients enrolled, projected completion December 2029) will answer this. Without those data, the cardiovascular event reduction benefit is inferred from the class effect of injectable PCSK9 inhibitors rather than directly demonstrated for enlicitide.

The injectable PCSK9 inhibitor story has been one of the most impressive in cardiovascular medicine to treat low-density lipoprotein cholesterol. When evolocumab and alirocumab received FDA approval in 2015, they produced LDL-C reductions in the range of 50 to 60% on top of maximally tolerated statin therapy, far exceeding what any other oral lipid-lowering agent could achieve. The subsequent cardiovascular outcomes trials, FOURIER for evolocumab and ODYSSEY OUTCOMES for alirocumab, confirmed that these LDL reductions translated into meaningful reductions in heart attacks, strokes, and cardiovascular death. The mechanism worked exactly as predicted.

But the drugs required injections. Subcutaneous self-injection every two weeks for evolocumab and alirocumab, or an intravenous infusion every six months for inclisiran. For many of the patients who would benefit most from PCSK9 inhibition, including patients already managing complex medication regimens for established cardiovascular disease, this route-of-administration requirement was the primary reason they were not using the drug. Studies of real-world PCSK9 inhibitor prescribing consistently showed that injection burden, needle anxiety, and the practical difficulty of adding a biologic self-injection routine to an already complex daily regimen contributed to low adoption in eligible populations.

Lipfendra (enlicitide, Merck) is the first oral PCSK9 inhibitor. Not a modified injectable. Not a new small-molecule working through a different mechanism. A once-daily tablet that directly inhibits PCSK9 with the same mechanism as the approved injectables, producing LDL-C reductions of 56 to 59% in Phase 3 trials, and doing so with an adverse event profile that was essentially indistinguishable from placebo in the large general population trial.

The most important limitation is the one that matters most: cardiovascular outcomes data. Whether enlicitide reduces heart attacks and strokes has not yet been established in a completed randomized trial. The LDL-C reduction is real, large, and consistent. Whether it translates into event reduction, as the class effect strongly predicts it should, will be confirmed by CORALreef Outcomes in 2029.

What LDL Cholesterol Is and Why Reducing It Matters

Low-density lipoprotein cholesterol is the primary atherogenic lipoprotein in human blood. LDL particles carry cholesterol from the liver to peripheral tissues, and when LDL-C levels are elevated, excess LDL particles deposit in arterial walls, where they are oxidized and trigger the inflammatory cascade that drives plaque formation. This atherosclerotic process underlies the most common causes of heart attack and stroke, collectively known as atherosclerotic cardiovascular disease (ASCVD).

The relationship between LDL-C and ASCVD risk is one of the most robust dose-response relationships in medicine, established through decades of Mendelian randomization studies, statin trials, and PCSK9 inhibitor outcomes trials. The Cholesterol Treatment Trialists’ Collaboration meta-analysis of over 170,000 participants in statin trials found that each 1 mmol/L (approximately 38.7 mg/dL) reduction in LDL-C reduces the risk of major vascular events by approximately 22%. Lower is better, with no observed threshold at which further LDL-C reduction stops providing benefit.

Current cardiovascular guidelines from the American College of Cardiology and American Heart Association define LDL-C targets based on individual ASCVD risk: below 70 mg/dL for patients with established ASCVD, and below 55 mg/dL for very high-risk patients including those with multiple ASCVD events or ASCVD plus additional high-risk features. Many patients on maximally tolerated statin therapy do not reach these targets, particularly those with familial hypercholesterolemia or those who are statin-intolerant.

What PCSK9 Is and How Inhibiting It Works

PCSK9 (proprotein convertase subtilisin/kexin type 9) is a liver-produced protein that serves as a natural regulator of LDL receptors. LDL receptors sit on the surface of liver cells and capture circulating LDL-C particles, drawing them inside the cell for processing. PCSK9 binds to LDL receptors and directs them to be degraded inside the cell rather than recycled back to the cell surface. When PCSK9 levels are high, fewer LDL receptors are available to clear LDL-C, so blood LDL-C levels rise. When PCSK9 is blocked, more LDL receptors return to the cell surface, LDL-C clearance increases, and blood LDL-C levels fall substantially.

The importance of PCSK9 in LDL-C regulation was first recognized through the discovery of gain-of-function mutations in the PCSK9 gene that cause severe familial hypercholesterolemia, and loss-of-function mutations that produce lifelong LDL-C levels 28% lower than average and a corresponding 88% reduction in coronary heart disease risk over a lifetime. Human genetics established the principle; the therapeutic agents confirmed it at scale.

The approved injectable PCSK9 inhibitors, evolocumab and alirocumab, are large monoclonal antibody proteins that bind to PCSK9 in the bloodstream and prevent it from interacting with LDL receptors. Inclisiran is an RNA interference agent that reduces PCSK9 production in the liver. All three require non-oral administration because of their molecular size or chemistry.

Enlicitide takes a fundamentally different approach at the molecular level, and that difference is what makes oral delivery possible.

What a Macrocyclic Peptide Is and Why It Changes Everything

The challenge with making a PCSK9 inhibitor orally available is the same challenge that has historically prevented oral biologics: large molecules are degraded in the gastrointestinal tract before they can be absorbed into the bloodstream, and even when absorption occurs, the efficiency is too low to achieve therapeutic concentrations.

Enlicitide is a macrocyclic peptide, a specific class of molecules that occupies a chemical space between conventional small molecules and large biologics. Macrocyclic peptides are larger than typical small-molecule drugs but far smaller than monoclonal antibodies. Their defining feature is a cyclic (ring) structure: the ends of the peptide chain are connected to each other, creating a closed loop rather than an open linear chain.

This cyclic architecture is what enables oral bioavailability for a PCSK9 binding agent. The ring structure provides several properties that linear peptides lack:

The cyclic conformation is more rigid and compact, reducing the peptide’s surface area exposure to the digestive enzymes that would otherwise rapidly cleave it. The ring also reduces the number of exposed hydrogen bond donors and acceptors, which improves membrane permeability and allows the molecule to cross intestinal epithelial cells more efficiently. And the specific chemical modifications incorporated into enlicitide’s structure (it is supplied as enlicitide decanoate, meaning a fatty acid ester modification that further improves oral absorption) optimize the pharmacokinetic profile for once-daily dosing.

The result is a molecule that, despite binding the same PCSK9 protein target as the large injectable antibodies, is small enough and chemically stable enough to survive gastric acid, be absorbed through the intestinal wall, and achieve blood concentrations sufficient to meaningfully inhibit PCSK9 activity throughout a 24-hour dosing interval.

As Merck’s president of Research Laboratories, Dr. Dean Y. Li, described it: enlicitide was designed to deliver antibody-like efficacy in the form of a once-daily oral tablet, leveraging macrocyclic peptide technology to achieve what conventional peptide chemistry could not.

The CORALreef Trials: Complete Data

CORALreef Lipids (NCT05952856): The Primary Pivotal Trial

CORALreef Lipids was a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial conducted across 168 sites in 14 countries. It enrolled 2,912 adults aged 18 years and older with hypercholesterolemia and either a history of a major ASCVD event (with LDL-C at or above 55 mg/dL) or intermediate-to-high risk for a first ASCVD event (with LDL-C at or above 70 mg/dL). All patients were required to be on stable lipid-lowering therapy including at least a moderate- or high-intensity statin, or have documented statin intolerance.

Participants were randomized 2:1 to enlicitide 20 mg orally once daily (n=1,942) or placebo (n=970) for 52 weeks. The primary endpoint was mean percent change in LDL-C from baseline at week 24. The primary results were published in the New England Journal of Medicine in 2026.

Endpoint	Enlicitide	Placebo	Difference/result
Mean percent change in LDL-C at week 24 (primary)	Approximately minus 57% from baseline	Approximately minus 1% from baseline	Placebo-adjusted minus 55.8 percentage points (95% CI minus 60.9 to minus 50.7); p less than 0.001
Mean percent change in LDL-C at week 52	Sustained	Sustained	Placebo-adjusted minus 47.6 percentage points; p less than 0.001
Non-HDL-C change at week 24	—	—	Placebo-adjusted minus 53.4 percentage points
ApoB change at week 24	—	—	Placebo-adjusted minus 50.3 percentage points
Lipoprotein(a) change at week 24	—	—	Placebo-adjusted minus 28.2 percentage points (median)
LDL-C below 70 mg/dL plus at least 50% reduction at week 24	70.3%	—	Guideline goal achievement (ACC/AHA secondary prevention target)
LDL-C below 55 mg/dL plus at least 50% reduction at week 24	67.5%	—	Guideline goal achievement (very high risk target)
Treatment adherence	97%	97%	Comparable, exceptionally high

Source: CORALreef Lipids NEJM 2026 publication; Merck press release November 8, 2025.

The 55.8 percentage-point placebo-adjusted LDL-C reduction at 24 weeks is clinically comparable to the LDL-C reductions achieved by injectable PCSK9 inhibitors in their pivotal trials (evolocumab reduced LDL-C by approximately 59% in FOURIER; alirocumab by approximately 62% in ODYSSEY OUTCOMES). Achieving this magnitude of reduction from an oral daily tablet represents a genuine pharmacological advance.

The guideline goal attainment numbers are particularly meaningful. More than two-thirds of patients (67.5%) on enlicitide achieved both LDL-C below 55 mg/dL and at least a 50% reduction from baseline, meeting the most stringent ACC/AHA guideline target for very high-risk patients. This degree of goal attainment is not achievable with statins alone in most high-risk patients and has historically required injectable PCSK9 inhibitors to reach reliably.

The week 52 data (47.6 percentage-point reduction versus placebo) shows some attenuation from the week 24 peak, a common finding in lipid-lowering trials that reflects a combination of regression to the mean and possibly some pharmacokinetic variability over extended follow-up. The reduction remains clinically substantial at one year.

CORALreef HeFH (NCT05952869): The Familial Hypercholesterolemia Trial

CORALreef HeFH was a Phase 3, randomized, double-blind, placebo-controlled trial enrolling 303 adults with heterozygous familial hypercholesterolemia who had a history of or were at risk for major ASCVD events, on stable background statin therapy. Patients were randomized 2:1 to enlicitide 20 mg daily or placebo. The mean baseline LDL-C was 119 mg/dL, reflecting the high residual LDL-C burden that persists in HeFH patients despite maximally tolerated statin therapy.

Endpoint	Result
Placebo-adjusted LDL-C change at week 24 (primary)	Minus 59%
LDL-C change at week 52	Statistically significant (maintained)
Non-HDL-C, ApoB, Lp(a) at week 24	Statistically significant improvements (all secondary endpoints met)
Treatment adherence	97%

The 59% LDL-C reduction in HeFH patients on top of existing statin therapy represents a clinically transformative magnitude of effect for this population. HeFH, caused by loss-of-function mutations in the LDL receptor gene or other genes in the LDL-C clearance pathway, drives markedly elevated LDL-C from birth and substantially increases the lifetime risk of premature ASCVD events. Many HeFH patients cannot achieve guideline-recommended LDL-C targets even on high-intensity statins plus ezetimibe, and have historically required injectable PCSK9 inhibitors to do so. An oral once-daily alternative that produces comparable LDL-C reduction is a meaningful practical advance for this population.

The PCSK9 Inhibitor Landscape After July 2026

Drug	Company	Mechanism	Route	Dosing frequency	LDL-C reduction
Repatha (evolocumab)	Amgen	Anti-PCSK9 monoclonal antibody	SC injection	Every 2 weeks or monthly	Approximately 59%
Praluent (alirocumab)	Sanofi/Regeneron	Anti-PCSK9 monoclonal antibody	SC injection	Every 2 weeks or monthly	Approximately 62%
Leqvio (inclisiran)	Novartis	siRNA targeting PCSK9 mRNA	SC injection (clinician-administered)	Twice yearly	Approximately 50 to 52%
Lipfendra (enlicitide)	Merck	Macrocyclic peptide binding PCSK9	Oral tablet	Once daily	Approximately 56 to 59%

Lipfendra is not more effective than the injectable PCSK9 inhibitors by LDL-C reduction alone. The magnitude of LDL-C lowering is comparable across the class. What Lipfendra provides is route-of-administration convenience that fundamentally changes the accessibility and scalability of PCSK9 inhibition.

The Unanswered Question: Cardiovascular Outcomes

The most important clinical limitation of the July 16, 2026 approval is the one that cannot yet be answered: whether LDL-C reduction with enlicitide translates into fewer heart attacks, strokes, and cardiovascular deaths.

For the injectable PCSK9 inhibitors, this question has been answered:

The FOURIER trial (evolocumab, n=27,564) showed a 15% relative risk reduction in the composite primary endpoint of cardiovascular death, heart attack, stroke, hospitalization for unstable angina, or coronary revascularization (HR 0.85; 95% CI 0.79 to 0.92; p less than 0.001).

The ODYSSEY OUTCOMES trial (alirocumab, n=18,924) showed a 15% relative risk reduction in the primary composite endpoint of death from coronary heart disease, nonfatal heart attack, ischemic stroke, or unstable angina requiring hospitalization (HR 0.85; 95% CI 0.78 to 0.93; p less than 0.001).

Both trials also showed dose-dependent mortality benefits in certain high-risk subgroups with very high baseline LDL-C.

Enlicitide does not have this data yet. The CORALreef Outcomes trial (NCT06008756), with over 14,500 participants enrolled, is the ongoing cardiovascular outcomes study. It has a projected completion date of December 2029. Until those data are available, the cardiovascular event reduction benefit of enlicitide is inferred from the class effect of PCSK9 inhibition and from the known relationship between LDL-C reduction and ASCVD event reduction, both of which are scientifically robust. But they are inferences, not demonstrated outcomes for this specific drug.

As the AJMC noted in coverage of the approval, the degree to which the reduction in LDL cholesterol levels with enlicitide will translate into a reduction in cardiovascular events is being tested in the ongoing CORALreef Outcomes trial, with a projected completion date of December 2029.

For patients and prescribers making treatment decisions now: the LDL-C reduction is established and clinically comparable to the injectable class. The cardiovascular outcomes evidence is pending but scientifically predicted. The FDA’s approval of enlicitide based on LDL-C reduction as the primary efficacy endpoint, while CORALreef Outcomes completes, follows the same standard applied to the injectable PCSK9 inhibitors at their initial approvals.

Safety: What the CORALreef Data Shows

The safety profile of enlicitide in the pivotal trials is one of the most favorable features of the approval. In CORALreef Lipids, the large general population trial, adverse event frequency was essentially identical between enlicitide and placebo. Discontinuation due to adverse events was similar across arms. No class-level safety concern emerged from this 2,912-patient, 52-week dataset.

In CORALreef HeFH, the HeFH-specific trial, two adverse reactions occurred at modestly higher frequencies with enlicitide than placebo:

Diarrhea: 7% (enlicitide) versus 2% (placebo)
Dizziness: 9% (enlicitide) versus 4% (placebo)

Both were predominantly mild in severity, and discontinuation rates due to adverse events were similar between groups despite the higher rate of these events. The mechanism underlying the diarrhea and dizziness signals in the HeFH population but not the general population trial is not fully characterized; it may reflect the smaller sample size of CORALreef HeFH making individual adverse event comparisons more variable, or it may reflect the HeFH population’s distinct disease and comorbidity profile.

No hepatotoxicity signal, no significant renal signal, no immune-mediated adverse events, and no injection site reactions (because there are no injections) were reported. The oral route eliminates the local tolerability issues that affect a proportion of patients on subcutaneous injectable PCSK9 inhibitors.

Key safety information from the Lipfendra prescribing information:

No boxed warning. The prescribing information requires disclosure of the most common adverse reactions occurring at higher rates than placebo (diarrhea and dizziness, from the HeFH trial). The absence of a boxed warning and the favorable adverse event profile in the large general population trial reflect a genuinely clean safety signal across 52 weeks in nearly 3,000 patients.

Embryo-fetal toxicity language is included in the label because all lipid-lowering therapies carry a contraindication in pregnancy due to the theoretical risk from lipid pathway perturbation and the known safety of discontinuing lipid-lowering therapy for the duration of pregnancy in most patients.

What This Means for Patients and Prescribers

For patients with high LDL-C who have not been prescribed a PCSK9 inhibitor

Several well-established barriers have limited PCSK9 inhibitor prescribing despite their efficacy. Insurance prior authorization requirements have been restrictive and time-consuming. Injection anxiety and the practical burden of self-injection have deterred many patients. And in some cases, the specialty pharmacy workflow required for injectable biologics has added friction to prescribing.

Lipfendra is a tablet. It does not require a specialty pharmacy in the same way. It does not require injection training. It can be prescribed by a primary care physician without the same hurdles as a biologic self-injection device. Whether these practical advantages translate into substantially higher PCSK9 inhibitor uptake in eligible patients will depend heavily on formulary placement, prior authorization criteria, and pricing, none of which have been fully established at the time of writing.

For patients already on injectable PCSK9 inhibitors who are satisfied with their treatment and tolerating their regimen well: the LDL-C reduction with enlicitide is comparable but not superior. There is no clinical imperative to switch for efficacy reasons. Patients who have struggled with injections, have injection site reactions, or who have found the biologic self-injection workflow burdensome are candidates for a conversation about switching.

For patients with HeFH

HeFH is a genetic condition affecting approximately 1 in 250 people, yet the majority of affected individuals are undiagnosed, and among those who are diagnosed and treated, many do not reach guideline-recommended LDL-C targets on statins alone. The 59% LDL-C reduction from enlicitide on top of stable statin therapy brings most HeFH patients to within or near guideline targets with a once-daily pill, a meaningful practical change from the every-2-week or monthly self-injection schedule of injectable PCSK9 inhibitors.

For prescribers

The conversation about PCSK9 inhibitor therapy for eligible patients is now different. The oral option removes several of the friction points that have historically limited uptake. The LDL-C reduction magnitude is comparable to the injectable class. The safety profile through 52 weeks is favorable. The cardiovascular outcomes data are pending but the class effect is established.

The CORALreef Outcomes results, expected around 2029, will be one of the most closely watched trials in cardiovascular medicine. If the event reduction mirrors what was seen with evolocumab in FOURIER and alirocumab in ODYSSEY OUTCOMES, the case for wide uptake of oral PCSK9 inhibition will be definitive.

Dr. Ann Marie Navar, a cardiologist at UT Southwestern Medical Center, noted that for the first time, patients have an oral PCSK9 inhibitor for LDL lowering, a significant development for a class that has struggled with adoption despite proven efficacy.

For related HED coverage on cardiovascular risk and lipid management, see our post on Awiqli (insulin icodec-abae), the first once-weekly basal insulin approved for adults with type 2 diabetes and our coverage of the daraxonrasib RASolute 302 data from ASCO 2026 showing a 60% reduction in risk of death in previously treated metastatic pancreatic cancer.

Sources

FDA approval announcement: FDA approves first oral therapy that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) to lower bad cholesterol in adults with high cholesterol. FDA.gov. July 16, 2026.

Merck FDA approval press release: Merck’s Lipfendra (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia. Merck. July 16, 2026.

Drugs.com approval news: FDA Approves Lipfendra (enlicitide) Oral PCSK9 Inhibitor to Reduce LDL-C in Adults with Hypercholesterolemia. drugs.com. July 16, 2026.

AJMC competitive landscape and Dr. Navar quote: FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol. ajmc.com. July 2026.

AJMC CORALreef Lipids detailed data: Oral PCSK9 Inhibitor Enlicitide Lowers LDL by 57% at 24 Weeks. ajmc.com.

Patient Care Online (HeFH baseline LDL-C, adverse reactions): FDA Approves First Oral PCSK9 Inhibitor to Reduce LDL-C in Adults With Hypercholesterolemia. patientcareonline.com. July 2026.

Pharmacy Times (CORALreef Lipids full data, mechanism detail): Enlicitide Meaningfully Lowers LDL-C at 24 Weeks in Patients At Risk for ASCVD Events. pharmacytimes.com.

Biopharma News / AppliedXL (CORALreef design, 2:1 randomization, 168 sites): FDA approves Merck’s oral PCSK9 inhibitor Lipfendra for high cholesterol. appliedxl.com. July 2026.

Merck CORALreef Lipids data press release (November 8, 2025): Merck’s Enlicitide Decanoate Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial. BusinessWire. November 8, 2025.

Merck CORALreef HeFH data press release (November 9, 2025): Merck’s Enlicitide Decanoate Significantly Reduced LDL-C in Adults with HeFH in Phase 3 CORALreef HeFH Trial. Merck. November 9, 2025.

The Cardiology Advisor (macrocyclic peptide mechanism detail): Oral PCSK9 Inhibitor Enlicitide Reduces LDL-C in Adults With Hypercholesterolemia. thecardiologyadvisor.com.

FCS Hematology Oncology Review (goal attainment data detail): CORALreef Lipids data table.

Family Heart Foundation (HeFH patient resources): FDA Approves Merck’s LIPFENDRA as First Once-Daily Oral PCSK9 Inhibitor. familyheart.org. July 2026.

CORALreef Lipids trial registration: NCT05952856. ClinicalTrials.gov.

CORALreef HeFH trial registration: NCT05952869. ClinicalTrials.gov.

CORALreef Outcomes trial registration: NCT06008756. ClinicalTrials.gov.

CORALreef Lipids primary NEJM publication: CORALreef Lipids. New England Journal of Medicine. 2026.

FOURIER cardiovascular outcomes trial (evolocumab): Sabatine MS et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. NEJM. 2017;376(18):1713-1722.

ODYSSEY OUTCOMES trial (alirocumab): Schwartz GG et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. NEJM. 2018;379(22):2097-2107.

PCSK9 biology overview: PCSK9 and LDL Receptor Regulation. PMC9290282.

ACC/AHA Cholesterol Guidelines (LDL targets): Grundy SM et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. JACC. 2019.

LDL-C and ASCVD risk (NHLBI): LDL Cholesterol. NHLBI.

Lipfendra prescribing information: LIPFENDRA (enlicitide) Prescribing Information. Merck Sharp and Dohme LLC. 2026.

Lipfendra approval history: Lipfendra FDA Approval History. drugs.com.

Patient resources: American Heart Association: Know Your Numbers | Family Heart Foundation (HeFH resources) | National Lipid Association | Merck Lipfendra patient support

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Lipfendra (enlicitide) is approved to reduce LDL-C; it has not yet been established in a completed randomized trial that enlicitide reduces cardiovascular events such as heart attacks and strokes. The CORALreef Outcomes cardiovascular trial is ongoing with results expected around 2029. All decisions about lipid-lowering therapy should be made in consultation with a qualified healthcare provider who can evaluate individual ASCVD risk, lipid levels, current medications, and treatment goals.

Sixty Percent of HR+/HER2- Breast Cancer Patients Who Progress on CDK4/6 Inhibitors Have PIK3CA Wild-Type Disease. Until Now, They Had No Approved Targeted Therapy. Revtorpyk Just Changed That.

July 17, 2026

The essentials: On July 14, 2026, the FDA approved Revtorpyk (gedatolisib, Celcuity Inc.) in combination with fulvestrant, with or without palbociclib (Ibrance), for the treatment of adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA mutation (PIK3CA wild-type), following progression on or after at least one line of endocrine therapy in the metastatic setting. Revtorpyk is the first FDA-approved multi-target PI3K/AKT/mTOR (PAM pathway) inhibitor, and the first targeted therapy approved for PIK3CA wild-type HR+/HER2- advanced breast cancer. What “PIK3CA wild-type” means and why it matters: approximately 40% of HR+/HER2- breast cancers carry activating PIK3CA mutations, for which alpelisib (Piqray) is approved. The remaining approximately 60% have PIK3CA wild-type disease, meaning no activating PIK3CA mutation is detected. This larger population has had no approved targeted inhibitor of the PI3K pathway because existing approved agents (alpelisib, inavolisib) require a PIK3CA mutation for indication. Gedatolisib works across both PIK3CA mutant and wild-type disease by targeting the pathway more comprehensively than PI3K-alpha-specific inhibitors. Mechanism: gedatolisib is a potent, pan-PI3K and mTORC1/2 inhibitor that blocks all four class I PI3K isoforms (alpha, beta, delta, gamma) plus both mTOR complexes simultaneously, providing comprehensive PAM pathway suppression that cannot be bypassed through isoform switching or mTOR feedback loops that limit single-target inhibitors. Administration: intravenous infusion over 30 minutes on days 1, 8, and 15 of a 28-day cycle. Lyophilized powder reconstituted before administration. The clinical basis: VIKTORIA-1 Study 1 (NCT05501886), Phase 3, open-label, randomized. PIK3CA wild-type cohort results published in JCO in March 2026. Median PFS: 9.3 months (gedatolisib plus palbociclib plus fulvestrant, triplet) versus 2.0 months (fulvestrant monotherapy); HR 0.24 (95% CI 0.17 to 0.35); p less than 0.001. 76% reduction in risk of progression or death with the triplet. Median PFS: 7.4 months (gedatolisib plus fulvestrant, doublet) versus 2.0 months; HR 0.33 (95% CI 0.24 to 0.48); p less than 0.001. 67% reduction in risk of progression or death with the doublet. ORR: approximately 32% (triplet) and 28.3% (doublet) versus approximately 1% (fulvestrant). Median DOR: 11.4 months (triplet) and 12.0 months (doublet). Regulatory pathway: NDA submitted November 2025 under the Real-Time Oncology Review (RTOR) program; Priority Review granted January 2026; Breakthrough Therapy Designation and Fast Track Designation previously granted. PIK3CA mutant indication: an sNDA for gedatolisib in PIK3CA-mutant HR+/HER2- breast cancer is planned for Q3 2026 submission, based on the PIK3CA-mutant cohort of VIKTORIA-1 (Study 2), presented at ASCO 2026.

HR-positive, HER2-negative breast cancer is the most common subtype of metastatic breast cancer, accounting for approximately 70% of all advanced cases. The treatment landscape has been transformed over the past decade by CDK4/6 inhibitors paired with endocrine therapy, which have extended median survival to several years for many patients. But the disease almost always progresses, and what comes after CDK4/6 inhibitor-based treatment is one of the most actively contested questions in breast oncology.

The PI3K/AKT/mTOR pathway is one of the most important drivers of endocrine resistance in HR+ breast cancer. Activating mutations in PIK3CA, the gene encoding the PI3K alpha catalytic subunit, are present in approximately 40% of HR+/HER2- tumors and lead to constitutive PI3K activation that drives cell proliferation regardless of hormone availability. For this 40%, alpelisib (Piqray) provides an approved PI3K-alpha-specific targeted option.

But 60% of HR+/HER2- breast cancers have PIK3CA wild-type disease. No activating mutation. No approved PI3K-directed targeted therapy. Until July 14, 2026.

Revtorpyk (gedatolisib, Celcuity Inc.) is the first drug approved for this population, and its approval rests on a biological insight that distinguishes it from every prior PI3K inhibitor: the PAM pathway drives endocrine resistance not only when PIK3CA is mutated but across the broader population, and blocking the pathway comprehensively rather than at a single node produces clinical benefit even in the absence of a defining mutation. The Phase 3 VIKTORIA-1 data in PIK3CA wild-type patients, with a 76% reduction in risk of progression with the triplet regimen versus fulvestrant monotherapy, are among the most striking efficacy numbers produced in post-CDK4/6 inhibitor breast cancer trials to date.

The HR+/HER2- Treatment Landscape After CDK4/6 Inhibitor Progression

HR-positive, HER2-negative breast cancer is driven primarily by estrogen receptor signaling. Endocrine therapy blocks this signaling, and the addition of CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) to endocrine therapy has produced median progression-free survival of 25 to 30 months or more in the first-line metastatic setting, a major advance over endocrine therapy alone.

After CDK4/6 inhibitor-based first-line therapy progresses, the standard approach depends on disease characteristics. For patients with ESR1 mutations (which develop in approximately 30 to 40% of patients on aromatase inhibitor-based therapy), elacestrant (Orserdu) or other agents targeting mutant ESR1 are options. For patients with PIK3CA mutations, alpelisib (and more recently inavolisib) provide PI3K-directed options. For patients with BRCA1/2 mutations, PARP inhibitors are relevant.

The PIK3CA wild-type population, approximately 60% of all post-CDK4/6 inhibitor HR+/HER2- patients, has had none of these mutation-matched targeted options. The available treatments are additional endocrine therapy combinations, everolimus (mTOR inhibitor)-based regimens, and increasingly antibody-drug conjugates like sacituzumab govitecan. Everolimus specifically targets mTORC1 in isolation, and its clinical benefit in this setting has been partial, limited by the feedback reactivation of PI3K that occurs when mTORC1 alone is blocked.

Gedatolisib’s approval provides this population’s first approved targeted inhibitor of the PAM pathway.

The Science: Why Pan-PI3K Plus Dual mTOR Inhibition Is Mechanistically Different

The PI3K/AKT/mTOR pathway is a master regulator of cell growth, survival, and metabolism. Its dysregulation is among the most common events in human cancer. In HR+ breast cancer, the pathway drives endocrine resistance through multiple mechanisms: it activates estrogen receptor independently of ligand, promotes cell cycle re-entry through CDK4/6 activation, and drives antiapoptotic signaling that keeps tumor cells alive despite endocrine blockade.

The pathway architecture is a cascade: growth factor signals activate PI3K (which phosphorylates PIP2 to PIP3), which activates AKT, which activates mTORC1 and mTORC2, which drive downstream transcription and protein synthesis for proliferation and survival. The cascade also includes a critical negative feedback loop: mTORC1 inhibition (as produced by everolimus) triggers PI3K reactivation through relief of the S6K1-IRS-1 feedback, partially undercutting the intended therapeutic effect.

Gedatolisib addresses the pathway comprehensively:

All four class I PI3K isoforms (alpha, beta, delta, gamma): In PIK3CA wild-type disease, other PI3K isoforms (PI3K-beta particularly) can compensate when PI3K-alpha alone is blocked by an alpha-specific inhibitor. By blocking all four isoforms simultaneously, gedatolisib prevents isoform switching that would otherwise allow the pathway to remain active.

Both mTOR complexes (mTORC1 and mTORC2): mTORC2 phosphorylates AKT at Ser473, maintaining AKT activity even when upstream PI3K is partially inhibited. By blocking mTORC2 as well as mTORC1, gedatolisib closes the reactivation loop that limits the efficacy of mTORC1-selective inhibitors like everolimus.

The result is a mechanistic approach that suppresses the PAM pathway more completely and more durably than any single-target inhibitor, and that does so regardless of which specific mutation (or absence of mutation) is driving pathway activation. This is why gedatolisib produces clinical benefit in PIK3CA wild-type patients, where no single-node inhibitor has succeeded: the wild-type pathway remains abnormally activated through other mechanisms (receptor tyrosine kinase signaling, loss of PTEN, AKT mutations), and comprehensive blockade addresses these regardless of which upstream event is present.

Dr. Sara Hurvitz, principal investigator for VIKTORIA-1, stated that the trial validates the PAM pathway as a molecular driver in HR+/HER2- advanced breast cancer regardless of PIK3CA mutation status, meaning the approach of comprehensive pathway blockade is supported across the full population rather than requiring a specific mutation.

Why PIK3CA wild-type disease still has an active PAM pathway The intuition that PIK3CA wild-type disease lacks meaningful PI3K pathway activation is incorrect. Multiple mechanisms drive abnormal PAM pathway activity without a PIK3CA mutation: overactivation of receptor tyrosine kinases (HER3, IGF-1R, FGFR) that signal through PI3K; loss of PTEN (the phosphatase that opposes PI3K activity), present in 15 to 30% of HR+ breast cancers regardless of PIK3CA status; activating mutations in AKT1 or other pathway components; and post-CDK4/6 inhibitor adaptive changes that upregulate pathway activity as a resistance mechanism. Gedatolisib’s clinical activity in PIK3CA wild-type disease confirms that the pathway is biologically active and targetable in this population even without a defining PIK3CA mutation.

The VIKTORIA-1 Study 1 Trial: Full Data for the Wild-Type Cohort

Design

VIKTORIA-1 (NCT05501886) is a Phase 3, multicenter, open-label, randomized trial with two independently powered cohorts: Study 1 (PIK3CA wild-type) and Study 2 (PIK3CA-mutant). The two cohorts were analyzed separately. The approval and this post cover Study 1.

Study 1 enrolled adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer with PIK3CA wild-type disease (no activating PIK3CA mutation detected by an FDA-authorized companion diagnostic assay) who had progressed on or after at least one line of endocrine therapy in the metastatic setting. The vast majority of enrolled patients had received prior CDK4/6 inhibitor-based therapy.

Patients were randomized 1:1:1 to three arms:

Gedatolisib plus palbociclib plus fulvestrant (triplet arm)
Gedatolisib plus fulvestrant (doublet arm)
Fulvestrant monotherapy (control arm)

Gedatolisib was administered as a 30-minute IV infusion on days 1, 8, and 15 of each 28-day cycle. Palbociclib was given at 125 mg orally on days 1 to 21 of each cycle. Fulvestrant was given at standard dosing (500 mg IM on days 1 and 15 of cycle 1, then day 1 of each subsequent cycle). The primary endpoint was progression-free survival (PFS) by blinded independent central review (BICR) in each gedatolisib-containing arm versus fulvestrant. Results were published in the Journal of Clinical Oncology in March 2026.

Primary efficacy results at median follow-up 12.8 months

Endpoint	Gedatolisib triplet	Gedatolisib doublet	Fulvestrant
Median PFS (BICR)	9.3 months	7.4 months	2.0 months
Hazard ratio versus fulvestrant	0.24 (95% CI 0.17 to 0.35)	0.33 (95% CI 0.24 to 0.48)	Reference
p-value versus fulvestrant	p less than 0.001	p less than 0.001	—
Risk reduction in progression or death	76% (triplet)	67% (doublet)	—
PFS incremental improvement	7.3 months	5.4 months	—

Source: Hurvitz SA et al. VIKTORIA-1 trial of gedatolisib plus fulvestrant with or without palbociclib in HR+/HER2-/PIK3CA wild-type advanced breast cancer. JCO. 2026. doi:10.1200/JCO-25-02643. NCT05501886.

The magnitude of these PFS improvements is exceptional for the post-CDK4/6 inhibitor setting, where standard second-line endocrine combinations typically produce median PFS of 4 to 6 months. A median PFS of 9.3 months for the triplet and 7.4 months for the doublet, compared to 2.0 months for fulvestrant alone, represents a clinically dramatic separation of the curves. The control arm median PFS of 2.0 months reflects the biological reality of post-CDK4/6 inhibitor PIK3CA wild-type disease: fulvestrant monotherapy provides very limited benefit in this setting, confirming the extent of endocrine resistance and the unmet need.

Response and durability

Endpoint	Gedatolisib triplet	Gedatolisib doublet	Fulvestrant
Objective response rate (ORR)	Approximately 32%	28.3%	Approximately 1%
Median duration of response (DOR)	11.4 months	12.0 months	Not determinable (only 1 response)

The ORR of approximately 32% for the triplet and 28% for the doublet versus approximately 1% for fulvestrant reflects a real tumor-shrinking activity in a population where endocrine monotherapy produces almost no responses. The durability of approximately 11 to 12 months in responders is consistent with meaningful clinical benefit.

VIKTORIA-1 Study 2: The PIK3CA-Mutant Data at ASCO 2026

Though the July 14, 2026 approval covers only the PIK3CA wild-type population based on Study 1, Celcuity presented the PIK3CA-mutant cohort (Study 2) results at the 2026 ASCO Annual Meeting as a late-breaking abstract (LBA1008). The data showed statistically significant and clinically meaningful PFS improvements with both gedatolisib combinations versus standard of care in PIK3CA-mutant patients as well, with hazard ratios in the same directionally strong range as the wild-type cohort. An sNDA for the mutant indication is planned for Q3 2026 submission. This means gedatolisib, if that sNDA is approved, will ultimately cover the full HR+/HER2- post-endocrine therapy population regardless of PIK3CA mutation status, making mutation testing a guide to which comparator benchmark to use rather than a gating criterion for eligibility.

The VIKTORIA-1 Study 1 Design: What Makes the Control Arm Comparison Meaningful

One important interpretive context for the VIKTORIA-1 data: the control arm is fulvestrant monotherapy, not an active CDK4/6 inhibitor combination or another targeted agent. This is an appropriate and clinically grounded comparator for the post-CDK4/6 inhibitor PIK3CA wild-type setting, where physicians currently have no approved targeted option beyond fulvestrant. But it means the absolute PFS numbers should be interpreted as comparison to the current clinical standard (fulvestrant) rather than to other active agents that are also used in this setting.

No head-to-head trial has compared gedatolisib directly to other agents used in this line (such as sacituzumab govitecan or everolimus/exemestane). Those comparisons will emerge from clinical experience and real-world data over time.

Dosing and Administration

Revtorpyk is supplied as a lyophilized powder that requires reconstitution before administration. This manufacturing form reflects the formulation chemistry needed to maintain stability of the compound; it is reconstituted by pharmacy personnel and administered to the patient as a ready-to-use infusion.

Dosing schedule:

Gedatolisib: reconstituted and administered as a 30-minute IV infusion on days 1, 8, and 15 of each 28-day cycle
Palbociclib (in the triplet): 125 mg orally once daily on days 1 to 21 of each 28-day cycle, with 7 days off
Fulvestrant (in both regimens): 500 mg IM on days 1 and 15 of cycle 1, then day 1 of each subsequent cycle

The weekly infusion schedule (3 infusions per 4-week cycle) is the most notable practical consideration for patients. This is more frequent clinical contact than the every-2-to-3-week infusion schedules of some other IV-administered oncology drugs, and it represents a meaningful time commitment for patients managing advanced breast cancer. The 30-minute infusion duration is relatively short compared to some IV biologics, but the weekly schedule means patients visit an infusion center three times every four weeks indefinitely.

PIK3CA testing requirement:

The approved indication specifies PIK3CA wild-type disease, meaning testing to confirm the absence of an activating PIK3CA mutation is required before initiating treatment. An FDA-authorized companion diagnostic assay must be used. This is a companion diagnostic requirement that should be incorporated into the workup for all patients with HR+/HER2- advanced breast cancer progressing on CDK4/6 inhibitor therapy, both to confirm gedatolisib eligibility and to identify the approximately 40% of patients who may instead be eligible for alpelisib, inavolisib, or the future PIK3CA-mutant gedatolisib indication.

Safety: The VIKTORIA-1 Profile

The safety profile of gedatolisib in VIKTORIA-1 is consistent with the known class effects of PAM pathway inhibition, with stomatitis and hyperglycemia as the most pharmacologically characteristic adverse events, and neutropenia as the dominant toxicity in the triplet arm due to the addition of palbociclib.

Grade 3 or higher treatment-related adverse events in Study 1

Adverse event	Gedatolisib triplet	Gedatolisib doublet	Fulvestrant
Neutropenia	62.3%	0.8%	0.8%
Stomatitis	19.2%	12.3%	0%
Rash	4.6%	5.4%	0%
Hyperglycemia	2.3%	2.3%	0%
Diarrhea	1.5%	0.8%	0%
Nausea	3.8%	0.8%	0%
Leukopenia (grade 4)	0.8%	0%	0%
Pneumonitis (grade 4)	0%	0.8%	0%
Treatment discontinuation due to TRAEs	2.3%	3.1%	—

Source: Hurvitz SA et al. JCO. 2026. PMC13075786.

Stomatitis: The most characteristic and commonly discussed gedatolisib-specific toxicity. Grade 3 stomatitis occurred in 19.2% (triplet) and 12.3% (doublet) of patients. Importantly, among patients who did develop stomatitis, the majority experienced grade 1 as their first event (57 of 90 in the triplet arm; 48 of 74 in the doublet arm), with fewer progressing to grade 2 or 3 as their initial presentation. Stomatitis is a class effect of PI3K and mTOR inhibitors and is managed with prophylactic mouthwash protocols, dose modifications, and patient education on early symptom reporting. The treatment discontinuation rate due to stomatitis alone was low (overall discontinuation for any TRAE was 2.3% in the triplet and 3.1% in the doublet).

Neutropenia in the triplet: The high grade 3 or higher neutropenia rate of 62.3% in the triplet arm is driven primarily by the palbociclib component, consistent with palbociclib’s established neutropenia profile in all of its approved regimens. CBC monitoring before each cycle and dose modification per the Revtorpyk and palbociclib prescribing information apply. The neutropenia rate in the doublet (0.8%) confirms that gedatolisib itself does not substantially contribute to bone marrow suppression; this is a palbociclib effect in the triplet.

Hyperglycemia: PI3K inhibition affects insulin signaling, and hyperglycemia is a known class effect. Grade 3 hyperglycemia occurred in 2.3% of patients in both gedatolisib arms. Blood glucose monitoring before treatment initiation and periodically during treatment, with dose modification and antidiabetic medication management as appropriate, follows the established management framework for PAM pathway inhibitors. Patients with pre-existing diabetes should be closely monitored.

Pneumonitis: Grade 4 pneumonitis occurred in 0.8% of doublet-treated patients. Pneumonitis is a known and serious risk associated with PI3K and mTOR inhibitors as a class. Patients should be monitored for new or worsening pulmonary symptoms; grade 2 or higher pneumonitis typically requires treatment interruption and corticosteroid management, with permanent discontinuation for grade 3 or higher.

Key warnings and precautions (from Revtorpyk prescribing information):

Warning	Clinical guidance
Hyperglycemia	Fasting glucose before initiating and periodically during treatment; dose modification for grade 3 or higher; may require antidiabetic medication initiation or dose adjustment
Stomatitis	Oral hygiene and prophylactic mouthwash regimens recommended before initiating; dose modification for grade 2 or higher; patient education on early reporting
Pneumonitis	Monitor for pulmonary symptoms; hold for grade 2 pneumonitis; permanently discontinue for grade 3 or higher
Embryo-fetal toxicity	Gedatolisib can cause fetal harm; effective contraception during treatment and for at least the period specified in prescribing information after last dose
Neutropenia (triplet)	CBC at baseline and before each cycle; dose modifications per palbociclib and Revtorpyk prescribing information for grade 3 or higher neutropenia

What This Means in Clinical Practice

For patients with HR+/HER2- PIK3CA wild-type advanced breast cancer

If you have HR-positive, HER2-negative metastatic breast cancer, your tumor has been tested and does not have a PIK3CA mutation, and your disease has progressed on or after prior endocrine therapy (including CDK4/6 inhibitor-based regimens), you are now in the patient population for which Revtorpyk is approved. This is the first targeted agent specifically approved for your PIK3CA status in this disease.

The treatment involves weekly IV infusions (three per four-week cycle) plus fulvestrant injections and, in the triplet, oral palbociclib. The clinical decision between the triplet and doublet depends on your prior therapy, current blood counts, and your oncologist’s assessment of the most appropriate regimen for your situation. Patients who have previously received a CDK4/6 inhibitor may or may not be candidates for the triplet re-challenge with palbociclib depending on the reasons for prior CDK4/6 inhibitor discontinuation.

For oncologists

VIKTORIA-1 Study 1 establishes gedatolisib plus fulvestrant, with or without palbociclib, as a new evidenced-based option for post-CDK4/6 inhibitor PIK3CA wild-type HR+/HER2- advanced breast cancer. The hazard ratios of 0.24 (triplet) and 0.33 (doublet) represent strong clinical benefit signals in a population with historically limited targeted options.

The companion diagnostic testing requirement adds a testing step to the treatment planning workflow that should now be standardized for all HR+/HER2- advanced breast cancer patients progressing on CDK4/6 inhibitor therapy, covering both PIK3CA mutation testing (to identify alpelisib/inavolisib-eligible patients) and confirming wild-type status for gedatolisib eligibility. ESR1 mutation testing for elacestrant eligibility remains a parallel testing requirement that the same blood sample or tissue can typically address.

The weekly infusion schedule is a meaningful practical factor in patient selection and treatment planning. Patients whose performance status, transportation access, and support systems make weekly clinic visits feasible are appropriate candidates; for patients where this frequency is a significant barrier, the clinical conversation should include the doublet, which has the same visit schedule but without the oral palbociclib complexity.

Dr. Joyce O’Shaughnessy of Baylor University Medical Center noted that in her opinion, this could be immediately practice changing, given the PFS data in both the PIK3CA wild-type and PIK3CA-mutant populations being consistently better than the control arm.

The upcoming sNDA for the PIK3CA-mutant indication (planned Q3 2026 submission) is the next major regulatory event to watch. If approved, gedatolisib will cover the full HR+/HER2- post-endocrine therapy population and PIK3CA testing will guide regimen selection and comparator benchmarking rather than drug eligibility.

For related HED coverage on HR+/HER2- breast cancer approvals, see our post on palbociclib (Ibrance) receiving its first HER2-positive breast cancer approval for HR+/HER2+ maintenance and our post on Trodelvy (sacituzumab govitecan) receiving two new first-line approvals for metastatic TNBC.

For patients and families navigating an HR-positive metastatic breast cancer diagnosis, the National Breast Cancer Foundation (nationalbreastcancer.org), the Susan G. Komen Foundation (komen.org; 1-877-GO-KOMEN), and the LBBC (Living Beyond Breast Cancer) maintain current resources on treatment options, clinical trials, and financial assistance.

Sources

FDA approval announcement: FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer. FDA.gov. July 14, 2026.

Celcuity FDA approval press release: Celcuity Announces FDA Approval of REVTORPYK (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer. GlobeNewswire. July 14, 2026.

Drugs.com approval news: FDA Approves Revtorpyk (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer. drugs.com. July 14, 2026.

VIKTORIA-1 Study 1 JCO primary publication (March 2026): Hurvitz SA et al. VIKTORIA-1 trial of gedatolisib plus fulvestrant with or without palbociclib in hormone receptor-positive/HER2-/PIK3CA wild-type advanced breast cancer. Journal of Clinical Oncology. 2026. doi:10.1200/JCO-25-02643.

VIKTORIA-1 trial registration: NCT05501886. ClinicalTrials.gov.

Celcuity JCO publication press release (March 9, 2026): Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study. GlobeNewswire. March 9, 2026.

CancerNetwork full efficacy and clinical context (with Dr. O’Shaughnessy quote): FDA Approves Gedatolisib for HR+, HER2- PIK3CA Wild-Type Advanced Breast Cancer. cancernetwork.com. July 2026.

Targeted Oncology (RTOR, Breakthrough Therapy designation, ASCO context): FDA Approves Gedatolisib for HR+/HER2-, PIK3CA Wild-Type Advanced Breast Cancer. targetedonc.com. July 2026.

Pharmacy Times (full safety table, mechanism detail): Gedatolisib Combination Approved for PIK3CA Wild-Type HR+, HER2- Breast Cancer. pharmacytimes.com. July 2026.

CURE (patient-facing dosing and administration detail): FDA Approves Revtorpyk for Advanced HR-Positive, HER2-Negative Breast Cancer. curetoday.com. July 2026.

VIKTORIA-1 ESMO 2025 presentation (Celcuity PDF): VIKTORIA-1 PIK3CA WT ESMO Presentation. celcuity.com. October 2025.

CancerNetwork VIKTORIA-1 Study 2 ASCO 2026 data (mutant cohort): VIKTORIA-1 Regimen Shows Efficacy in PIK3CA+ Breast Cancer. cancernetwork.com. June 2026.

VIKTORIA-1 Study 2 ASCO 2026 abstract: Hurvitz SA et al. VIKTORIA-1 Study 2. J Clin Oncol. 44, 2026 (suppl 17; abstr LBA1008). doi:10.1200/JCO.2026.44.17_suppl.LBA1008.

FCS Hematology Oncology Review (complete grade 3/4 safety table): VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib. fcshemoncreview.com.

PI3K/AKT/mTOR pathway biology: PI3K/AKT/mTOR Signaling in Cancer. PMC7734386.

Breast cancer overview: Breast Cancer. StatPearls. NCBI.

Alpelisib FDA approval (PIK3CA-mutant reference): FDA approves alpelisib for breast cancer. FDA.gov.

Revtorpyk prescribing information: REVTORPYK (gedatolisib) Prescribing Information. Celcuity Inc. 2026.

Revtorpyk approval history: Revtorpyk FDA Approval History. drugs.com.

Patient resources: National Breast Cancer Foundation | Susan G. Komen Foundation: 1-877-GO-KOMEN | Living Beyond Breast Cancer | Celcuity Revtorpyk patient support

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Revtorpyk (gedatolisib) requires PIK3CA wild-type confirmation by an FDA-authorized companion diagnostic assay before initiating treatment. Treatment decisions for HR-positive, HER2-negative advanced breast cancer, including regimen selection following CDK4/6 inhibitor-based therapy, should be made in close collaboration with a board-certified medical oncologist experienced in breast cancer management and familiar with the full clinical context including prior therapy, mutation status, and performance status.